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ABSTRACT 
 
Men who have sex with men (MSM) are at increased risk of anal cancer as a result of anal HPV 
infection. Routine HPV vaccination is recommended for all MSM up through age 26; however, 
vaccine uptake among this population is low. The Integrative Model of Behavioral Prediction 
(IM) was used to identify, describe, and explain psychosocial factors related to HPV vaccine 
decision-making for young MSM. A sequential mixed-methods approach consisting of semi-
structured interviews, a quantitative survey, and a qualitative open-ended survey was used to 
address the following aims: (1) Determine salient outcome, normative, efficacy, and control 
beliefs related to HPV-vaccination among young MSM; (2) Identify information needs and 
trusted sources of information regarding HPV vaccination among young MSM; and (3) Develop 
and test a structural equation model guided by the Integrated Model of Behavioral Prediction. 
The purpose and objectives of this research address priorities outlined in the Institute of 
Medicine’s report on health disparities among lesbian, gay, bisexual, and transgender (LGBT) 
populations. Results highlight the lack of information and knowledge regarding HPV prevention 
in this population. The majority of respondents had heard of the HPV vaccine but generally 
perceived it as a women’s health issue. Attitudes toward vaccination were generally positive, as 
was behavioral intention to get vaccinated within the next 12 moths. Salient behavioral beliefs 
described physical benefits such as lowering risk and promoting overall health. Psychological 
benefits were described as protecting sex partners and providing peace of mind. There was some 
concern regarding the risks of vaccination including contracting HPV from the vaccine, not 
viii 
knowing if it would be effective, and potential side effects. Normative influences on decision-
making were minimal. Availability, cost, and convenience were among the most salient external 
control factors. Issues surrounding disclosure of sexual minority status influenced control factors 
including self-efficacy. Addressing the specific beliefs and concerns expressed by MSM can help 
to improve the effectiveness of health education interventions promoting vaccination. Empirical 
findings support the proposed behavioral model of vaccine decision-making.  
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CHAPTER 1: INTRODUCTION 
 
 
 The incidence of anal cancer is increasing in the U.S. and men who have sex with men 
(MSM) are disproportionally at risk (Daling et al., 2004; Johnson, Madeleine, Newcomer, 
Schwartz, & Daling, 2004; Joseph et al., 2008). Between 1973 and 2000, the incidence of anal 
cancer in the U.S. increased among both men and women; however, the incidence among men 
increased at a higher rate (160% vs. 78%) (Johnson et al., 2004). The incidence rates of anal 
squamous cell carcinoma (SCC), the dominant histologic anal cancer type in the U.S., increased 
an average of 2.6% per year between 1998 and 2003 (Joseph et al., 2008). The demographic 
trends in anal cancer changed after 2000, when the combined incidence of SCC and carcinoma in 
situ were higher in men than in women (Nelson, Levine, Bernstein, Smith, & Lai, 2013).  Most 
of this increase, however, has been attributed to the HIV epidemic and the disproportional risk 
faced by MSM (Cress & Holly, 2003; Daling et al., 2004; Nelson et al., 2013). 
It is estimated that the incidence of anal cancer is approximately 12.5-36.9 cases per 
100,000 MSM compared to just 1 case per 100,000 heterosexual males (~ 20 times higher for 
MSM) (D’Souza et al., 2008; Daling et al., 1987). This rate is substantially greater in MSM 
infected with HIV. Since 1996, the anal cancer incidence of HIV-positive MSM was estimated to 
range from 59.4-96.2 cases per 100,000 (Machalek et al., 2012).  
Further evidence indicates that a sizable proportion of MSM exhibit anal squamous 
intraepithelial lesions (ASILs), which are considered biological precursors of anal cancer. In 
their investigation of HIV-negative MSM recruited from four U.S. cities, Chin-Hong and 
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colleagues (2005) found that 20% of MSM had ASILs, with 5% of these classified as high-grade 
lesions (i.e., invasive cancer precursors). A study of HIV-positive MSM found the prevalence of 
ASILs to be approximately 81% with 13% classified as high-grade lesions (Palefsky et al., 
2005). Similar rates of ASILs were reported in studies of MSM residing in European countries 
(Kreuter et al., 2010; Piketty et al., 2004). The high rate of ASILs among populations of MSM, 
as well as the increase risk of invasive anal cancer, suggests that anal cancer prevention targeting 
MSM is of significant public health importance.  
Overall, the current risk for anal cancer for MSM is comparable to women’s risk for 
cervical cancer prior to widespread implementation of cytological screening (Qualters, Lee, 
Smith, & Aubert, 1992). While most attention has focused on the well-established link between 
human papillomavirus (HPV) and cervical cancer, infection with oncogenic HPV types (e.g., 
HPV -16 and -18) is also a primary causal factor in the etiology of anal cancer (Grulich et al., 
2012). In a meta-analysis of anal HPV-related disease, the prevalence of anogenital HPV 
infection was as high as 92.6% and 69.9% in studies of HIV-positive and HIV-negative, MSM, 
respectively (Machalek et al., 2012). The prevalence of oncogenic high-risk types was also high 
in these populations, averaging 73.5% in HIV-positive and 37.2% in HIV-negative MSM. These 
infections are effectively prevented through prophylactic vaccination (Giuliano et al., 2011).  
In 2009 the U.S. Food and Drug Administration approved the quadrivalent HPV vaccine, 
Gardasil, for the prevention of genital warts in males ages 9-26. Indications of Gardasil were 
extended in 2011 to include the prevention of anal cancer and anal intraepithelial neoplasia in 
both males and females. The Centers for Disease Control and Prevention (CDC) recently 
recommended routine vaccination of males aged 11 and 12, and catch-up vaccination in males 
between the ages of 13 and 21. Permissive use was recommended for men between the ages of 
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22 and 26; however, the Advisory Committee on Immunization Practices (ACIP) recommended 
routine vaccination of MSM up through age 26 (Centers for Disease Control and Prevention, 
2011b). There is a paucity of behavioral research focusing on adult MSM ages 18-26 regarding 
their readiness to initiate HPV vaccination.  
Preliminary research suggest that a reasoned action approach, as represented in the 
Integrative Model of Behavioral Prediction (IM), is a viable theoretical framework from which to 
understand HPV vaccine decision-making and to design tailored interventions. According to this 
model, health education interventions must address the salient HPV-related outcome, normative 
and control beliefs expressed by young MSM in order to effectively promote vaccination among 
this population. These beliefs and perceptions cannot be generalized a priori from other research 
domains or study populations but require careful formative elicitation research conducted with 
the priority population. The salient beliefs elicited in the current study can be used to create 
innovative culturally appropriate interventions promoting HPV vaccination among young MSM.  
Statement of Need 
There is limited theory-based research on HPV vaccine acceptability and intentions 
among men in general, and even fewer studies focusing on MSM for whom the need is even 
greater. Overall, men have been found to have limited knowledge about HPV (Gerend & 
Magloire, 2008; Klug, Hukelmann, & Blettner, 2008), to be largely unaware of the link between 
HPV infection and cancer in men (Gerend & Barley, 2009), and to have widely varying attitudes 
toward HPV vaccination (Liddon, Hood, Wynn, & Markowitz, 2010).  The few studies that have 
focused on MSM have reported a wide range of HPV awareness, knowledge, and vaccine 
acceptability in MSM (Reiter, Brewer, McRee, Gilbert, & Smith, 2010; Simatherai et al., 2009; 
Tider, Parsons, & Bimbi, 2005; Wheldon, Daley, Buhi, Nyitray, & Giuliano, 2011). Much of this 
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research is limited by its focus on MSM living in a few large metropolitan cities, and by 
measures that did not assess knowledge of the oncogenic risk of HPV infection in men. One 
national study of MSM found high awareness of HPV but limited knowledge about the direct 
health effects of HPV infection on males (Gilbert, Brewer, Reiter, Ng, & Smith, 2010). For 
example, although 79% of men in this study had heard of HPV, only 32% knew HPV could 
cause anal cancer.  
Collectively, the utility of this body of research for intervention planning is limited by 
three important caveats: (1) most of this data were collected with regard to a hypothetical HPV 
vaccine since, at the time, no vaccine had been approved for the prevention of HPV in males; (2) 
participants were on average much older than males who are in the current recommended age 
range for HPV vaccination; and (3) social and cultural beliefs and perceptions salient to young 
MSM were not explored. These limitations in the extant literature limit the ability of public 
health professionals to tailor health education interventions to the specific needs of gay, bisexual, 
and other MSM.  Widespread acceptance and uptake of the HPV vaccine is needed in order for 
prophylactic vaccination to be an effective—both in terms of reach and cost—public health 
strategy to decrease the burden of HPV-related cancers among male sexual minorities. Health 
education research aimed at promoting vaccination is therefore an essential component of such a 
strategy.  
Research Plan 
Purpose of the Study 
The long-term goal of this research is to decrease the incidence of anal cancer and other 
HPV-associated diseases among MSM by preventing infection of HPV types -6, -11, -16 and -18 
through vaccination. The purpose of this study was to understand the factors important to young 
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MSM when making decisions about HPV vaccination. A multi-phase, multi-method study was 
conducted in order to develop measures of relevant theoretical constructs and to test an 
integrative model of HPV vaccine intentions in a sample of young MSM. The following aims 
were addressed: (1) Determine salient outcome, normative, efficacy, and control beliefs related 
to HPV-vaccination among young MSM; (2) Identify information needs and trusted sources of 
information regarding HPV vaccination among young MSM; and (3) Develop and test a 
structural equation model guided by the Integrated Model of Behavioral Prediction that identifies 
the psychosocial determinants of young MSM’s HPV vaccine intentions. The specific aims and 
associated research questions are summarized in Table 1.    
The goal of this research is to inform health education interventions that will increase 
HPV vaccine uptake among young adult MSM; however, since the vaccine has only recently 
been approved for males, and the number of young MSM who have actually received the HPV 
vaccine is very small, it is not possible at this time to study vaccine uptake directly. Therefore, 
the main outcome of interest for this research is intent to receive the HPV vaccine, which is 
theoretically the most proximal determinant of future vaccination (Montano & Kasprzyk, 2008).  
The target population for this research includes (1) men between the ages of 18 and 26, 
(2) who reside in the United States, (3) are able to read and comprehend English, (3) who have 
not initiated the HPV vaccine series, and (4) who have ever engaged in sexual contact with 
another male or who identify as gay or bisexual. This conceptual population includes both gay 
identified and non-gay identified MSM in order to be inclusive of all those who engage, or may 
engage at some point, in similar behaviors that increase the risk of HPV infection. It also focuses 
on adult males who do not need parental permission to receive the vaccine.  
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Rationale for the study 
The use of empirically supported behavioral models of HPV vaccination specific to MSM 
will increase the efficacy of health education messages and interventions targeting MSM, which 
will result in greater rates of vaccination and decreased risk of anal cancer and other HPV-
associated diseases. By identifying the salient psychosocial factors associated with HPV-
vaccination among young MSM and testing a theoretical behavioral model that identifies specific 
beliefs and perceptions that can affect intentions to get vaccinated, the outcomes of this research 
can be used to develop tailored health education programs aimed at increasing vaccine uptake 
among this population. The strategies for behavioral change, for example, would differ 
significantly if this research identifies normative influences as the strongest predictor of vaccine 
intentions and attitudinal factors as largely unimportant. Furthermore, by eliciting salient 
influential individuals or groups, and measuring indirect effects of normative influences 
(normative beliefs and motivation to comply), the final model will provide a rich source of 
information to plan behavior change strategies.  
Future directions include the use of Intervention Mapping to apply the determinants of 
HPV vaccine intentions identified in the current study to the creation of specific change 
objectives, which represent empirically validated “pathways” that can yield the most immediate 
changes in motivation and behavior (Bartholomew, 2011). This approach will also involve the 
identification of relevant stakeholders and community resources that can be leveraged to 
disseminate health education messages and programs, with the ultimate goal of increasing HPV 
vaccine awareness, acceptability, and uptake among diverse populations of young MSM. 
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Table 1: Aims and Research Questions 
Research Aim Research Question 
Research Aim #1:  (a) Describe salient outcome, 
normative, efficacy, and control beliefs related to 
HPV-vaccination among young MSM 
 
(b) Determine factors that underlie these beliefs  
 
1. What do YMSM believe are the advantages 
and/or disadvantages of receiving the HPV vaccine? 
 
2. (a) How do YMSM perceive others who receive 
the HPV vaccine?  (b) Who are the individuals 
and/or groups that influence YMSM decisions 
regarding HPV vaccination? 
 
3.What factors or circumstances would enable 
YMSM to initiate HPV vaccination and what 
factors or circumstances would inhibit their ability 
or willingness to get vaccinated? 
 
 
 
Research Aim #2:  Identify information needs and 
trusted sources of information regarding HPV 
vaccination among young MSM. 
 
 
4. What sources of health-related information do 
YMSM access and trust? What information would 
help influence their HPV vaccine decisions?  
 
Research Aim #3:  Develop and test a structural 
equation model guided by the Integrated Model 
(IM) of Behavioral Prediction that identifies the 
psychosocial determinants of young MSM’s HPV 
vaccine intentions 
5. What are the structural relationships between 
factors from the IM and what is their relationship to 
HPV vaccine intentions? 
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CHAPTER 2: LITERATURE REVIEW 
 
Human papillomavirus as a public health problem 
Human papillomavirus (HPV) is a common infectious agent that infects the epithelial 
tissues after abrasion or trauma (Schiller, Day, & Kines, 2010). Though there are many types of 
HPV, it is principally known and described as a sexually transmitted infection (STI). Currently 
there are more than 40 known HPV types that infect epithelial tissues in anogenital regions of 
males and females. Assessment activities surrounding the study of HPV as a public health 
problem include epidemiological investigations designed to quantify the distribution and 
determinants of HPV infection and HPV-related diseases. These types of surveillance activities 
are essential to inform policy development and the assurance of provisions and resources.  
It is estimated that 6.2 million sexually active Americans between the ages of 15 and 44 
will acquire HPV every year (Weinstock, Berman, & Cates, 2004). Given that cross-sectional 
studies often find a 50% prevalence of HPV infection, it's likely that a larger proportion of the 
population gets HPV infection during the lifetime (Dunne et al., 2007; Dunne, Nielson, Stone, 
Markowitz, & Giuliano, 2006). The majority of HPV infections will spontaneously regress with 
only a small percent of HPV infections persisting beyond two years (Baseman & Koutsky, 
2005).  Prevalence estimates of HPV in the U.S. vary as a result of geographic variations in study 
samples, anatomical sites from which specimens were collected (e.g., cervicovaginal, glans, 
corona, prepuce, anus, etc.), as well as the processing methods used to analyze the samples 
(Dunne et al., 2006; Nielson et al., 2007; Smith & Travis, 2011). Estimates range from just 1.3% 
 9 
to 72.9% in studies assessing multiple anatomical sites (Dunne et al., 2006). Because of the 
wide-ranging prevalence estimates across populations, an overall estimate of HPV infection is 
not useful. This is further substantiated when one considers sex differences in HPV prevalence 
and persistence.  
Unlike patterns of HPV infection in females, the prevalence of genital HPV in males does 
not concentrate as highly in younger age cohorts indicating sex differences in persistence or 
reinfection (becoming infected with same HPV-type after initially clearing the infection) (Smith, 
Melendy, Rana, & Pimenta, 2008). These sex differences may also be reflected in observations 
of lower antibody prevalence for specific HPV types and lower titer levels in males compared to 
females (Giuliano et al., 2008). Therefore, age does not appear to be as strongly associated with 
genital HPV prevalence in males, in general, as it is in females. It is still unknown if age-based 
sex differences exist in anal HPV infection.  
Results are more conclusive, however, with regard to determinants of infection. Sexual 
behavior is consistently associated with HPV prevalence in both males and females. A greater 
number of lifetime and recent sex partners increase risk of HPV (Svare et al., 2002). Having 
multiple sex partners is also positively associated with co-infection with multiple HPV types 
(Nielson et al., 2009; Rousseau et al., 2003). For men, multiple-type HPV infections may be 
more common in particular anatomical sites such as the penile shaft and to a lesser extent the 
glans penis/coronal sulcus; whereas other sites such as the perianal and anal canal may be less 
likely to harbor multiple type infections (Nielson et al., 2009).  
Therefore, the prevalence and type of HPV infection also appears to vary across men 
based on their history of same-sex sexual behaviors. Men with a history of oral and/or anal sex 
with men have been shown to have a higher prevalence of specific anal HPV genotypes when 
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compared with men without a history of same-sex behavior (Nyitray, da Silva, Baggio, Lu, 
Smith, Abrahamsen, Papenfuss, Quiterio, et al., 2011). For example, the prevalence of combined 
genotypes 6/11, the two HPV types responsible for the majority of anogenital warts, were found 
to be more common in men who have sex with men (MSM) and men who have sex with men 
and women (MSMW) when compared to men who have sex with women (MSW) (Nyitray, da 
Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Quiterio, et al., 2011). Similarly, the 
prevalence of any HPV type at the perianal region or in the anal canal is strongly associated with 
a history of same-sex sexual behavior. And while anal HPV infection among MSW is not 
uncommon, these type-specific infections tend to co-occur at anal and genital sites in MSW, but 
less so among MSM (Nyitray, da Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Quiterio, et 
al., 2011). This pattern of infection suggests self-inoculation between anatomical sites among 
MSW (Hernandez et al., 2008). 
Among MSM and MSMW, there are a number of factors associated with the prevalence 
of anal HPV infection. One of the strongest behavioral factors is history and frequency of 
receptive anal intercourse (Chin-Hong et al., 2004; Vajdic et al., 2009). Infection with HIV also 
increases risk of HPV.  MSM seropositive for HIV were significantly more likely to be infected 
with both oncogenic and nononcogenic HPV types compared to HIV seronegative MSM (Vajdic 
et al., 2009; van der Snoek et al., 2003).  
Anal HPV infection is also common among females. In a recent cohort study of women, 
the period prevalence over an average of 1.3 years for anal HPV infection was 70% (Goodman et 
al., 2008). The incidence of infection (inclusive of 18 high-risk HPV DNA types) was nearly 20 
per 1,000 woman-months after a year of follow-up. A greater number of sexual partners and 
baseline cervical HPV infection was positively associated with anal HPV infection among 
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women in this cohort study; however, anal intercourse was not significantly associated with anal 
HPV infection. This finding is in accordance with some previous research on anal HPV infection 
in women that failed to find an association between anal HPV infection and receptive anal 
intercourse (Palefsky, Holly, Ralston, Da Costa, & Greenblatt, 2001). In contrast, research 
among MSM has consistently found strong associations between receptive anal intercourse and 
anal HPV infection (Chin-Hong et al., 2004; Vajdic et al., 2009). Collectively, these findings 
suggest divergent routes of transmission responsible for the acquisition of anal HPV infection in 
heterosexual men and women, compared to homosexually active men.  
High-risk and low-risk HPV  
A better approach to the surveillance and monitoring of HPV infections is to focus on 
those specific types that result in the greatest disease burden given the wide variation in the 
distribution of HPV infection among diverse populations, the various determinants that lead to 
these infections, and the differences observed in persistence of infection.  A small subset of 
genotypes is responsible for the largest proportion of clinical diseases such as anogenital warts 
and certain cancers. Those associated with anogenital warts are considered low-risk, as they do 
not result in malignant cancers. Two types of low-risk HPV (type -6 and -11) cause 
approximately 90% of genital warts. In contrast, 12-18 types of HPV are considered high-risk 
because of their relationship with invasive cancer (Muñoz et al., 2003).  
HPV-associate disease burden 
Genital warts 
Genital warts, or Condylomata acuminate, occur at multiple anogenital sites in both men 
and women. They can also develop in the larynx, eyes, and nose. The majority of genital warts 
are caused by HPV type -6 or -11 (Garland et al., 2009). Infection with these HPV types is very 
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common in the United States. In a recently published study, the seroprevalence of HPV types 
6/11 was 20.8% for females and 7.3% for males (Markowitz, Sternberg, Dunne, McQuillan, & 
Unger, 2009); however, these are likely lower bound estimates due to lower antibody response 
and titer levels for specific HPV types in males (Giuliano et al., 2008).  
Despite the high prevalence of infection with these HPV types in the population, the 
majority of infections do not result in genital warts because the infections are cleared by the 
body’s immune system. Analysis of private insurance claims estimate the incidence density rate 
of genital warts in the United States to be approximately 1.7 per 1,000 person years (Insinga, 
Dasbach, & Myers, 2003). Self-report data from a population-based sample of men and women 
aged 18 to 59 residing in the US indicated approximately 6% of this population has ever been 
diagnosed with genital warts (Dinh, Sternberg, Dunne, & Markowitz, 2008). There is some 
indication that the rate of genital warts is increasing in the United States and is highest among 
men and women in their twenties (Insinga et al., 2003; Koshiol, Laurent, & Pimenta, 2004). 
Furthermore, anogenital warts may be more prevalent among MSM, and are associated with 
certain sexual behaviors and tobacco use (Hansen et al., 2010; Fengyi Jin et al., 2007; Wiley et 
al., 2009). 
Though anogenital warts are relatively benign, treatment options and the likelihood of 
reoccurrence result in significant health care costs and utilization (Giuliano, 2007). Developing 
anogential warts also exerts a significant psychosocial burden in both men and women and 
negatively impacts their quality of life (Jeynes, Chung, & Challenor, 2009; Scarbrough Lefebvre, 
Van Kriekinge, Gonçalves, & de Sanjose, 2011; Skaaby & Kofoed, 2011). Furthermore, 
anogenital warts may increase the risk for HIV infection among high-risk populations of men 
(Jin et al., 2010).  
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Cervical cancer 
Initial assessments of the public health impact of HPV began in the 1970s when genital 
warts was linked to HPV infection in returning war veterans; however, it was not until the 1980s 
that HPV infection was linked to squamous cell carcinomas of the cervix (Boshart et al., 1984). 
It is now well understood that HPV infection is a necessary cause of cervical cancer 
(Walboomers et al., 1999), which is the second most common type of cancer in women 
worldwide and is estimated to develop in approximately 8.1/100,000 women every year in the 
United States (Howlader et al., 2011). This rate is far less than the rate of cervical cancer in 
previous decades, as the incidence in the United States has decreased almost 70% among white 
women due to the widespread implementation of cytological screening (Devesa et al., 1987; 
Kitchener, Castle, & Cox, 2006). Despite the success of these prevention efforts, cervical cancer 
is still a significant cause of cancer-related morality in the United States, particularly among 
Black and Hispanic women (Barnholtz-Sloan et al., 2009). Infection with a high-risk type of 
HPV is a necessary cause of cervical cancer. Specifically, HPV-16 and -18 account for the 
highest proportion of cervical cancers (Clifford, Smith, Plummer, Munoz, & Franceschi, 2003). 
Other HPV-associated cancers  
These same HPV types have also been implicated as primary causal agents of anal cancer 
(Carter et al., 2001; Frisch et al., 1999; Melbye & Frisch, 1998), and are strongly associated with 
cancers of the oropharynx, vulva, vagina, and penis (Gillison, Chaturvedi, & Lowy, 2008). 
Collectively, these noncervical HPV-associated cancers result in over 19,000 cancers per year in 
the United States. Among these, anal and oropharyngeal cancers represent the largest burden of 
noncervical HPV-associated cancers. Furthermore, as shown below, there are notable disparities 
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in the incidence of these cancers, particularly with regard to incidence among men (Palefsky, 
2010b). 
Head and neck cancer 
In contrast to the declining rates of cervical cancer in the United States, rates of non-
cervical HPV-associated cancers are static or increasing (Gillison et al., 2008). For example, 
persistent infection with high-risk HPV types can result in a series of invasive cancers in both 
men and women including anal and head and neck cancers. Cancers of the head and neck include 
all of those cancers developing in the oral cavity, salivary glands, sinus and nasal cavities, 
pharynx, or larynx. The role of HPV infection in the development of head and neck cancer 
depends largely on the site of the tumor. The association of HPV infection is strongest for 
cancers of the oropharynx with approximately 60% of these cancers attributable to HPV 
infection (Gillison et al., 2008). The burden of these HPV-related oral cancers has increased over 
the last two decades, particularly among younger men (Chaturvedi et al., 2011; Marur, D’Souza, 
Westra, & Forastiere, 2010; Westra, 2009). There are an estimated 7,000 cases of oropharyngeal 
cancer annually in the US, with approximately 5,600 of those cases occurring among men (CDC, 
2011). Similar to cervical cancer, HPV -16 and -18 are the most prevalent HPV types found in 
oropharyngeal cancers (Giuliano et al., 2008).  
Anal cancer 
There is a growing body of evidence that suggests most anal cancers (more than 90%) are 
caused by HPV infection (Gillison et al., 2008). In 2009, an estimated 5,290 men and women in 
the U.S. were reported with cancers of the anus, anal canal, or anorectum (Jemal et al., 2009). 
And while overall survival rates from anal cancer are similar to survival rates from other cancers 
of the digestive system, there is a significant quality of life lost depending upon the 
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recommended treatment (Allal, Sprangers, Laurencet, Reymond, & Kurtz, 1999). Furthermore, 
the incidence of anal cancer is increasing, and certain subpopulations are at disproportional risk 
of this disease. Between 1973 and 2000, the incidence of anal cancer in the United States 
increased among both men and women; however, the incidence among men increased at a higher 
rate (160% vs. 78%) (Johnson et al., 2004). The incidence rates of anal squamous cell carcinoma 
(SCC), the dominant histologic anal cancer type in the U.S., increased an average of 2.6% per 
year between 1998 and 2003 (Joseph et al., 2008). The demographic trends in anal cancer 
changed after 2000, when the combined incidence of SCC and carcinoma in situ were higher in 
men than in women (Nelson et al., 2013).   
Most of this increase, however, has been attributed to the disproportional risk faced by 
MSM (Cress & Holly, 2003; Daling et al., 2004). Epidemiological evidence strongly suggests 
that MSM are at increased risk of developing anal cancer. The incidence of anal cancer in MSM 
was estimated to be approximately 12.5-36.9 cases per 100,000 MSM compared to just 1 case 
per 100,000 heterosexual males (Daling et al., 1987). A prospective cohort study of married 
same-sex partners in Denmark found that homosexually partnered men had over 31 times the risk 
of anal cancer compared to the rest of the general population (Frisch et al., 1997).  
The prevalence of anal squamous intraepithelial lesions (ASILs), some of which are 
likely biological precursors of anal cancer, provides additional evidence of anal cancer risk in 
MSM. Analysis of anal cytology results among sexually active HIV-negative MSM determined 
that 5% of the men had biological precursors of anal cancer (Chin-Hong et al., 2005). The risk of 
ASILs increase significantly for HIV infected individuals. Prevalence estimates of ASILs from a 
study of HIV-positive MSM were as high as 81% (Palefsky et al., 2005). These findings are 
consistent with the incidence of anal cancer found in HIV-positive MSM (D’Souza et al., 2008). 
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At nearly 80 cases per 100,000, HIV-positive MSM are nearly 40 times more likely to develop 
anal cancer than HIV-negative MSM. Overall, risk estimates for anal cancer among MSM are 
comparable, and even exceed, women’s risk for cervical cancer prior to widespread 
implementation of cytological screening (Qualters et al., 1992). 
Penile cancer 
HPV infection is also associated with a number of penile cancers, which are rare 
compared to other HPV-associated cancers. The estimated average annual number of HPV-
associated cases of penile cancer in the US is 298 (Gillison et al., 2008). This low occurrence 
equates to less than 1 case per 100,000 men. Unlike cervical cancer, in which HPV is a necessary 
cause, penile cancer is a histologically heterogeneous disease where approximately 40-50% of 
cases are associated with HPV infection (Giuliano et al., 2008). The association of HPV 
infection with penile cancer is clarified when stratified by histology with a much larger 
proportion of warty/basaloid cancers testing positive for HPV DNA (~75-80%) compared to the 
more common squamous cell carcinomas (~30-60%) (Giuliano et al., 2008; Palefsky, 2010). Of 
these HPV-associated penile cancers, the majority (~87%) can be attributed to infection with 
HPV type 16 and/or 18 (Gillison et al., 2008). 
HPV Prevention 
The prevention of HPV infection among males has garnered increased attention in recent 
years, both because of the indirect benefit to females resulting from lower population prevalence, 
as well as the growing awareness of the health sequelae of HPV infection in men.  Identifying 
factors associated with the increased risk of HPV transmission provides targets for primary 
prevention efforts. The primary modes of transmission of HPV include vaginal and anal 
intercourse (Burchell, Winer, de Sanjosé, & Franco, 2006). Prevalence of HPV infection is 
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commonly associated with a greater number of lifetime and recent sexual partners (Dunne et al., 
2006). Significantly decreasing exposure through the modification of sexual behaviors is 
unlikely given the highly transmissible nature of HPV and increasingly permissive social norms 
regarding sexual behavior (Thornton & Young-DeMarco, 2001).  
In addition, the protective effect of condom use against HPV transmission during sexual 
intercourse is undetermined (Manhart & Koutsky, 2002) and is likely site specific. Consistent 
condom use with female partners seems to offer some degree of protection from genital HPV 
infection, particularly at covered sites such as the penile shaft and glans (Baldwin et al., 2004; 
Nielson et al., 2010). Always using condom was also found to be protective against anal HPV 
infection among MSM (Nyitray, da Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Villa, et 
al., 2011). Despite these findings, condom use was not associated with risk of anogenital warts 
among men in a previous study (Wiley et al., 2005). The association between condom use and 
HPV prevalence appears to be moderated in part by biological sex differences, given that women 
appear to benefit less from condom use than men (Manhart & Koutsky, 2002; Vaccarella et al., 
2006). Studies investigating the association of condom use and HPV have several 
methodological limitations (e.g., HPV sites measured) that limit our ability to draw valid and 
reliable conclusions; however, it is clear that the overall impact of condom use as a viable HPV 
prevention strategy is limited by the potential for transmission during noncoital sexual actively.  
The data regarding the protective effects of male circumcision is more definitive. A 
recent meta-analysis reviewed 23 articles published through September of 2010 and found 
consistent evidence for reduced risk of HPV among circumcised men (Larke, Thomas, dos 
Santos Silva, & Weiss, 2011). The strongest effect was for reduced prevalent infections, 
particularly at the glans/corona and sites more proximal to the foreskin. There was further 
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evidence indicating that circumcision is protective against incident infections and may result in 
increased clearance of acquired infections. There is some related evidence that the protective 
effect of circumcision may decrease the prevalence of HPV-associated diseases. For example, 
childhood circumcision is associated with reduced risk of invasive penile cancer  (Larke et al., 
2011); and, among men with a history of multiple sex partners, a decreased risk of cervical 
cancer has been observed in their female partners (Castellsagué et al., 2002). No data is available 
regarding circumcision risk of anal HPV infection or anal cancer.  
Circumcision as a population-based HPV prevention strategy is limited, however, by its 
overall impact on HPV transmission as well as limited modifiability. Based on current data, 
circumcision can reduce HPV transmission by an estimated 43% (Larke et al., 2011); however, 
there is wide variation in this estimate and may be as low as 29%. Furthermore, the overall 
prevalence of male circumcision in the United States has steadily decreased since the 1970s (Xu, 
Markowitz, Sternberg, & Aral, 2007), and is associated with strong cultural values and 
increasingly negative attitudes that may be resistant to modification (Zoske, 1998).  
More recent efforts to prevent HPV infection involve prophylactic vaccination as a 
primary prevention strategy. A quadrivalent HPV vaccine has been shown to have high efficacy 
for preventing infection of HPV types -6, -11, -16, and -18, and also clinical diseases such as 
anogenital warts and external genital lesions (Giuliano et al., 2011). The reported efficacy of the 
quadrivalent vaccine in preventing infections (types -6, -11, -16, and -18), external genital 
lesions, and genital warts was found to be approximately 90% in vaccinated males who were 
naïve to the four HPV genotypes prior to vaccination. A bivalent HPV vaccine (types -16 and -
18), Cervarix, is also available and is indicated for the prevention of cervical cancer; however, 
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the efficacy of Cervarix in preventing HPV 16/18 and associated cancers in males is currently 
unknown.  
In 2009, the U.S. Food and Drug Administration approved an HPV vaccine, Gardasil, for 
the prevention of genital warts, and in 2010 approved the vaccine for the prevention of anal 
cancer and anal intraepithelial neoplasia in both males and females. The most recent expansion 
of the ACIP’s HPV vaccine recommendations to include routine vaccination of boys aged 11 or 
12, catch-up vaccination of young men 13 through 21 years who have not been previously 
vaccinated, and permissive vaccination of males 22 through 26 (Centers for Disease Control and 
Prevention, 2011b). The ACIP also issued a risk-based recommendation for the routine 
vaccination of MSM through age 26 (a nonavalent vaccine was approved by the FDA in 2014 
but at the time of this writing this vaccine had not been recommended for adult males). 
It should be noted that these recommendations create a 5-year period between the ages of 
22 and 26 in which routine vaccination of males is not recommended unless the male belongs to 
the “risk population” defined as “men who have sex with men” or if he is infected with HIV. It is 
unclear if this risk population includes men who identify as a sexual minority (e.g., gay or 
bisexual) but who have not yet been sexually active with men. Implementing these divergent 
policy recommendations require population-based vaccine promotion programs targeting male 
sexual minorities.  
In order for the vaccine to be an effective strategy at reducing the incidence of HPV and 
HPV-associated diseases, widespread acceptance and uptake of the vaccine is necessary. The 
most recent estimates indicate low uptake of HPV vaccine among adult MSM. In 2011, just 5% 
of MSM surveyed as part of the National HIV Behavioral Surveillance System had received one 
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dose of the HPV vaccine. A Harris LGBT Interactive Panel survey conducted in 2013  reported a 
13% uptake among MSM 18 to 26 years old.  
HPV vaccine behavioral research 
Currently there is little consensus in the extant research literature on the acceptability of 
HPV vaccination in adult males. The results are difficult to compare given the differences in 
methodology, the populations sampled, as well as whether the data were collected prior to the 
FDA’s approval of the use of Gardasil in males. In addition, the age at which vaccination is 
sought, either by the individual adult or his parent/guardian, determines who should be the focus 
of the research. The research reviewed here will focus on studies from the perspective of adult 
men, compared to the parents or guardians of adolescent males, due to the lack of research on the 
latter. Furthermore, these two groups of males—those in the target age vs. those in the catch-up 
group—will require unique interventions with divergent targets and strategies to increase vaccine 
uptake.  
Early studies on the acceptability of vaccination against sexually transmitted infections 
among college students suggest that this population is overwhelmingly supportive of such 
vaccinations (Boehner, Howe, Bernstein, & Rosenthal, 2003). These findings suggest that adult 
college students have positive attitudes toward new vaccine technologies targeting sexually 
transmitted infections and may adopt such technologies in large numbers; however, it is well 
established that general attitudes toward a broad set of behaviors (e.g., vaccination against a class 
of diseases) are poor predictors of actual behavioral performance compared to more specific 
attitudes toward a well-defined behavior (Fishbein & Ajzen, 2010). Therefore, the major 
weakness of this early work is the focus on hypothetical vaccines. 
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The degree to which men are even aware and knowledgeable about HPV and the HPV 
vaccine will significantly impact the likelihood that they will be receptive to vaccine 
recommendations. A meta-analysis of research published between 1992 to 2006 found a wide 
range of awareness and knowledge about HPV in both men and women (Klug et al., 2008). Since 
the quadrivalent vaccine was not available to females until 2006, the research surveyed reflects 
the awareness and knowledge of participants prior to widespread media coverage and marketing 
of the vaccine. The authors found that awareness of HPV ranged from 13% to 92% and was 
generally higher among women than men.  
There is a widespread lack of knowledge that infection with HPV causes diseases such as 
anogenital warts and cancers (Klug et al., 2008). This lack of knowledge was most evident prior 
to the implementation of the HPV vaccination campaigns. In a survey of college freshmen 
conducted in 2000, the majority of men (96%) and women (95%) had heard of genital warts, but 
only 4% of men and 12% of females knew that HPV causes genital warts (Baer, Allen, & Braun, 
2000). Similarly, students in this study were unaware of the etiological connection between 
dysplasia of the cervix and penis and HPV infection, and expressed a poor understanding of the 
transmission of HPV relative to that of genital warts. These findings are not limited to this single 
study but are consistent with findings from a large body of research conducted during this time 
period (Klug et al., 2008). 
Limitations inherent in sex education programs that rely on the dissemination of “simple 
messages of prevention” have been identified as one possible explanation for the wide-spread 
lack of basic information about HPV (Braun & Phoun, 2010, p.50). The transmission dynamics 
of HPV limit the ability to construct simple messages around preexisting “safer sex” discourses, 
such as those applied to the prevention of HIV/AIDS. As a result, HPV as an important sexually 
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transmitted infection was largely ignored (Braun & Phoun, 2010). Others have identified 
incomplete media coverage of HPV that systematically lacked information about sexual 
transmission and the relationship of HPV infection to clinical diseases (Anhang, Stryker, Wright, 
& Goldie, 2004). These larger social phenomena provide a context from which to understand 
public perceptions of HPV and identify potential barriers to vaccine promotion among men.  
A series of media reports and a direct-to-consumer advertising campaign shortly followed 
the initial FDA approval of Gardasil in 2006. In what was seen as an attempt to deemphasize the 
sexual nature of HPV in order to limit the opposition of vaccinating young girls, the majority of 
the initial media coverage and related advertisements failed to provide information about HPV 
including its transmission, prevalence, and clinical manifestations other than cervical cancer 
(Braun & Phoun, 2010; Mamo, Nelson, & Clark, 2010). As a result, the predominant focus on 
Gardasil as cancer prevention technology is thought to have created unrealistic perceptions of the 
probability of HPV infection resulting in cervical cancer—a proposition that has some empirical 
support (Munsell, Gray, Reed, Vasquez, & Vlasak, 2010)—and may foster a general lack of 
susceptibility or concern about HPV infection among men.  
A number of studies have assessed men’s awareness of HPV and the HPV vaccine 
following the licensure of the vaccine for females and the ensuing mass media attention (Allen, 
Fantasia, Fontenot, Flaherty, & Santana, 2009; M. A. Gerend & Barley, 2009; M. A. Gerend, 
Shepherd, & Monday, 2008; Jones & Cook, 2008; Nielsen, Munk, Liaw, & Kjaer, 2009). As 
previously described, however, much of the reporting on the vaccine, as well as the formal 
direct-to-consumer advertising campaign implemented by Merck, framed Gardasil almost 
exclusively as a technology to prevent cervical cancer while omitting information about HPV as 
a sexually transmitted infection (Braun & Phoun, 2010). As a result—though awareness of HPV 
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increased among men following the availability of the vaccine for females—men’s knowledge of 
HPV remained low (Klug et al., 2008). In fact, the initial marketing of Gardasil may have 
actually created the perception that HPV is only of concern for females (Wailoo, Livingston, 
Epstein, & Aronowitz, 2010).  
After more than two years following the availability of Gardasil, male students 
participating in a series of focus groups at a large urban university were well aware of HPV and 
the HPV vaccine (Allen et al., 2009). However, there was a general sense expressed in these 
groups that men were not susceptible to HPV or that HPV infection in men was not serious. In 
fact, many of the men referred to HPV as a “women’s disease” (Allen et al., 2009). As late as 
2009—just prior to the FDA’s approval of Gardasil for males—as many as 45% of male college 
students in one survey believed that males could not even acquire HPV, and 74% of those who 
were aware that men could become infected with HPV were under the impression that HPV 
infection in men was rare (Katz, Krieger, & Roberto, 2011). The majority of these men reported 
commercials and advertisements as the primary source of their information regarding HPV, 
whereas few men had received information about HPV through health education programs or 
healthcare providers (Katz et al., 2011).  
Results from these studies demonstrate that awareness of HPV increased following the 
initial licensing of Gardasil for females, but men continued to have poor knowledge of HPV in 
general, and specifically regarding clinical manifestations of HPV infection in men (Liddon et 
al., 2010; Nadarzynski, Smith, Richardson, Jones, & Llewellyn, 2014). Information about the 
etiological relationships between HPV infection, genital warts and cancers in men was largely 
absent from initial public discourse surrounding HPV. To date, behavioral surveys continue to 
indicate that a large proportion of men remain unaware of the potential clinical manifestations of 
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HPV. For example, in a series of recent studies men were largely unaware that genital warts are 
caused by HPV infection (Gilbert et al., 2010; Nandwani, 2010; Tider et al., 2005; Wheldon et 
al., 2011) and even fewer were aware that HPV is associated with oral, penile or anal cancers 
(Gerend & Barley, 2009; Gilbert et al., 2010; Wheldon et al., 2011). 
Brewer, Ng, McRee, and Reiter reported that a majority of heterosexual (62%) and 
gay/bisexual (79%) men participating in a national survey of men in the United States were 
aware of HPV but had low knowledge about HPV-related diseases (Brewer, Ng, McRee, & 
Reiter, 2010). And while findings from this study suggest that gay and bisexual men—who were 
hypothesized to be more sensitized to sexual health concerns—were more aware of HPV and had 
higher knowledge of HPV-related diseases than heterosexual men, their level of knowledge was 
still quite low (Brewer et al., 2010; Gilbert et al., 2010). For example, only 15% of gay/bisexual 
men knew HPV infection can cause anal cancer. Furthermore, the majority of men in this study 
expressed the belief that HPV vaccine would not benefit men.  
There have been very few studies that have surveyed men about HPV following the 
initial approval of Gardasil for men in late 2009. A recent study of Australian college students 
found moderate knowledge of HPV but highlighted important misconceptions held by many of 
the men sampled. Most men correctly identified that HPV causes cervical cancer, but few were 
aware of HPV-related diseases in men (Petrovic, Burney, & Fletcher, 2011). Similarly, young 
gay and bisexual men in the US exhibited high awareness of HPV as a cause of cervical cancer, 
but were much less aware of the possible clinical manifestations in men (Wheldon et al., 2011). 
More than 40% of men participating in this survey were unaware that genital warts are caused by 
HPV infection, and less than half were knowledgeable about the link between HPV and oral, 
anal, or penile cancers.  In addition, more than a year following the approval of Gardasil for 
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males, only a quarter of the men in this sample were aware that an HPV vaccine was available to 
them.   
Barriers to HPV vaccine uptake among men 
There are a number of important barriers to widespread uptake of HPV vaccine among 
adult males in the catch-up age range of 18 to 26. Key among these, as previously outlined, is a 
widespread lack of knowledge and awareness of HPV and HPV-associated disease in men. Men 
consistently demonstrate lack of basic information about HPV and HPV vaccination. 
Furthermore, while knowledge is not consistently predictive of HPV vaccine acceptability 
(Daley et al., 2010; Ferris et al., 2009; Gerend & Barley, 2009; Gilbert et al., 2010; Reiter et al., 
2010) or intentions among men (Petrovic et al., 2011; Wheldon et al., 2011; Young et al., 2011), 
knowledge and awareness are considered fundamental or background factors that operate 
indirectly through more salient perceptions and beliefs (Fishbein & Ajzen, 2010). For example, 
knowledge of the high prevalence and transmissibility of HPV may result in greater perceived 
susceptibility to HPV infection among men. This is important because perceived susceptibility of 
HPV or HPV related diseases has been shown to positively correlate with HPV vaccine 
acceptance and intentions (Crosby, DiClemente, Salazar, Nash, & Younge, 2011; Daley et al., 
2010; Gerend & Barley, 2009; Gilbert et al., 2010; Reiter et al., 2010; Wheldon et al., 2011). 
Therefore, the existing research that suggests men, particularly those in the vaccine-licensed age 
cohort, do not feel susceptible to HPV is concerning and is a significant psychosocial barrier to 
widespread vaccine uptake among this population.  
In a recent study, the majority of young men (~54%) who were surveyed two months 
after the approval of Gardasil for males expressed low perceived susceptibility to HPV (Crosby 
et al., 2011). In turn, men with low perceived susceptibility to HPV were found to be 
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significantly less likely to express a desire to receive an HPV vaccine. The association between 
perceived susceptibility to HPV infection and positive intent to receive an HPV vaccine has been 
found in a number of other studies in diverse populations of men (Daley et al., 2010; Gerend & 
Barley, 2009; Reiter, McRee, Kadis, & Brewer, 2011).  
These results suggest that health education interventions focusing on correcting 
widespread misperceptions that HPV infection among men is rare may result in greater 
perceptions of susceptibility and in turn create positive motivation for HPV vaccination. 
However, it is well established that perceived susceptibility of a given health condition will 
increase intrinsic motivation only if that health condition is also perceived as being a serious 
threat to physical and or psychological well being (Fishbein & Ajzen, 2010).  
Men’s general lack of knowledge regarding the clinical manifestations of HPV infection 
would suggest that they would express ambiguous beliefs with regard to the seriousness of such 
an infection. In fact, a wide range of perceptions regarding the seriousness of HPV infection has 
been reported (Brewer et al., 2010; Bynum, Brandt, Friedman, Annang, & Tanner, 2011; Crosby 
et al., 2011; Daley et al., 2010; Gerend & Barley, 2009; Katz et al., 2011; Wheldon et al., 2011; 
Young et al., 2011). Presumably, the perceived severity of HPV infection would be higher 
among men who are knowledgeable about the potential health consequences of such an 
infection; unfortunately, these associations have not yet been reported in any of the published 
literature. There is some indirect support for this hypothesis in the consistent finding that men 
who express a positive belief in the potential health benefits of HPV vaccination—suggesting 
that they perceive negative health consequences from HPV infection—have higher vaccine 
intentions (Gerend & Barley, 2009; Gilbert et al., 2010; Wheldon et al., 2011).  
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Concerns about the overall safety of HPV vaccination have also been identified as a 
significant barrier to vaccine uptake in men (Liddon et al., 2010). In a recent study immediately 
following the approval of Gardasil for use among males, a majority of men (67%) expressed 
concern about the vaccine’s safety (Crosby et al., 2011). There was a general consensus among 
the men in this survey that they did not have enough information about Gardasil and that they 
should “wait awhile before deciding about getting vaccinated” because the vaccine was “too 
new” (Crosby et al., 2011).. Men’s concerns about side effects associated with HPV vaccination 
are commonly reported (Daley et al., 2010; Gerend & Barley, 2009; Young et al., 2011), but it is 
unclear to what degree these concerns about safety are actually specific to HPV vaccination, in 
contrast to more general concerns about vaccinations. Unfortunately, these studies typically 
measure safety concerns specific to HPV vaccination (Crosby et al., 2011; Gerend & Barley, 
2009; Reiter et al., 2011; Wheldon et al., 2011) safety concerns about vaccinations in general 
(Daley et al., 2010; Ferris et al., 2009). Without measuring both indicators of safety concerns 
within the same study, the subsequent analyses are unable to empirically determine the 
collinearity of these factors.  
Consequently, there is some evidence to suggest that while men commonly express 
concerns about vaccine safety, these concerns are not very salient in their appraisals of their 
overall vaccine intentions. This is evidenced by consistent null findings for safety concerns in 
multivariable statistical models of HPV vaccine intentions (Daley et al., 2010; Gerend & Barley, 
2009; Reiter et al., 2011; Wheldon et al., 2011). Studies that do find positive associations 
between safety concerns and vaccine intentions typically limit their analyses to zero-order 
correlations, and are therefore unable to control for spurious relationships (Ferris et al., 2009).  
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In addition, expressed concern about vaccine safety may actually be an indicator of a 
more general negative attitude toward recommended health behaviors. In a recent study 
assessing the associations between HPV vaccine intentions and a variety of health behaviors, 
there was a positive association between wearing a seatbelt and vaccine intentions. In this same 
study, vaccine intentions were not associated with being “extremely concerned” about vaccine 
safety (Ferris et al., 2009). Instead, one of the more significant differences between these men 
was the degree to which they believed that vaccines are important. The majority (67%) of men 
who wanted the HPV vaccine believed that it is “extremely important” to get vaccinated for all 
recommended vaccines. Collectively, these findings suggest that concerns over vaccine safety 
are of less importance in HPV vaccine-related decision-making than are more positive 
dispositions toward health behaviors (e.g., general vaccinations, seatbelt use).  
Other barriers, such as the actual or perceived cost of vaccination, demonstrate much 
more stable associations with HPV vaccine intentions (Gerend & Barley, 2009; Wheldon et al., 
2011; Young et al., 2011).  The current cost of the HPV vaccine series (approximately $400.00) 
is far greater than the out-of-pocket cost men found to be acceptable for this vaccine (Gilbert et 
al., 2010). Consequently, men have indicated that the high cost of the vaccine series is a primary 
reason that they would not be immunized (Crosby et al., 2011). The negative association 
between cost and HPV vaccine intention was also commonly reported as a barrier to vaccination 
among women (Brewer & Fazekas, 2007). But recent research that controlled for cost in the 
study design has demonstrated that cost may actually be of less concern than indicated by 
statistical models (Vanderpool, Casey, & Crosby, 2010). Additional research needs to clarify this 
relationship but it is clear that third party payers will play an important role in ensuring vaccine 
uptake across socioeconomic strata.   
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An often-overlooked barrier to vaccine promotion among young men is the lack of 
healthcare utilization by this demographic (Mansfield, Addis, & Mahalik, 2003). Men, 
independent of age, are much less likely than women to utilize routine medical services such as 
an annual physical exam (Chabot, Lewis, de Bocanegra, & Darney, 2011; Vaidya, Partha, & 
Karmakar, 2012). The lack of interaction with the healthcare system limits the opportunities of 
healthcare providers to counsel eligible men about HPV vaccination. This is a significant barrier 
considering that provider recommendation has been shown to be one of the strongest predictors 
of HPV catch-up vaccination among women (Brewer & Fazekas, 2007; Rosenthal et al., 2011) 
and there is growing evidence that men are generally more accepting of vaccination when 
recommended by a healthcare provider (Daley et al., 2011; Ferris et al., 2009; Reiter et al., 
2011). Furthermore, providers have indicated a willingness to recommend HPV vaccination to 
their male patients and are therefore a vital resource in vaccine promotion efforts (Zimet & 
Rosenthal, 2010). Future studies should assess the ability to overcome access barriers by offering 
vaccine in informal settings where men are more likely to be engaged (Kierans, Robertson, & 
Mair, 2007).  
Psychosocial issues surrounding HPV vaccination of male sexual minorities 
There is a growing amount of behavioral research focused specifically on HPV 
vaccination among gay, bisexual, and other men who have sex with men referred to as “MSM” 
from this point forward) that warrants further consideration (Nadarzynski et al., 2014). It has 
been argued that MSM—as a subpopulation of men—stand to receive the greatest direct benefit 
from HPV vaccination due to their increased risk of anal cancer (Palefsky, 2010a, 2010b). As 
early as 2005, researchers began assessing HPV-related knowledge and beliefs among MSM 
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living in large urban cities (Tider et al., 2005). This research demonstrated a general lack of 
knowledge about HPV infection similar to that found among men in general.  
Collectively the body of behavioral research on HPV and MSM demonstrate low levels 
of knowledge and concern about HPV (Nadarzynski et al., 2014).  Comparisons of MSM with 
heterosexual men have found that a greater proportion of MSM had previously heard of HPV 
and had greater awareness of HPV related diseases in men (Brewer et al., 2010). Despite these 
statistically significant differences, the overall knowledge of HPV in this study was low. The 
most poorly understood aspect of HPV infection in men is the clinical manifestations of HPV 
with regard to non-cervical HPV-associated cancers (Reiter et al., 2011; Wheldon et al., 2011).  
Despite the limited information about HPV and HPV vaccination reported by the 
majority of MSM surveyed, the acceptability of HPV vaccination among this population widely 
varies from study to study (Nadarzynski et al., 2014). Two studies operationalizing vaccine 
intentionality as a multidimensional construct, reported disparate rates of vaccine intentions 
among MSM (Reiter et al., 2011; Wheldon et al., 2011). Wheldon et al. reported (2011) that only 
36% of the men in their study were considered likely to get vaccinated even after they were 
provided basic information about HPV-vaccines and HPV-associated diseases. By comparison, 
Reiter and colleagues found 74% of MSM in their study were willing to receive HPV vaccine 
(Reiter et al., 2011). There are a few possible explanations for these findings. For instance, there 
are notable differences in the age of respondents in these studies. Older men with a greater 
number of lifetime sexual partners may perceive themselves at greater risk of HPV-related 
diseases and therefore may express more willingness to receive HPV vaccine. Lower vaccine 
intentions were found in the study that sampled MSM between the ages of 18 and 29 (Wheldon 
et al., 2011); whereas, the higher estimate of vaccine acceptability resulted from a sample 
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inclusive of men as old as 59 (Reiter et al., 2011). In fact, Thomas and Goldstone (2011)—in 
their study of off-label HPV vaccination of MSM attending an anorectal surgical clinic—
reported high demand for HPV vaccination among MSM in their mid-to-late 30s. 
Another important difference between these two studies is that Gardasil was approved 
and available for use in men at the time of data collection of the latter investigation. This enabled 
the researchers to specify a timeframe (i.e., within the next 12 months) in which participants 
rated their intentions to get vaccinated (Wheldon et al., 2011). In the prior study, intentionality 
was measured with regard to a hypothetical vaccine in which participants rated the likelihood 
that they would get vaccinated at some point in the future (Reiter et al., 2011). Research across a 
variety of health domains has consistently found better predictive validity from measures of 
intention that specify a time-based context as it relates to the performance of a target behavior 
(Fishbein & Ajzen, 2010). Therefore, the more precise measure of vaccine intentionality is 
theoretically more predictive of actual vaccination. In this case, the more precise measure 
revealed lower vaccine intentions (Wheldon et al., 2011).  
Secondary prevention efforts aimed at decreasing morbidity and mortality of HPV-related 
diseases may be of particular value given the limited efficacy of prophylactic vaccination of men 
who have likely been previously exposed to multiple HPV types. Gay men’s health advocates 
who identified anal cancer as a gay health threat in the late 1990s proactively advocated for 
secondary prevention options, such as the anal Pap smear (Epstein, 2010). The social and 
political organizations that emerged from the HIV/AIDS epidemic were brought to bear against 
“heteronormative medical assumptions” that rendered anal cancer as an invisible disease for 
which no preventive interventions were available (Epstein, 2010, p. 69). To date, there is no 
official indication with regard to the use of anal Pap smear for the screening of anal cancer or 
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precancerous lesions; although, there is a growing body of research which suggests that regular 
cytological screening is a useful and cost effective measure for the secondary prevention of anal 
cancer in both HIV-negative and –positive MSM (Park & Palefsky, 2010). Other studies have 
examined the addition of HPV reflex testing to screening protocols to increase the detection of 
anal cancer development (Goldstone, Enyinna, & Davis, 2009); however, the exiting literature is 
limited by observational study designs (Chiao, Giordano, Palefsky, Tyring, & Serag, 2006) and 
lack a clear understanding of the most important outcome to measure. Randomized clinical trials 
are still needed in order to determine the efficacy of anal cytology screening and to inform 
screening guidelines for the secondary prevention of anal cancer.  
Based on the available research it is clear that prophylactic HPV vaccination represents 
the most viable and effective prevention strategy currently available to reduce the future 
incidence of HPV and its associated diseases among younger generations of MSM (i.e., those 
under age 27 years). Due to elevated risk for anal cancer, a concerted effort to vaccinate MSM 
up through age 26 years is warranted; however, secondary prevention through early detection of 
anal disease will remain important for a large number of MSM who will not benefit from 
vaccination. Health behavior research is needed in order to assess the acceptability of these 
prevention efforts among MSM and to create vaccine promotion programs tailored for this 
population.  
Preliminary Data  
A preliminary study was completed to identify psychosocial correlates of HPV vaccine 
intentions among young MSM (Wheldon, Buhi, & Daley, 2013; Wheldon et al., 2011), and to 
assess the utility of the Health Belief Model (Rosenstock, 1974) and Theory of Planned Behavior 
(Ajzen, 1991)in predicting intent to receive HPV vaccine. The sample included a total of 179 
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men between the ages of 18 and 29 years (Mean age = 22) who identified as gay or bisexual or 
who had a history of sexual activity with men. These men were recruited in the fall of 2010 
through gay and lesbian student organizations at 23 colleges and universities across the 
Southeastern U.S. and through a social networking Internet site.  
Similar to previous findings, the majority of young MSM (93%) in this study had heard 
of HPV prior to participation, but were generally unaware of the causal association of HPV with 
anal, penile, and oral cancers. Only 26% were aware of the availability of an HPV vaccine for 
males. Just 12% of young MSM indicated that they intended to get vaccinated within the next 
year yet 66% indicated that they would like to learn more about the vaccine. Constructs from the 
Health Belief Model (HBM) and Theory of Planned Behavior (TPB) explained a large 
proportion of the variance in a composite index of vaccine intentions (48% and 46%, 
respectively). However, the percent of explained variance changed very little (~5%) in a 
combined model (HBM + TPB), indicating redundancy in the explanatory power of these 
theories.  
The problem of overlap in constructs from the HBM and TPB has been extensively 
discussed, and an alternative model has been developed that integrates concepts from the HBM 
and TPB, as well as from social cognitive theory (Fishbein et al., 2001). The resulting model, 
called the Integrated Model of Behavioral Prediction (IM), brings together theoretical constructs 
proven to be proximate determinants of health behaviors. The IM was used as the theoretical 
foundation for this study. These theoretical approaches will be discussed in more detail below.  
Theoretical Framework 
It has been well established that health promotion and behavior change interventions are 
more effective if they are based in behavioral theory (Green, 2000). As a set of interrelated 
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concepts, definitions, and propositions that present a systematic view of phenomena (Glanz & 
Rimer, 2005), theory enables researchers and practitioners to condense and organize knowledge, 
as well as to explain and predict specific behaviors (e.g., HPV vaccination). Thus researchers are 
able to build generalizable knowledge within a field or discipline by building theory, testing 
theories, and adjusting theories with findings from empirical investigations. These are the 
foundational activities of all scientific fields. Therefore, a well-defined theoretical approach is 
necessary to study HPV-related prevention behaviors if the purpose of that study is to develop 
and evaluate scientific knowledge needed for prevention activities. 
HPV preventive behaviors, such as vaccination, can (and should) be studied from a 
variety of perspectives including that of the priority population (young gay and bisexual men in 
this study), health care providers who administer the vaccine, community-based organizations 
that serve the priority population, as well as through the analysis of social institutions (e.g., 
media). A first step is to assess what the priority population knows about the health risks and the 
preventive behavior, as well their readiness or intention to engage in the behavior. Social and 
behavioral science theories are needed in order identify and understand the psychological and 
social factors that determine an individual’s acceptance of a medical intervention and their 
readiness to complete that intervention. What follows is a discussion of key health behavior 
theories focusing on individual decision-making and behavior. 
Theories of health behavior 
 Intrapersonal level theories posit that the most proximate determinants of a given health 
behavior are the affect, behavior, and cognitions of the individual actor. A number of 
intrapersonal health behavior theories have been articulated, each conceptualizing the 
relationships among a number of key concepts in distinct ways (Noar & Zimmerman, 2005). The 
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Health Belief Model (HBM), the Theory of Planned Behavior (TPB), and Social Cognitive 
Theory (SCT) are commonly used theoretical approaches to explain discrete health behaviors 
and to inform behavioral interventions.  
Health Belief Model (HBM) 
The intellectual roots of the HBM stem largely from the field of psychology, and most 
notably from the German-American psychologist Kurt Lewin and his developmental field theory 
(Glanz & Rimer, 2005). Lewin, credited as the founder of modern social psychology, 
emphasized the study of individual-environment interactions as key to understanding human 
behavior. In contrast to behaviorism, the dominant paradigm at the time, Lewin’s Field Theory 
understood behavior as purposive and a product of an individual’s personality, perceptions, and 
social interactions. The social environment (or “life space”) was of particular importance. Lewin 
conceptualized this environment as a field containing behavioral objects in which the individual 
actor appraised as either desirable or undesirable (i.e., positive and negative valance) 
(Rosenstock, 1974). One could then predict an individual’s behavior by assessing this appraisal 
process. Individuals would act in ways to avoid objects perceived as negative and to move 
toward or engage objects perceived as positive.  
In the early 1950s, social psychologists Rosenstock, Hochbaum, and Kegels developed 
the HBM while working in the U.S. Public Health Service (Rosenstock, 1974). The original 
intent of the HBM was to explain why individuals were not taking advantage of a free 
tuberculosis health-screening program. The HBM includes elements from Lewin’s field theory 
and emphasizes the subjective perceptions of the individual in understanding health behavior 
(Maiman & Becker, 1974). Diseases were understood as objects in which an individual 
perceived as negative, and would therefore behave in ways that would move the individual away 
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from that object (i.e., prevent or treat the disease). But in order for this appraisal to occur, the 
individual must first perceive himself or herself at risk for the disease.  
The HBM conceptualizes these cognitive processes into four key constructs: (1) 
perceived susceptibility, (2) perceived severity, (3) perceived benefits, and (4) perceived barriers.  
It was proposed that perceived susceptibility (individual's perception of the risk of 
illness/disease) and perceived severity (beliefs about the physical and social consequences of the 
illness/disease) form the threat element that motivates action; whereas, perceived benefits 
(beliefs about the benefits of criterion specific health behavior) and barriers (beliefs about the 
real or imagined costs of the criterion specific behavior) provide information about the likely 
path to action. Two additional constructs, cues to action and self-efficacy, are also used in the 
HBM. Cues to action, although an underdeveloped construct in the model, describe those 
somatic and/or environmental events that elicit action. Self-efficacy describes an individual’s 
confidence in his/her ability to take action in a variety of situations or circumstances.  
The HBM also emphasizes the role of modifying factors that may attenuate the 
relationship among the constructs. These modifying factors are often conceptualized as 
sociodemographic influences, but could also include knowledge as well as personality 
characteristics that may influence individual perceptions. The relationships among the constructs 
themselves are not well conceptualized in the HBM. In certain circumstances, modifying factors 
may actually be antecedents to perceived threat, which is often the case with knowledge. 
Similarly, perceived barriers or benefits may act as modifying variables, or they may mediate the 
relationship between perceived threat and the desired health behavior. These structural 
ambiguities have significant ramifications for how this model is applied in research and practice.  
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Theory of Planned Behavior (TPB) 
The Theory of Planned Behavior (TPB) is the result of an adaptation of the Theory of 
Reasoned Action (TRA) (Fishbein, Triandis, Kanfer, et al., 2001). Social psychologist Martin 
Fishbein developed the TRA to overcome the limitations of behavioral research that 
conceptualized attitudes as the most proximate cause of behavior. The problem was that, across 
many studies and behavioral domains, attitudes were inconsistently correlated with behavior. 
Given the equivocal nature of these findings, Fishbein introduced the TRA, which 
conceptualized behavioral intention as the factor mediating the relationship between attitudes 
and behavior. The TRA includes three main constructs: (1) Behavioral intentions, (2) attitudes, 
and (3) subjective norms.  
Behavioral intentions are said to capture the motivational qualities that lead to adoption 
of a behavior, and are theorized to be a function of attitudes and subjective norms. Attitudes are 
further subdivided into behavioral beliefs and evaluations of behavioral outcomes. Essentially, 
attitudes are “latent dispositions or tendencies to respond with some degree of favorableness or 
unfavorableness to a psychological object” (p. 76) and are composed of beliefs regarding the 
attributes and outcomes of the object (Fishbein & Ajzen, 2010). The evaluation, or appraisal, of 
these beliefs leads to the formation of attitudes. Similarly, subjective norms are conceptualized 
as the normative beliefs and the motivation to comply with these beliefs. Normative beliefs refer 
to the approval or disapproval of others within an individual’s social environment. Subjective 
norms are formed when these beliefs are weighted by an individual’s evaluation of how 
motivated he or she is to comply with those in their network.  
The TPB includes these important constructs, with the addition of perceived behavioral 
control (PBC). Ajzen argued that an individual, despite having positive attitudes and normative 
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support for a behavior, might be inhibited by external factors (Ajzen, 1991). Therefore, PBC was 
added to account for individual volition to perform a behavior. Like attitudes and subjective 
norms, PBC is composed of a belief and an evaluative component. Control beliefs are an 
individual’s beliefs regarding his or her ability to perform a given behavior based on what 
external factors will inhibit or facilitate their ability to act. In PBC, these beliefs are weighted by 
the perceived strength of these factors to inhibit or facilitate behavioral performance. It is 
theorized that the importance of PBC is diminished when there is a high degree of volition 
associated with a specific behavior (Fishbein & Ajzen, 2010). 
The relationships among constructs in the TPB, unlike those in the HBM, are clearly 
defined. Attitudes, subjective norms, and perceived control are all theorized to have a direct 
effect on intentions to perform a given behavior, which in turn is said to be a proximate cause of 
behavioral performance. However, the strength of the relationship between any of the three main 
constructs and behavioral intention will vary according the specific behavior under investigation. 
In general, if an individual believes that a given behavior will lead to a desired outcome, that 
important and respected people in his/her life are supportive of the behavior, and that there are 
strong external facilitators but few barriers, then it is theorized that behavioral intentions will be 
strong for the behavior and will lead to behavioral performance.  
Social Cognitive Theory 
Alfred Bandura developed Social Learning Theory, now Social Cognitive Theory (SCT), 
in a response to the limitations of the then dominant behaviorism paradigm. This new approach 
to learning emphasized the role of the social environment in determining behavior, and in 
particular, the importance of the interaction between the individual actor and the social 
environment. The most recent iterations of this theory were heavily influenced by the emergence 
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of the cognitive paradigm in psychology, which lead to a greater emphasis on the cognitive 
processes in learning and behavior (Bandura, 2001). The result is the current form of the SCT, 
which conceptualizes behavior as the product of intrapersonal and interpersonal factors. In other 
words, individual level factors interact with interpersonal factors to influence behavior; however, 
the SCT also posits that an individual can affect change in the environment and regulate their 
own behavior. This relationship is represented by the concept of reciprocal determinism. Other 
organizing concepts include psychological determinants of behavior, observational learning, 
environmental determinants of behavior, and moral disengagement.  
Psychological determinants of behavior are inclusive of those concepts dealing with 
individual beliefs and perceptions. There are three key concepts that are grouped into 
psychological determinants: outcome expectations, self-efficacy, and collective efficacy. 
Outcome expectations are an individual’s beliefs about the outcome of a particular behavior, and 
the value he or she places on this outcome. This conceptual definition is nearly identical to the 
concept of behavioral beliefs from the TPB. Self-efficacy describes an individual’s confidence in 
his/her ability to take action in a variety of situations or circumstances. Similarly, collective 
efficacy in the SCT refers to an individual’s confidence in the ability of a group, community, or 
organization to affect change in some desirable outcome.  
Observational learning is learning through observation, or by observing the behavior of 
others. This can occur by observing someone in real life or through some other media such as 
video, audio, or text. The SCT proposes four processes involved in observational learning: 
attention, retention, production, and motivation. Observational learning is facilitated if the 
learner is attentive to the modeling of the behavior, is able to retain the information observed 
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(either directly or through interaction with some media), is able to perform the behavior, and is 
motivated to perform the behavior.  
There are two concepts inclusive of environmental determinants of behavior. The first 
concept, incentive motivation, is adapted from operant conditioning and includes the use of 
rewards and punishments to inhibit or reinforce behavior. Similarly, facilitation includes the 
resources, skills, and environmental aspects that are constructed to encourage the adoption of a 
specific behavior. While operant conditioning and facilitation represent those environmental 
conditions that either increase or decrease the probability of performing a specific behavior, self 
regulation is inclusive of cognitive strategies that an individual utilizes to monitor their own 
behavior, set goals, seek feedback, reward himself or herself, talk through a problem or barrier, 
and enlist support from others.  
And finally, moral disengagement is a concept that represents the means by which 
individuals divorce themselves from moral standards and expectations in order to justify some 
ethically questionable behavior. Moral disengagement is said to operate through four cognitive 
processes: euphemistic labeling, dehumanization and attribution of blame, diffusion and 
displacement of responsibility, and perceived moral justification. Euphemistic labeling is said to 
enable moral disengagement by using descriptions or words of morally questionable actions that 
downplay the emotional or social impact. Similarly, through the dehumanization and 
construction of an in-group/out-group mentality, individuals are able to justify actions and apply 
blame that would not be acceptable in other circumstances. Conversely, diffusion and 
displacement of responsibility attempts to divert or minimize the consequences resulting from 
one’s actions. Perceived moral justification is the attempt to reverse the perception of an action 
by constructing it as a needed benefit rather than an objectionable act.  
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An integrative framework 
Despite the similarities among the constructs proposed by these health behavior theories, 
they are typically understood and applied in research and practice as independent theoretical 
approaches. There have been surprisingly few attempts to empirically compare the predictive 
validity of these models or to clarify inconsistent conceptual definitions and measurements, as 
well as poorly explicated causal propositions (Fishbein et al., 2001; Noar & Zimmerman, 2005; 
Painter, Borba, Hynes, Mays, & Glanz, 2008; Weinstein, 1993, 2007). The absence of these vital 
research activities impede the scientific growth of health behavior research, restricts the 
cumulative body of knowledge created from empirical investigation, and ultimately limits the 
creation of effective health behavior interventions (Noar & Zimmerman, 2005).  
In an attempt to move the science of behavior research forward, key authors of the most 
widely used health behavior theories convened at a National Institute of Mental Health workshop 
to discuss issues regarding redundancy in conceptual definitions, appropriate measurement of 
key constructs, and propositional hypothesis among constructs (Fishbein et al., 2001). The 
Integrative Model of Behavioral Prediction (IM) is the result of these discussions (Fishbein, 
2009).  
The IM posits—that given appropriate awareness, knowledge, and skills, and in the 
absence of significant environmental constraints—behavioral intention, or readiness to act, is the 
mechanism through which attitudes, perceived norms, and perceptions of personal agency affect 
behavior (Fishbein, 2009). The intervening role of behavioral intention was previously 
highlighted in the TRA and TPB, but was absent from the HBM and SCT. As such, the IM 
conceptualizes behavioral intention as the necessary determinant of any given behavior; and, 
when measured on a continuum of the strength of a persons intention, it is thought to encompass 
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the concept of readiness that was previously introduced in stages of change models (DiClemente 
& Prochaska, 1986). Individual health beliefs and perceptions are therefore understood to 
influence behavior indirectly through behavioral intention.  
The strength of behavioral intentions to either perform or abstain from a given health 
behavior are proposed to be a function of (1) attitudes toward performing the behavior, (2) 
perceived normative influence with regard to the behavior, and (3) self-efficacy or perceived 
control over one’s ability to successfully perform the behavior (Fishbein, 2009). These 
propositions are nearly identical to those in the TPB, except that in the IM Fishbein argues that 
the concept of perceived behavioral control is identical to self-efficacy as defined by Afred 
Bandura in the SCT (Fishbein & Ajzen, 2010). As such, these constructs are simply defined as 
personal agency in the IM. Thus, attitudes, perceived norms, and personal agency are theorized 
to account for a substantial amount of the variation in behavioral intentions, though the strengths 
of the relationships are thought to vary across different populations and behavioral domains. 
Identifying the underlying beliefs and cognitive processes of these three psychosocial 
factors are of fundamental importance to designing effective behavioral interventions. As 
explicated in the IM, attitudes, perceived norms, and personal agency result from a process of 
cognitive evaluation of salient beliefs regarding the possible outcomes of a behavior, the 
normative proscriptions, and perceived barriers and/or facilitators. In other words, attitudes are 
formed from an individual’s evaluation of beliefs regarding the outcome expectancies of a 
behavior including the positive and negative results. Therefore, behavioral beliefs are thought to 
encompass the physical, psychological, or social outcome expectancies described in the SCT, as 
well as the perceived benefits and barriers from the HBM. Similarly, normative influences and 
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personal agency are thought to result from cognitive appraisals of injunctive and describe 
normative beliefs as well as efficacy-related beliefs, respectively.  
There are a number of additional constructs labeled as “background influences” in the IM 
that were identified during the NIMH theorist workshop (Fishbein et al., 2001). These include 
socio-demographic factors, knowledge, and other individual difference variables (e.g., perceived 
threat/risk, personality, mood, and emotions). Background influences, such as perceived threat, 
are theorized to indirectly affect intentions and subsequent behavior by contributing to 
underlying mental model regarding a given behavior. This view stands in contrast to the 
propositions explicated in the HBM that conceptualize perceived threat as a direct predictor of 
health behavior. The role of perceived threat, or risk perception more generally, as a direct 
determinant of a given health behavior has also been called into question by other health 
behavior theorists (Leventhal, Kelly, & Leventhal, 1999) and is equivocal in the empirical 
literature (Brewer et al., 2007; Floyd & Prentice-Dunn, 2000; Harrison, Mullen, & Green, 1992). 
However, the importance and causal relationship of perceived threat to health behavior is an 
empirical question and will ultimately be determined through ongoing research.  
The IM is best suited for a study of HPV vaccination in adult men for a number of 
important reasons. First among these is its conceptualization of behavioral intentions as a 
mediating variable that can stand as a proxy measure of vaccine initiation. The IM also 
incorporates key constructs from multiple health behavior theories, which increases its 
explanatory power and reduces issues of multicollinearity involved in multivariate statistical 
analyses. Finally, the IM clearly defines causal propositions including intervening relationships 
that are important for future intervention planning.   
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A theoretical approach to HPV vaccine promotion among male sexual minorities 
 According to the IM, the most proximate determinant of HPV vaccination among young 
gay and bisexual men (YMSM) is a strong behavioral intention to receive the vaccine. Thus, 
behavioral intention is an important outcome measure for HPV vaccination behavioral research 
given that few men—and even fewer YMSM—will have initiated the vaccine series. Therefore, 
intention provides the closest proxy measure of vaccination and allows for better estimates of 
future vaccine uptake in this population.  
 Understanding the factors that contribute to an individual’s intention or readiness to 
receive the HPV vaccine is also necessary in order to effectively communicate and educate the 
public in a way that will increase vaccine uptake. The IM has an advantage over other 
individual-level health behavior theories in that it identifies the most proximal determinates of 
behavior from decades of empirical research covering a variety of health domains and 
incorporates them into a comprehensive model. This not only reduces potential issues of 
multicollinearity among redundant constructs, but it also specifies structural relationships among 
these constructs, that when empirically validated, can help to identify modifiable factors for 
targeted interventions (e.g., specific beliefs about HPV vaccination).  
 According to the propositions present in the IM, in order for gay and bisexual men to 
form strong behavioral intentions toward receiving the HPV vaccine, they first need to (see 
Figure 1): (1) have positive attitudes towards HPV vaccination; (2) perceive that valued and 
respected friends, family, and/or significant others will support and encourage them to receive 
the HPV vaccine; and (3) feel confident in their ability to perform all of the tasks required to 
receive the vaccine (e.g., identify a health care provider who can administer the vaccine, discuss 
the vaccine with a health care provider etc.). Collectively, these three constructs (Attitudes, 
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Perceived Norms, and Personal Agency/Self-efficacy) represent the most proximate determinants 
of behavioral intention to initiate HPV vaccination; however, the strength of the relationships 
between any one of these determents and behavioral intention will vary across populations and 
within populations depending on relevant background characteristics (See Figure 1). For 
example, MSM with stronger links to established gay communities might rely more on 
normative influences than MSM who are isolated from such communities. The objective of 
empirical research is to determine if the target behavior is primarily under attitudinal, normative, 
and/or control influences, which is accomplished by quantifying the explanatory power of each 
construct with respect to behavioral intentions.   
 In addition, the propositional structure of the IM places special emphasis on the 
underlying beliefs, or antecedents, of the most proximate determinants of behavioral intention. 
As indicated by the IM, attitudes are formed through the appraisal of beliefs—or in other words, 
an individual’s evaluation of their beliefs—regarding the perceived outcomes of a given 
behavior. The valance and weight of these beliefs are the indicators of the attitude toward the 
behavior. For example, if a young man believes that the HPV vaccine will help prevent him from 
developing anal cancer later in life, and if he values that outcome, then it is theorized that his 
attitudes toward the HPV vaccine will reflect these beliefs. However, this is but one example of a 
series of possible outcome beliefs that collectively contribute to the formation of attitudes toward 
the HPV vaccine. The same is true for the valances and weights that underlie the formation of 
evaluative beliefs with regard to perceived norms and personal agency. 
Elicitation research is the primary empirical tool used to describe the most salient 
outcome, normative, and agency-related beliefs relevant to the priority population (Middlestadt, 
Bhattacharyya, Rosenbaum, Fishbein, & Shepherd, 1996). Interventions aimed at influencing 
 46 
attitudes, perceived norms, and perceived agency/self-efficacy would therefore attempt to 
influence these salient beliefs. It is this combination of clearly explicated explanatory constructs 
and propositions (i.e., the reasoned action approach emphasizing proximal determinants of 
behavior) with population-specific antecedent beliefs that strengthen the IM as a useful 
theoretical framework for identifying personal determinants of behavior and describing change 
objectives for intervention programs.  
 
 
Figure 1: An integrated theoretical model of HPV vaccine promotion 
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CHAPTER 3: METHODS 
 
 
The long-term goal of this research is to decrease the incidence of anal cancer and other 
HPV-related diseases among MSM by preventing infection of HPV types -6, -11, -16, and -18 
through prophylactic vaccination. The purpose of this research was to understand the factors that 
were important to young MSM when making decisions about HPV vaccination. The Integrative 
Model of Behavioral Prediction (IM) was used as the theoretical framework for this study. The 
following specific aims were addressed: 
1. (a) Describe salient behavioral, normative, efficacy, and control beliefs related to HPV 
vaccination among young MSM; and (b) Determine factors that underlie these beliefs 
2. Identify information needs and trusted sources of information regarding HPV vaccination 
among young MSM 
3. Develop and test a structural equation model guided by the Integrative Model of 
Behavioral Prediction that identifies the psychosocial determinants of young MSM’s 
HPV vaccine intentions 
Mixed-Methods Study Design 
 A multi-phased, mixed-methods, cross-sectional approach was used to comprehensively 
address these aims and to build upon the theoretical and empirical research previously described. 
By combining methods inclusive of both qualitative and quantitative approaches, this research 
was able to provide an in-depth understanding of the beliefs, perceptions, and sociocultural 
factors underlying HPV vaccine decision-making. This approach allowed for the elicitation of 
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salient beliefs surrounding HPV vaccination specifically, but also allowed the flexibility to 
explore broader psychosocial issues that may indirectly impact HPV vaccine related attitudes and 
beliefs. The qualitative methods in this study provided rich descriptions of the theoretical 
constructs and conceptually extended the integrative model to better understand decision-making 
processes regarding HPV vaccination among young MSM. The quantitative methods allowed for 
the systematic testing of the proposed theoretical model and for the identification of those 
psychosocial factors most predictive of HPV vaccine intentions.  
 The overall study design is displayed in Figure 2 and includes specific actions (i.e., 
conducting Phases 1, 2, and 3), inputs/outputs (i.e., the findings), and the products (i.e., how the 
findings were used). The mixed-method design employed in this study followed a three-phase 
sequential approach starting with semi-structured qualitative interviews (Phase 1). Findings from 
these interviews included salient beliefs and background factors that were used to construct the 
measures used in the quantitative survey (Phase 2) and the open-ended survey items used in the 
qualitative survey (Phase 3). Findings from Phase 1 were also used to create a vignette for Phase 
3.  
The quantitative survey (Phase 2) provided a direct test of the theoretical model, while 
the qualitative survey (Phase 3) provided confirmation of the salient beliefs and background 
factors identified in Phase 1 and elicited information regarding sources of HPV-related 
information and vaccination. Phase 3 consisted of a subsample of participants from Phase 2. A 
major strength of this research design is that aims 1 and 3—both providing valuable information 
for health education interventions—are addressed by two distinct methods with two separate 
samples allowing for the triangulation of data and methods.  
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Figure 2: Study design 
 
Priority Population 
The goal of this research is to inform health education interventions that will increase 
HPV vaccine uptake among young adult MSM; however, since the HPV vaccine has only 
recently been approved for males, and the number of young MSM who have actually received 
the HPV is very small (Reiter, McRee, Katz, & Paskett, 2015), it is not possible at this time to 
study vaccine uptake directly. The main outcome of interest for this research is intent to receive 
the HPV vaccine (i.e., vaccine intentions) within the next year, which is theoretically the most 
proximal determinant of future vaccination (Montano & Kasprzyk, 2008). The target population 
for this research was (1) men from 18 to 26 years of age, (2) who reside in the United States, (3) 
are able to read and comprehend English, (4) who have not initiated the HPV vaccine series, and 
(5) who have ever engaged in sexual contact with another male or who identify as gay or 
bisexual. This conceptual population includes both gay identified and non-gay identified MSM 
in order to be inclusive of all those who engage, or may engage at some point, in behaviors that 
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substantially increase the risk of HPV infection. It also focuses on vaccine-eligible adult males 
who do not need parental permission to receive the vaccine. 
 
Phase 1 Methods: Semi-Structured Interviews 
A qualitative descriptive approach was used was used in Phase 1. This approach is less 
interpretive than other qualitative methods (e.g., grounded theory) but offers a comprehensive 
summary of an event or phenomena in everyday terms (Sandelowski, 2000). Individual, semi-
structured interviews were used to elicit perceptions, attitudes, and beliefs regarding HPV 
vaccination, including information regarding trusted sources of health information and preferred 
locations for vaccination. Findings from Phase 1 were used to (1) construct items for the 
quantitative and qualitative surveys, (2) to fully describe an integrated theoretical model of HPV 
vaccine decision-making specific to male sexual minorities, and to (3) inform the creation of a 
vignette used in the open-ended, self-administered survey. The use of multiple methods also 
allowed for the triangulation of data increasing the authenticity and validity of the findings 
(Patton, 1999).  
Sampling and recruitment 
Purposive sampling was used to maximize variation with regard to HPV vaccine attitudes 
and related experiences. Maximum variation sampling is an emergent approach that allows initial 
interviews to guide subsequent sampling strategies rather than predetermining sampling quotas 
by characteristics of the individual (e.g., age or race) (Sandelowski, 1995). This approach was 
accomplished by sampling from diverse venues, organizations, and virtual sites. The principal 
investigator distributed palm cards at community-based organizations that provide services (e.g., 
HIV testing, treatment, social support) for young adult MSM. Student gay pride organizations at 
local colleges and universities were sent information about the study and asked to disseminate 
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this information among their members. In addition to these passive recruitment methods, a direct 
recruitment strategy was employed using publically available social networking mobile phone 
applications. The principal investigator (PI) created profiles on social network applications. 
These profiles contained the PI’s name and affiliation with the University of South Florida. All 
local users of the applications could view the profiles. The PI then randomly selected users by 
viewing their public profiles (filtered by age) and sending users a personalized study invitation 
using the native messaging system.  
A total of 22 interviews were completed before data saturation occurred. For the purpose 
of this study, data saturation was defined as “the point in data collection and analysis when new 
information produces little or no change to the codebook” (Guest, 2006). During the initial 
phases of data analysis, men infected with HIV expressed different perspectives and experiences 
with regard to their health, HPV status specifically, so the last five participants were targeted 
based on self-reported HIV status (an option in the social networking applications).  
Procedure 
Interviews were conducted either in person (n = 14) or on the telephone (n = 8), 
depending on the preference or availability of the participant, and lasted between 20 and 50 
minutes.  The interviews were conducted in private locations that were convenient to the 
participants. Most took place at the University of South Florida. A waiver of documentation of 
informed consent was granted by the USF IRB in order to maintain the confidentiality of 
participants. Participants were asked to complete a brief pre-screening questionnaire that 
collected demographic information. Each interview began with a verbal acknowledgment that the 
participant understood the consent document and agreed to be recorded. Interviews were 
recorded and transcribed (omitting identifiers). 
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Incentive 
 All participants were remunerated in the form of a $25 gift card.  
Instrument 
A semi-structured interview guide was used for the Phase 1 qualitative interviews. The 
interview questions (see Appendix 1) were derived from the IM and were used to elicit the 
beliefs and perceptions that underlie attitudes toward HPV vaccination, perceived norms 
regarding HPV vaccination, and personal agency with regard to HPV vaccination. Standard 
questions for formative research using this theoretical approach were included as appropriate 
(Fishbein & Ajzen, 2010). Additional questions and probes were added as new insights were 
discovered through successive interviews. Content and face validity were established by eliciting 
feedback from experts experienced in health behavior theory and qualitative research. The 
interview questions were also piloted with members from the priority population. Questions were 
assessed according to the degree to which they were appropriate, given the stated aims of the 
project. 
Data analysis 
Descriptive qualitative content analysis was used to summarize the informational content 
of the data (Elo & Kyngäs, 2008). Rather than approaching data analysis without a priori 
theoretical framework, as is common in other types of qualitative analyses (e.g., grounded 
theory), a combination of deductive (or “directed”) and inductive content analytic approaches 
were used (Hsieh & Shannon, 2005). This method provided rich descriptions of the proposed 
theoretical constructs and conceptually extended the IM specifically with regard to the criterion 
specific behavior (i.e., HPV vaccination) and the priority population (i.e., young adult MSM).   
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The directed approach to content analysis is used when an existing theory has demonstrated 
explanatory power with regard to a given phenomena but needs further description and 
specification (Hsieh & Shannon, 2005). This type of formative phase, or elicitation phase, is an 
essential step in the application of the IM for a specific health behavior (Fishbein & Ajzen, 
2010). In the current study, directed content analysis was used to frame and understand the 
experiences and perceptions of the participants—as expressed in the interview text—with regard 
to HPV vaccination. This process was combined with an inductive approach in order to further 
define the theoretical constructs, or main categories, of the IM using the words and expressions 
of the participants.  
All interviews were digitally recorded and transcribed verbatim. Transcripts were 
imported into MAXQDA qualitative data analysis software, which was used for coding and data 
reduction. No identifying information was retained in the transcripts. A five-step process—
largely based on the strategies of deductive and inductive qualitative content analysis outlined by 
Elo and Kyngäs (2008)—was used as the data analytic framework. This included (1) coding the 
transcripts using the main categories from the IM; (2) using in-vivo coding to identify text within 
the main categories that exemplify that category; (3) classifying those in-vivo codes into more 
generic categories as they relate specifically to HPV vaccination; (4) further refining those 
generic categories into more specific and conceptually meaningful sub-categories; (5) and 
assessing the trustworthiness of the findings. An example of this data reduction method is 
presented in Figure 3.   
Trustworthiness 
In qualitative research, issues of validity and reliability are often approached in terms of 
trustworthiness. The trustworthiness of findings from qualitative research centers on issues of 
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credibility, transferability, dependability, and confirmability (Lincoln & Guba, 1985). These 
issues were addressed in the current investigation by (1) employing a multi-method qualitative 
research design that allows for the triangulation of methods and data; (2) maximizing diversity 
among participants through purposive sampling; and (3) utilizing secondary coders to assess the 
consistency of the analytic decisions made by the PI. 
 
 
Figure 3: Example of the coding process 
 
Inter-coder agreement was assessed in three distinct ways. First, after coding three 
randomly selected transcripts, the degree to which the coders used each code in the codebook in 
a given transcript was assessed, and secondly, the percent agreement on the frequency with 
which each code was used to describe the text. A criterion of 80% agreement, as recommended 
by Miles and Huberman (1994), was determined to represent sufficient reliability in the 
application of the main categories. Agreement ranged from 82 to 98 percent across three 
interview transcripts. Thirdly, the application of sub-codes to their representative quotes. Two 
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secondary coders analyzed representative quotes using a revised codebook containing the 
emergent sub-codes (see step 4 of the data analytic framework). These quotes were extracted 
from the text and were determined by the PI to represent the fundamental defining characteristic 
of the sub-category. Inconsistencies in the application of the sub-codes were discussed and the 
codebook was revised. In the revised codebook, codes with overlapping conceptual definitions 
were combined and further refined. A third coder coded the data with the revised codebook and 
the percent agreement was calculated as the proportion of correctly coded text segments. 
Agreement was determined to be sufficient at 84%.  
 
Phase 2 Methods: Quantitative Internet-based Survey 
Overview 
A cross-sectional, close-ended, self-administered, Internet-based survey provided the data 
used to quantify the behavioral intentions of young MSM to receive the HPV vaccine. Direct 
measures of attitudes toward the HPV vaccine, perceived normative influences for vaccination, 
and perceived behavioral control/efficacy in obtaining the vaccine were described, and the 
relationships with vaccine intentions were explored. Furthermore, outcome, normative, efficacy, 
and control beliefs, as well as individual evaluations of these beliefs were investigated in order to 
better understand the modifiable factors underlying the formation of attitudes, perceived norms, 
perceived control, and self-efficacy with regard to HPV vaccination.  
Sampling and recruitment 
Participants were recruited for the quantitative survey using three distinct approaches: (1) 
a snowball sampling of college students affiliated with campus-based LGBT student 
organizations across the Southeast United States; (2) Internet-based recruitment focused on 
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social media; (3) Paid advertisements targeting young MSM using social and sexual networking 
sites/apps.  
A growing number of studies of young MSM demonstrate that Internet-based recruiting 
strategies—particularly those focused on social and sexual networking sites—can successfully 
recruit large diverse samples of sexual minority youth at low cost and in short periods of time 
(Bolding, Davis, Sherr, Hart, & Elford, 2004; Carter, Ding, & Rose, 2011; Parsons, Vial, Starks, 
& Golub, 2012; Ross, Månsson, Daneback, Cooper, & Tikkanen, 2005). Internet-based 
recruitment strategies allow for inclusion of research participants from geographically disparate 
areas and are better able to reach socially isolated individuals or “hidden” populations that may 
not be available otherwise. This offers a great advantage when conducting research with young 
MSM. This is particularly true for those who reside outside of large urban centers without well-
established gay communities where venue-based recruitment strategies are difficult to 
implement. Another advantage to conducting Internet-based recruitment is the flexibility of time 
and resources. Banner advertisements can easily be targeted to specific populations (e.g., age, 
sexual orientation) using user-generated profile information, and can accommodate small 
budgets. Banner advertisements were purchased from two networking websites: a social 
networking site and a sexual networking mobile application. These advertisements were targeted 
to men who meet inclusion criteria for this study based on the information they entered in their 
site-specific user profiles (e.g., age, location, and sexual orientation).  
Procedure 
Participants recruited from Internet-based social networking sites were directed to the 
study website through the banner advertisements. Likewise, after successfully making contact 
with a representative of a LGBT student organization (in most cases this was the organization’s 
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student-elected president), the PI emailed the organization’s representative with information 
describing the study and provided a URL to the study website. They were asked to forward this 
information to their members who meet inclusion criteria. Participants were directed to the study 
website containing informed consent information.  
All participants were asked to give their consent via the electronic form. If they agreed to 
participate and gave their electronic consent, they were directed to the survey hosted on a secure 
server at the University of South Florida. The survey was created using Qualtrics Survey 
Software and took participants an average of 13 minutes to complete. All study procedures and 
instruments were reviewed and approved by the USF IRB. 
Incentive 
 Participants could elect to enter into a drawing for one of ten $25 gift cards from 
Amazon. To enter they provided an email address where the gift card could be sent. This email 
address could not be linked to their survey data.  
Instrument 
A self-administered quantitative survey was developed from the formative elicitation 
research guided by the IM (Phase 1). Self-administered surveys can be given over large 
geographic areas and offer a sense of privacy and anonymity for research participants. Internet-
based surveys are particularly useful for this research population, which is young and can 
reasonably be expected to have high computer literacy.  
It has been demonstrated that Internet-based surveys can increase a participant’s sense of 
anonymity and help to decrease social desirability bias (Rhodes, Bowie, & Hergenrather, 2003). 
Furthermore, the use of Qualtrics Survey Software allowed for the implementation of 
preprogrammed skip patterns and dynamic pages. These features helped to minimize survey 
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fatigue. Internet-based surveys also increase the privacy and confidentiality of participants by 
allowing them to complete the survey in a location and time of their choosing and by encrypting 
responses that are transmitted electronically.  
Measures 
Measures were constructed according to the guidelines specified for the measurement of 
constructs from the IM and from the elicitation research previously described (Phase 1) 
(Fishbein, 2000; Fishbein et al., 2001; Montano & Kasprzyk, 2008). The full survey instrument 
can be found in appendix 2. Direct measures of attitude (A), perceived norms (N), and perceived 
behavioral control (C) were measured according to standard measurement procedures (Fishbein 
& Ajzen, 2010). The expectancy-value framework was used to measure indirect attitudes, norms, 
and behavioral control by creating an index of beliefs weighted by their evaluation. For example, 
a behavioral belief of strength bi (e.g., The HPV vaccine will help me to prevent anal cancer) is 
weighted by a measure of the relevance or importance of that specific outcome ei  (Preventing 
anal cancer is important to me). The cross product of these two variables is the expectancy-value 
score for that specific belief (biei). These scores were summed to represent an index of the salient 
beliefs (6biei). This was done to create separate indexes for behavioral beliefs, normative beliefs, 
and control beliefs. The behavioral, normative, and control beliefs measured in this study were 
identified in Phase 1 qualitative interviews.  
Intentions (INT). Three items were used to measure vaccine intentions (D = .90). They 
assess intention to “find out more information about HPV,” “make an appointment to talk to a 
doctor or health care provider about the HPV vaccine,” and to “get your first HPV shot.” Each 
item specified a timeframe “within the next 12 months.’ Responses were recorded on a 5-point 
bipolar scale (Unlikely-Likely).  
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Attitude (ATT). Attitudes toward HPV vaccination were measured using a 5-point 
semantic differential scale (D = .86) including the following adjectives (1) not worth it—
worthwhile, (2) harmful—beneficial, (3) a bad thing for me—a good thing for me, (4) 
unimportant—important, (5) ineffective—effective. These items followed the statement, 
“Overall, I think that getting the HPV vaccine is….” Higher values represent a more positive 
attitude toward HPV vaccination.  
Perceived norm (Norm). Three items were used to measure perceived norm (D = .70). 
Two items assessed subjective norms: (1) “In general, people who are important to me would 
encourage me to receive the HPV vaccine” and (2) “I can think of at least one person in my life 
who would like for me to get the HPV vaccine.” One item assessed descriptive norms: (3) “Most 
of my gay/bisexual male friends would get the HPV vaccine if it were offered to them free of 
charge.” Responses were recorded on a 5-point bipolar scale (disagree-agree). Higher values 
represent more supportive norms.  
Perceived behavioral control (PBC). Three items were used to measure perceived 
behavioral control (D = .70). This construct is believed to consist of perceptions of self-efficacy 
and controllability (Fishbein & Ajzen, 2010). Thus, one item measured self-efficacy: (1) “I am 
confident that I can get the HPV vaccine in the next 12 months.” Two items were used to 
measure controllability: (2) “There are factors beyond my control that would prevent me from 
getting the HPV vaccine in the next 12 months” and (3) “Getting the HPV vaccine sometime in 
the next 12 months would be…Impossible for me—Possible for me.” Items 1 and 2 were 
recorded on a 5-point bipolar scale (disagree-agree) and item 3 used the 5-point impossible-
possible scale. Higher values indicate higher agency.  
 60 
Behavioral beliefs (BB). Ten behavioral beliefs were measured representing physical 
advantages, psychological advantages, and disadvantages/concerns associated with HPV 
vaccination.  For example, “It would prevent me from getting genital and anal warts,” “Feel like 
there is one less thing to worry about,” and “I would have side effects from the HPV vaccine.” 
Each belief item was followed by an item measuring its corresponding outcome evaluation (e.g., 
“Preventing genital and anal warts is...”). Outcome evaluations were recorded on a 5-point 
bipolar scale (unimportant-important). Belief strength (bi) was recording on a 5-point bipolar 
scale (unlikely-likely). The BB score is equal to biei. These scores were summed to create the BB 
index for physical and psychological advantages (6biei). Higher scores represent a greater 
endorsement of positive behavioral beliefs associated with HPV vaccination. The same 
procedure was used to measure a belief in the side effects of HPV vaccination. In order to avoid 
items with double negatives, the perceived disadvantages (e.g., “not being completely protected” 
and “the vaccine may not work for me”) were only measured by their belief strength (bi). 
Responses to these two items were averaged and labeled as “Low efficacy” (D = .71). A single 
item was used to measure the belief that “I will contract HPV from the vaccine itself.” This 
measure was also assessed using a 5-point bipolar scale (unlikely-likely). In total, 5 behavioral 
belief measures were created: (1) Physical advantages, (2) Psychological advantages, (3) Low 
efficacy, (4) Contract HPV, and (5) Side effects. The physical and psychological advantages 
were combined (D = .90) for structural equation modeling because of their high intercorrelation.  
Normative beliefs (NB). Four referents (mother, father, gay male friends, and straight 
friends) were used to assess normative beliefs. Participants reported on the degree to which each 
referent would be disapproving-approving of him getting the HPV vaccine (ni). Responses were 
recorded on a 5-point bipolar scale. Participants could choose “not applicable” in cases where 
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this person/group was not present. “Not applicable” was recoded to represent the neutral 
midpoint of the scale so that a scale index could be calculated for each participant. Four 
subsequent items were used to measure the degree to which responses were motivated to comply 
with each referent (mi). The question stem read: “When deciding whether or not to get the HPV 
vaccine, would you seriously consider the advice/opinion of…” Responses were recorded on a 5-
point bipolar scale (unlikely-likely). The NB score is equal to nimi. These scores were summed to 
create the NB index (6nimi). Higher scores on this index represent more social influence over 
HPV vaccine decisions.  
Control beliefs (CB). Four control beliefs (ci) were assessed: (1) “I can find out where to 
go to get vaccinated,” (2) “I will have health insurance next year,” (3) “I can find a place to get 
vaccinated where I don’t need to make an appointment,” and (4) “I will get tested for HIV in the 
next 12 months.”  The degree to which these control beliefs would make it “more difficult” or 
“much easier” for respondents to “get the HPV vaccine in the next 12 months” was assessed by 
weighting the control measured on a 5-point bipolar scale (disagree-agree) with a 5-point bipolar 
perceived power scale (pi) (more difficult—much easier).  The CB score is equal to cipi. These 
scores were summed to create the CB index (6nimi). Higher scores on this index represent a 
greater perception of control over behavioral performance.   
Self-efficacy (SE). Two items were used to assess the degree of confidence in getting the 
HPV vaccine in the event that “you had to talk to your doctor or healthcare provider about your 
sexual orientation (e.g., that you are gay or bisexual)” and “your sexual behaviors (e.g., your 
sexual history).” Responses were recorded on a 5-point unipolar scale (not at all confident-
extremely confident).  Reponses were averaged to form a self-efficacy score (D = .90).  
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Perceived threat (Threat). Four indicators of perceived threat—threat of warts on the 
penis or scrotum, anal warts, anal cancer, and HPV infection—were used to construct the latent 
threat variable. The indictor variables were composites created by taking the product of 
perceived susceptibility (e.g., “Without the HPV vaccine, what do you think the likelihood is that 
you will get anal HPV?”) with its corresponding measure of severity (e.g., “How serious would it 
be for you if you became infected with HPV?”). Responses were recorded on 5-point bipolar 
scales (unlikely-likely and not at all serious-extremely serious). Therefore, each composite 
indicator had a theoretical range from 1 to 25 with higher values indicating greater perceptions of 
a likely and serious threat.  A threat scale was created to use in bivariate analyses by averaging 
all four composite scores (D = .96). 
Health information orientation (INFO). Three items were used to assess health 
information orientation, which was defined as degree of motivation an individual has to seek out 
relevant health information and to process that information (Dutta-Bergman, 2009). These items 
were adapted from a previously developed and validated health information orientation scale 
(Dutta-Bergman, 2009). Items were found to represent a single latent factor. The items used in 
the current study were: (1) “When I take medicine, I try to get as much information as possible 
about its benefits and side effects,” (2) “Before making a decision about my health, I find out 
everything I can about the issue,” and (3) “It’s important to be informed about health issues 
affecting gay and bisexual men.” Responses were recorded on a 5-point bipolar scale. A scale 
score was calculated by taking the average of the three items (D = .80). Higher values indicate a 
greater degree of orientation toward relevant health information. 
Suspicion of LGBT cultural competence. Four items were used to assess suspicion of 
LGBT cultural competence, which was defined as having a previously received lower quality 
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healthcare as a result of sexual orientation, expressing discomfort talking to a doctor about 
sexual orientation or sexual behaviors, expressing a preference that a doctor or healthcare 
provider not know one’s sexual orientation, and expressing a belief that sexual orientation is not 
relevant to medical care. Responses were recorded on a 5-point bipolar scale (disagree-agree). A 
scale was created using the average of the three items (D = .71).    
Nebraska Outness Scale-Concealment (NOS-C). The concealment subscale of the 
Nebraska Outness Scale (NOS) was included in the survey with the following item stem: “How 
often do you avoid talking about topics related to or otherwise indicating your sexual orientation 
when interacting with members of these groups (e.g., not talking about your significant other, 
changing your mannerisms)?” This was followed with 5 items: (1) members of your immediate 
family (e.g., parents and siblings), (2) members of your extended family (e.g., aunts, uncles, 
grandparents, cousins), (3) people you socialize with (e.g., friends and acquaintances), (4) people 
at your work/school (e.g., coworkers, supervisors, instructors, students), and (5) strangers (e.g., 
someone you have a casual conversation with in line at the store). Responses were recorded on a 
ratio scale ranging from never (0%) to always (100%). In previous research the NOS-C 
demonstrated good internal reliability, as well as discriminant, convergent and predictive validly 
(Meidlinger & Hope, 2014). Reliability was acceptable in the current study (D = .71). No 
existing research has investigated the factor structure of the NOS ,so it was included as a 
measured variable in the structural equation models.  
Data Analysis 
Data cleaning. A total of 806 respondents met inclusion criteria for age (18-26), sex at 
birth (male), sexual minority status (either self identifying as gay, bisexual, or unsure and/or ever 
having a male sex partner), location (United States), and HPV vaccine history (did not initiate 
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HPV vaccination). A total of 225 (28%) participants exited the survey before completion. Survey 
fatigue is a commonly reported problem in Internet-based surveys and similar, or even 
higher,rates of non-completion have been noted in MSM Internet research (Krakower et al., 
2012). The majority of non-completers withdrew from participation prior to the midpoint of the 
survey. These participants were excluded from analyses. An additional six cases were removed 
because they had more than 20% of missing data. The final analytic sample consisted of 575 
respondents.  
Data quality. Invalid data is an issue to consider in web-based surveys (Bauermeister et 
al., 2012). Automatic validation of survey items—including a mixture of forced and requested 
responses—was implemented in the survey design to minimize falsification and 
misrepresentations. In addition, IP addresses were examined to identify duplicate entries. There 
were no duplicate IP addresses out of the 575 responses in the analytic sample. As an additional 
check, surveys for participants who completed the survey in less than ten minutes (the lowest 
quartile of response time) were examined for repeated patterns (e.g., skipped questions, out-of-
range responses, or inconsistent responses). Based on these criteria all 575 responses appeared 
valid.  
Statistical analyses. The SAS statistical software version 9.1 (SAS Institute, Cary, NC) 
was used to conduct univariate and bivariate analysis. Univariate analyses were conducted on all 
of the scale variables to generate measures of central tendency, distribution, and to evaluate 
distributional assumptions. All of the variables violated assumptions of univariate normality; 
however, the magnitudes of the sample skewness and kurtosis were small, and none surpassed an 
absolute value of 2. It is suggested that values less than two represent acceptable amounts of 
nonnormality (Tabachnick & Fidell, 2007).  The sample size is large enough to assume that the 
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distributional assumptions were met for parametric tests. Non-parametric tests were also 
conducted for each analysis to check for concordance of results (e.g., Spearman rank order 
correlations in place of Pearson product moment correlations).  
Zero-order correlations were calculated to provide a cursory analysis of the relationships 
among the scales. Mplus version 7 (Muthén & Muthén, 2007) was used to conduct Structural 
Equation Modeling (SEM). SEM was used to test and modify the proposed theoretical model of 
HPV vaccine intentions. SEM is useful in developing and testing theoretical models as it allows 
for the simultaneous estimation of the associations among latent and measured variables and 
attempts to remove measurement error from these estimates (Buhi, Goodson, & Neilands, 2007). 
This allows the complete propositional structure of a theory to be tested, including direct and 
indirect effects. Mplus offers a variety of features including advanced statistical methods for 
estimating missing data as well as maximum likelihood estimates that are robust to violations of 
normality (Muthén & Muthén, 2007). The maximum likelihood estimator with robust standard 
errors was used to estimate parameters that are robust to non-normality and allowed for the full 
information maximum likelihood method to handle missing data (Buhi et al., 2007; Buhi, 
Goodson, & Neilands, 2008).   
A two-step approach (Anderson & Gerbing, 1988) was used to build the models starting 
with estimating the measurement model (fit of only the latent factors regressed on the measured 
indicator variables) and then adding the structural paths (i.e., the structural model). Model fit was 
evaluated for all models using the following indices: the chi-square test of goodness-of-fit index, 
the Comparative Fit Index  (CFI), the Standardized Root Mean Square Residual (SRMR), and 
the root mean square error of approximation (RMSEA) (Hu & Bentler, 1999). Aside from the 
chi-square test, which is significantly biased by sample size, goodness of fit indices do not 
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produce asymptotic p-values and are thus not statistical tests of overall model fit. Therefore, the 
interpretation of these indices is less objective. Hu and Benter’s (1999) guidelines were used as a 
basis from which to evaluate model fit in the current investigation; however, absolute cutoff 
criteria were not used as “golden rules” but as general guidelines in combination with a focus on 
theoretical relevance of specified models and model modifications (Marsh, Hau, & Wen, 20004). 
A good fitting model would therefore contain: (1) CFI values close to .95, (2) RMSEA values 
close to .06, (3) SRMR values close to .10, and (4) provide meaningful theoretical results (Hu & 
Bentler, 1999).  
Phase 3 Methods: Open-Ended Qualitative Survey 
An Internet-based, qualitative survey with open-ended response format and pre-
programmed probing questions allowed for the exploration of salient beliefs related to HPV 
vaccination from a large cross-section of young MSM with a greater degree of anonymity than is 
possible with individual interviews. This method has been successfully applied in research on 
stigmatized populations or when studying sensitive issues involving sexuality (Middlestadt et al., 
1996). Given the sensitive nature of the current project, increasing a participant’s sense of 
anonymity may result in unique and unexpected findings. Thus this method was used as a 
supplementary method to the semi-structured interviews (Phase 1).  
Internet-based, qualitative surveys also allow for enhanced design capabilities to increase 
the interactivity and personalization of survey questions tailored for specific respondents. 
Including interactive, probing questions in Internet-based, self-administered surveys is an 
innovative way of improving the quality and depth of responses to open-ended questions 
(Holland & Christian, 2009). A vignette was used to provide context regarding HPV vaccination 
and guide the Internet-based open-ended survey.  
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Vignettes in qualitative research 
Vignettes are short stories or scenarios that provide a context to which responds are asked 
to answer questions (Hughes & Huby, 2002). They can include text, images, and other 
multimedia to provide stimuli and add further interactions. Vignettes are commonly used in 
health research to study attitudes, beliefs, and perceptions regarding sensitive issues (Barter & 
Renold, 2000; Hughes & Huby, 2002). They were employed in the current study to help guide 
participants through a decision-making process regarding HPV vaccination. It was discovered in 
Phase 1 that young MSM had very little context in which to understand HPV vaccination; 
therefore, the vignette was created using finding from those interviews. For example, anogenital 
warts were a key factor in the decisions and circumstances surrounding the few men who had 
already initiated HPV vaccination. In addition, men in Phase 1 had very little working 
knowledge of HPV, and they identified alternative settings to offer HPV vaccination. These 
points were incorporated into the vignette in the following ways: (1) key information about HPV 
was provided; (2) anogenital warts were used to increase perceived threat of HPV infection; and 
(3) alternative settings for vaccination were explored. The vignette can be found in Appendix 3.  
Sampling and recruitment 
A subsample of men from Phase 2 was recruited to complete the Phase 3 open-ended 
surveys. Upon completing the Phase 2 quantitative surveys, participants were asked if they were 
interested in participating in a follow-up study. They provided an email address through 
Qualtrics Survey Software if they wanted to receive more information. All participants who 
provided an email address (n=1,157) were invited to participate in Phase 3. A total of 1,141 of 
those emails were valid. Of the 1,141 delivered emails, 361 (33%) of participants viewed the 
study website and 328 began the survey. Two-hundred and forty one (73%) of the starters 
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completed the survey. Respondents not meeting inclusion criteria (i.e., unvaccinated males 
between the ages of 18 and 26; n = 125) were removed resulting in 116 completed surveys.  
Procedure 
All participants were asked to give their consent via the electronic form. If they agreed to 
participate and gave their electronic consent, they were directed to the survey hosted on a secure 
server at the University of South Florida. The survey was created using Qualtrics Survey 
Software. The survey took an average of 32 minutes to complete. All study procedures and 
instruments were reviewed and approved by research/institutional review board (IRB). 
Incentive 
 Participants could elect to enter into a drawing for one of ten $25.00 gift cards from 
Amazon. To enter they were asked to provide an email address where the gift care could be sent. 
This email address could not be linked to their survey data.  
Instrument  
Participants completed an open-ended questionnaire based on constructs from the IM 
(See Appendix 3). The questionnaire was developed by the PI with feedback and 
recommendations from an expert panel of qualitative researchers.  In addition, feedback from 5 
members of the study population was used to assess the questionnaire for clarity, the wording of 
questions, and interest and identification with the vignette. The survey contained a vignette 
consisting of four main sections: (1) the opening scenario providing HPV information, (2) the 
decision uncertainty scenario in which a decision to get vaccinated or not is being considered, (3) 
the anal warts threat scenario, and (4) deciding on where to go to get vaccinated. Open-ended 
questions followed each of the scenarios.  
 
 69 
Data analysis 
Responses to the open-ended surveys were imported into MAXQDA for analysis. The 
analytical approach from Phase 1 was used in Phase 2 in order to describe responses within the 
IM framework but allow for emerging categories to be explored (See Phase 1 Data Analysis). 
The revised codebook from Phase 1 provided the a priori codes. Responses to each question 
were initially coded using this codebook. New codes were created as necessary. A structural 
coding strategy was also used in order to explore reactions to the specific contexts provided by 
the vignette. Structural coding is a question-based method that serves to index responses to 
specific questions and is often used in the analysis of open-ended survey data (Saldana, 2009). 
For example, responses to the question “What do you thing Brandon should do?” were indexed 
(i.e., coded) according to specific decisions (e.g., “get vaccinated,” “talk to a doctor,” etc.). Data 
were then sorted by decision and analyzed further to uncover more descriptive codes about that 
decision. 
Trustworthiness 
A random selection of responses (10%) to questions from each of the four sections were 
extracted and recoded by the PI and an independent coder with a Ph.D. in Public Health with 
expertise in qualitative research among MSM. Discrepancies were discussed and another random 
selection of responses were extracted and recoded. Agreement was greater than 80%.  
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CHAPTER 4: RESULTS 
 
Overview 
 Results were presented separately based on the three phases of the current study. A 
synthesis of the results, and how the various methods assessed the specific aims and research 
questions, will be provided in the discussion. However, it is useful here to describe the complete 
study sample across the three phases.  
 As part of the study design, the age of participants was restricted to range from 18 to 26 
encompassing vaccine-eligible adult males. The average age was 22 in each phase, and there 
were similar proportions of men in the 18-20, 21-23, and 24-26 age groups. The ethno-racial 
identity of participants varied considerably across the three phases. The proportion of ethno-
racial minorities was highest in Phase 1, reflecting the purposive oversampling of these 
populations. Across all phases approximately three in five were current college students and 
most had health insurance. Overall there were a small number of self-reported HIV-infected 
men, but a large percentage of respondents reported never receiving an HIV antibody test.  
The majority of participants in all three phases self-identified as gay; however, a sizable 
number of men identified as bisexual in Phases 2 and 3. Participants in Phase 3 were a subsample 
of Phase 2 participants; thus, the demographics characteristics of these two phases were similar 
aside from ethno-racial identity. There was a larger proportion of whites who completed Phase 3.  
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Table 2: Descriptive characteristics of participants by study phase 
 
 Phase 1 
(N = 22) 
Phase 2 
(N = 575) 
Phase 3 
(N = 116) 
Characteristic n (%) n (%) n (%) 
Age [Mean (SD)] 22 (2.58) 22 (2.43) 22 (2.11) 
  18-20 8 (36) 167 (29) 25 (22) 
  21-23 6 (27) 217 (38) 43 (37) 
  24-26 8 (36) 191 (33) 33 (28) 
Sexual identity    
  Gay 21 (95) 431 (75) 82 (71) 
  Bisexual 1 (5) 127 (22) 31 (27) 
  Heterosexual -- 2 (0) -- 
  Not sure -- 11 (2) 1 (1) 
  Other -- 5 (1) 2 (2) 
Ethno-racial identitya    
  White 9 (41) 363 (63) 83 (72) 
  African American/Black 5 (23) 121 (21) 9 (7.8) 
  Hispanic/Latino 6 (27) 91 (16) 4 (3.4) 
  Asian 1 (5) 34 (6) 8 (7) 
  Native American -- 11 (2) 1 (1) 
  Pacific Islander -- 2 (0) -- 
  African -- 10 (2) -- 
  Other 1 (5) 16 (3) 11 (9) 
College student      
  Yes 13 (59) 329 (58) 68 (59) 
  No 9 (41) 241 (42) 48 (41) 
Educational attainment    
  Less than high school -- 16 (3) -- 
  High school / GED 5 (23) 100 (17) 14 (12) 
  Some college 11 (50) 254 (44) 44 (38) 
  2-year college degree -- 47 (8) 11 (10) 
  4-year college degree 5 (23) 132 (23) 41 (35) 
  Graduate/Professional degree 1 (5) 23 (4) 6 (5) 
Health insurance    
  Yes 20 (91) 476 (83) 98 (84) 
  No 2 (9) 89 (15) 18 (16) 
  Unsure -- 10 (2) -- 
HIV statusb    
  HIV-Negative -- 383 (67) 76 (66) 
  HIV-Positive 5 (23) 35 (6) 3 (3) 
  Never tested -- 156 (27) 37 (32) 
  Missing 17 (78) 1 (0)  -- 
HPV vaccination    
  Yes 5 (23) -- -- 
  No 17 (78) 528 (92) 112 (97) 
  Not sure -- 47 (8) 4 (3) 
Note. Percentages may not add up to 100 due to rounding.  
a Some participants identified in more than one Ethnoracial category.  
b HIV status was not asked directly in Phase 1. If participants discussed being HIV positive in the interview, they were counted as positive; 
otherwise, they were classified as missing.  
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Phase 1 Results: Semi-Structured Interviews 
 A total of 22 interviews were completed in 2014 with MSM between the ages of 18 and 
26. Characteristics of the study sample are presented in Table 2. Participants were on average 22 
years old, and most were in college (59%) or had some type of post-secondary education. They 
were diverse with nearly 60% identifying as an ethno-racial minority.  Most identified as gay, 
and all had been sexually active with male partners.  
Five of the participants were self-reported to be HIV-positive. HIV-status was not 
addressed systematically in order to determine if HIV-status would emerge during the interviews 
as a salient factor surrounding HPV vaccination. Five participants identified their HIV-status as 
positive, and for each of these HIV-infected participants, HIV infection was central to his 
experience with the healthcare system and his subsequent view on HPV vaccination. The main 
findings from the interviews are presented according to major categories from the IM along with 
the more specific subcategories defined through content analysis. In Table 4, the main categories 
of behavioral, normative, and control/efficacy beliefs are presented along with their generic and 
subcategories. The beliefs expressed in each of these categories are represented by selected 
quotes taken from the interview transcripts. Survey items that were created to measure the salient 
beliefs represented in Table 4 are listed in the last column. Direct quotations are attributed to the 
participants by referencing their individual participant ID numbers (e.g., P01), age, and 
ethnoracial identities.
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Table 3. Salient beliefs, representative quotes, and survey item
s 
M
ain C
ategory 
G
eneric C
ategory 
Sub-C
ategory 
R
epresentative Q
uotes 
Survey Item
s 
B
ehavioral 
beliefs 
  
Physical 
advantages to 
vaccination 
Low
ers 
risk/Prom
otes 
health 
“Y
ou're just healthier and low
ering risks.” (P04, 
21, Latino) 
 “I w
ould be less susceptible to anal cancer at least 
from
 H
PV
.” (P12, 24, Latino) 
 “It w
ould be a safe bet.” (P18, 24, M
ultiracial) 
 “D
o you w
ant to have surgery on your ass? If not 
go get a shot.” (P02, 26, W
hite) 
  
If I got vaccinated for H
PV
 w
ithin the next 
year…
 
 
(1) It w
ould m
ake m
e healthier (B
eing 
healthier is [very im
portant to m
e-
not at all im
portant to m
e] 
(2) It w
ould prevent m
e from
 getting 
genital and anal w
arts 
(3) It w
ould prevent m
e from
 getting 
anal cancer 
 
Psychological 
advantages to 
vaccination 
 
Protects partners 
“Y
ou w
ouldn’t have to w
orry about giving it to 
anyone else.” (P08, 19, B
lack) 
 “I could be spreading it w
ithout even realizing it.” 
(P15, 20, Latino) 
 “I don’t w
ant to spread anything.” (P16, 24, 
W
hite) 
 
If you got vaccinated for H
PV
 w
ithin the 
next year, how
 true are the follow
ing things 
likely to happen for you? W
ould you...? 
(4) B
e less likely to spread H
PV
 to 
your future sex partners?  
 
Peace of m
ind 
“Feel a little better. A
 little m
ore protected.” (P09, 
24, W
hite) 
 “M
ake m
e feel safer.” (P16, 24, W
hite) 
 “It w
ould give m
e one less thing to w
orry about.” 
(P17, 22, B
lack) 
 
(5) Feel protected from
 H
PV
 
(6) Feel like there is one less thing to 
w
orry about 
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Table 3 (C
ontinued) 
 
R
isks of getting 
vaccinated 
 
C
ontract H
PV
 
“T
here is alw
ays a risk that you can contract it 
from
 getting the vaccine...it just depends on how
 it 
interacts w
ith your body.” (P16, 24, W
hite) 
H
ow
 likely do you think the follow
ing 
things are to happen to you if you got 
vaccinated? If I got vaccinated for H
PV
 
w
ithin the next year... 
        (7) I w
ill contract H
PV
 from
 the vaccine 
U
nknow
n 
efficacy 
“N
ot know
ing if it really w
orks, cause you don’t 
know
 if you technically have it.” (P12, 24, Latino) 
 “I w
ould not feel com
pletely protected. In this 
w
orld you can't really ever feel com
pletely 
protected.”(P09, 24, W
hite) 
 “Y
ou still have the possibility that you m
ay get it.” 
(P20, 23, B
lack) 
 
       (8) The vaccine m
ay not w
ork for m
e 
       (9) I w
ould not be com
pletely protected 
from
 future H
PV
 infection 
  
Side effects 
“E
very vaccine has side effects.” (P16, 24, W
hite) 
 “So I believe you’re taking a chance w
ith getting 
any type of vaccine.” (P18, 24, M
ultiracial) 
 “…
if your body rejects it.” (P20, 23, B
lack) 
 
(10) I w
ould have side effects from
 the H
PV
 
vaccine 
N
orm
ative 
beliefs 
 
Supportive 
referents 
 
H
ealth care 
providers as 
referent others 
“M
y doctor w
ould probably be the one...the first 
one to say get it.” (P20, 23, B
lack) 
 
Listed below
 are som
e people in your life 
w
ho m
ay approve or disapprove of you 
getting the H
PV
 vaccine.  
 W
hat do you think their opinions w
ould be? 
If you don't have a relationship w
ith the 
specific person just choose "not applicable." 
1 = V
ery D
isapproving, 3 = N
either 
A
pproving/D
isapproving, 5 = V
ery 
A
pproving 
 (1) Y
our health care provider 
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Table 3 (C
ontinued) 
 
 
Friends as 
referent others 
“T
o be quite honest w
ith you, m
y gay m
ale friends 
are very like touch and go. W
e w
ill m
eet up for 
drinks, have a good tim
e, kiki for a little bit, and 
w
e leave.” (P12, 24, Latino) 
 “I'm
 pretty sure m
ost of them
 are clueless about 
it.” (P04, 21, Latino) 
 “W
ell m
y gay friends, all w
e do is just go out all 
the tim
e. So it’s not really som
ething like w
e talk 
about, you know
.” (P11, 19, Latino) 
 “M
y older gay friend w
hen I m
et w
hen I w
as 18 I 
definitely learned a lot from
 him
. H
e w
as the first 
one that told m
e I should go get H
IV
 tested.” (P04, 
21, Latino) 
 
(2) M
ost of your gay m
ale friends 
(3) Y
our straight friends 
Im
m
ediate fam
ily 
m
em
bers are 
referent others 
“I don't really talk too m
uch to m
y fam
ily.” (P16, 
24, W
hite) 
 “I’m
 a big m
om
m
a’s boy, so I think she w
ould be 
very all-pro for it, too.” (P12, 24, Latino) 
 “M
y father w
ould have had no opinion probably 
and m
y m
other w
ould have probably encouraged 
m
e cause she's in the m
edical field so you w
ould 
have probably encouraged it.” (P01, 21, W
hite) 
 “I guess just telling her that, just a conversation 
you w
anna avoid. L
ike you don’t w
anna tell your 
m
om
 that you’re sexually active, so you feel like 
you need to have this shot.” (P07, 19, W
hite) 
 
(4) Y
our m
other 
(5) Y
our father 
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Table 3 (C
ontinued) 
 
Supportive 
referents 
G
eneral 
acceptance 
“Everyone w
ould be supportive. I can't see anyone 
saying, ‘O
h you shouldn't do that.’ " (P04, 21, 
Latino) 
 “W
hy w
ould anybody disapprove of som
eone 
getting a vaccine.” (P09, 24, W
hite) 
 
(1) I can think of at least one person in m
y 
life w
ho w
ould like for m
e to get the H
PV
 
vaccine. 
    
U
nsupportive 
referents 
Judgm
ent from
 
others 
“Som
e of the friends that I do have in particular 
w
ould probably think that I'm
 just being extrem
ely 
prom
iscuous sleeping around w
ith guys like every 
night and everything.” (P15, 20, Latino) 
 “She'd [his m
other] be upset, ‘oh great now
 he's 
gonna be riskier’.” (P04, 21, Latino) 
 
N
ot m
easured 
D
escriptive norm
s 
K
now
 som
eone 
w
ho got H
PV
 
vaccine 
“I know
 [about H
PV
 vaccine] because m
y sister 
got it.” (P12, 24, Latino) 
 “T
he one nursing student had just gotten it and I 
rem
em
ber I had m
et him
. O
ne m
ale that I knew
, a 
gay m
ale.” (P01, 21, W
hite) 
 “A
nd then there is an H
PV
 shot for w
om
en and for 
m
en, but like every girl in m
y high school had it.” 
(P04, 21, Latino) 
 
(1) D
o you personally know
 som
eone w
ho 
has gotten the H
PV
 vaccine?  
 
C
ontrol beliefs 
 
External control 
factors 
 
A
vailability 
“B
ut I think a lot of it is getting the know
ledge 
and inform
ation and know
ing w
here to get the 
test.” (P16, 24, W
hite) 
 “If it w
as available on cam
pus.” (P06, 21, W
hite) 
W
hat w
ould m
ake it easier for you to get the 
H
PV
 V
accine? It w
ould m
ake it 
____________to get the H
PV
 vaccine in the 
next 12 m
onths... 
1 = m
ore difficult to 5 = m
uch easier for m
e  
 (1) If I could quickly find out w
here to get 
vaccinated 
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ontinued) 
 
 
C
ost 
“M
y insurance paid for it. H
ad I had to pay for it I 
probably w
ould have been like...nah.” (P14, 26, 
B
lack) 
  “It w
ould be a barrier depending on the cost.  I am
 
a poor graduate college student.  I'm
 having 
trouble paying for school let alone a vaccine.” 
(P12, 24, Latino) 
 “M
oney is a big issue!” (P06, 21, W
hite) 
 
(2) If m
y health insurance covered the 
vaccine 
 
C
onvenience 
“I w
ould rather go to M
etro W
ellness. E
specially 
if...M
aybe if I w
on't like rush to get the vaccine. 
I’d probably w
ait m
aybe until m
y next H
IV
 test.” 
(P17, 22, B
lack) 
 “A
nd the location of the place. T
he tim
e of the day 
I can get it.” (P17, 22, B
lack) 
  
(3) If I could get it w
ithout m
aking an 
appointm
ent 
 (4) If I could get it w
hen I get tested for H
IV
 
Efficacy beliefs 
Internal control 
factors 
Feeling 
uncom
fortable 
disclosing 
“I just feel w
eird talking to som
eone like that 
about those kind of things.” (P03, 19, A
sian) 
 “E
ven w
hen I first cam
e out, they [health care 
providers] w
ould ask m
e that [sexual behavior] 
and I lied. So I kind of w
asn’t out. I knew
 I w
as, 
and I knew
 I w
as doing things, but I…
at first I w
as 
very uncom
fortable, so I kind of alm
ost didn’t 
accept it, so I didn’t say anything.” (P12, 24, 
Latino) 
 “I'd be very selective on answ
ering questions. 
B
ecause a lot of people aren't open...like they w
ill 
ask the question but they are not ready to receive 
the answ
er.” (P20, 23, B
lack) 
(1) H
ow
 confident are you in your ability to 
get the H
PV
 vaccine if you had to talk to 
your doctor or healthcare provider about 
your sexual behaviors (e.g., your sexual 
history)? 
 (2) H
ow
 confident are you in your ability to 
get the H
PV
 vaccine if you had to talk to 
your doctor or healthcare provider about 
your sexual orientation (e.g., that you are 
gay or bisexual)? 
 `
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Behavioral beliefs 
Physical advantages to vaccination 
 When asked to describe the “advantages” or “good things” about getting the HPV 
vaccine, most participants talked about the physical benefits to vaccination. They described how 
their personal risks would be lower and that they would be doing something to promote their 
health. For instance, one participant—after reading a brief fact sheet about HPV (See Appendix 
4)—endorsed the belief that he would be “less susceptible to anal cancer at least from HPV” 
(P12, 24, Latino). Others talked about how it would “be a safe bet” and that taking steps to 
protect the “anus” was “important.” Overall, few gave specific details about preventing genital 
warts or anal cancer, instead relying on general statements about how vaccination “lowers risk” 
and promotes “immunity.” This seemed to reflect their limited knowledge about HPV and HPV 
vaccination.  
 For some participants, their perceptions about the health benefits of HPV vaccination 
were clearly influenced by their prior health issues/concerns. One man who described his 
experience with reoccurring anal warts and their surgical excision stated, “…if it [HPV 
vaccination] can prevent you from going through what I’ve gone through, it’s well worth it” 
(P02, 26, White).  Another man, who had experienced reoccurring anal warts, mentioned that he 
wished he had received it [the HPV vaccine] before and inquired if the vaccine would prevent 
him from “contracting different strains” (P21, 26, White). One participant reflected on his own 
family history of cancer and how getting vaccinated would help minimize some of this risk. 
Overall there was a positive attitude toward getting vaccinated, primarily resulting from 
perceived health advantages.  
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Psychological advantages to vaccination 
 In addition to the perceived physical health benefits of getting the HPV vaccine, many 
participants talked about psychological advantages, including protecting future sex partners and 
giving them “peace of mind.” One participant mentioned that he “wouldn’t have to worry about 
giving it to anyone else” expressing a general concern about spreading STIs. The focus of these 
statements was clearly on the infection itself and not on HPV-related disease. When informed 
that the majority of sexually active people will become infected with HPV at some point, and 
that the majority of those infections will clear without any symptoms of disease, one participant 
responded: “It doesn’t matter. It’s still an STD. You’re still tainted” (P09, 24, White).  
 Others talked about feeling “safer,” “feeling better,” and having “one less thing to worry 
about.” The following statement highlights the general focus on wellbeing and the importance of 
feeling that they have taken steps to protect their health: 
Knowing if I’m infected or not, you know, that would be concerning. But the fact of 
knowing, “Ok, well I don’t know, but I’m taking steps in case I’m not,” that would put 
my mind at ease (P12, 24, Latino). 
Again this statement expresses a general concern about being “infected,” with prevention of 
HPV-related disease as a secondary concern.  
Risks of getting vaccinated 
 When asked about the “disadvantages” or “bad things” associated with getting vaccinated 
for HPV, respondents reported minimal concerns over side effects. Responses to this question 
tended to focus on the side effects generally associated with any vaccine or medication. For 
instance, participants mentioned that “every vaccine has side effects,” (P16, 24, White) and that 
people are “taking a chance with getting any type of vaccine” (P18, 24, Multiracial).  There was 
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also an ambiguous concern of the body “rejecting” the vaccine. The importance or value placed 
on these concerns was minimal. In fact, many of the comments about side effects where phrased 
in ways that minimize the concerns. For instance, one participant said, “There’s side effects for 
everything, so that’s not a big worry on my plate” (P06, 21, White). Others mentioned that they 
have not heard anything risky about the HPV vaccine and explicitly stated, “I know there’s anti-
vaccine views out there, and I don’t agree with those” (P03, 19, Asian).   
 For the most part, concerns about the vaccine reflected doubts about its efficacy. Given 
that they were all sexually active and that there is no way to test if they had been previously 
exposed to HPV, they were unsure if vaccination would confer any direct benefits. Some stated 
that they would “not feel completely protected” (P09, 24, White) or that they “still have the 
possibility” (P20, 23, Black) of getting infected. This concern seemed to reflect the larger public 
health focus on vaccinating young children.  
 A few participants asked whether the HPV vaccine was a “live virus” and one expressed 
a concern about contracting HPV from the vaccine itself. One participant made explicit mention 
of this: “There is always a risk that you can contract it from getting the vaccine…it just depends 
on how it interacts with your body”(P16, 24, White).  
Normative beliefs 
Supportive referents 
 When asked what individuals or groups would approve of their decision to get the HPV 
vaccine, the majority of participants expressed a very clear sentiment that this would not be a 
decision that they would widely discuss with anyone prior to getting vaccinated. Some 
mentioned that their “doctor would probably be the one” (P20, 23, Black) or that their doctor’s 
opinion was the “only opinion that mattered” (P18, 24, Multiracial) regarding this issue.  Probes 
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about the support of friends or family were countered with general statements about their 
expected approval or statements diminishing the influence of these individuals. One participant 
stated, “I’m pretty sure most of them [his friends] are clueless about it” (P04, 21, Latino). This 
same participant, along with one other, identified an older gay friend as a potential source of 
health information. He stated that his older friend told him the “HPV shot came out a few months 
ago” and that he “really should get it.” This recommendation was influential in his decision to 
get vaccinated. In general, similarly aged peers were not considered valuable sources of 
informational or emotional support regarding HPV vaccination.  
 Perceived support from family members was even more ambiguous. Some respondents 
generally accepted that their family would be supportive but it’s not something they would 
discuss with them unless there was a specific reason (e.g., parent was a medical professional).  
Others rejected the idea, explaining that they didn’t talk to or were alienated from their families. 
 Overall the men in this sample described general perceived support for HPV vaccination 
among their friends, family and medical providers; however, these referents—aside from health 
care providers—were not deemed to be valuable in their decision-making process.  
Unsupportive referents 
 There was not a strong sentiment about unsupportive friends or family, but some 
participants talked about anticipated negative responses from family, and friends. In particular, 
they expressed a concern that—because HPV is an STI—their mothers would assume they 
wanted to get vaccine so they can “be a whore” or be “riskier.” One participant talked about 
potential judgment from his straight friends who might assume he needed the vaccine because he 
was “being extremely promiscuous” (P15, 20, Latino). When probed about these concerns, all of 
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the participants stated that despite these potential negative assumptions, their friends and family 
would still support their decision to get vaccinated.  
Descriptive norms 
 No questions in the interview guided asked directly about descriptive norms but knowing 
someone personally who has gotten the HPV vaccine came up often in conversations about HPV 
knowledge.  Participants were asked how they first heard about HPV (if they had) and the most 
commonly mentioned source of HPV information was from female friends or family (i.e., sisters) 
who had gotten vaccinated. Only one participant knew of another gay male who had received the 
vaccine. In general, the overwhelming perception “about people who receive the HPV vaccine” 
is that they are female.  
Control and efficacy beliefs 
External control factors 
 Participants were asked what factors or circumstances would “help you” or “make it 
easier” to get vaccinated. Their responses centered around three primary reasons including 
availability, cost, and convenience. Many participants expressed uncertainty about where to go to 
get vaccinated. In general, participants did not see a primary care provider for regular physicals 
or checkups apart from HIV testing. They tended not to have established relationships with 
specific providers who they could ask about HPV vaccination. Therefore knowing where the 
vaccine was available would make it easier for them to access it. 
Convenience was also mentioned on multiple occasions. Participants mentioned clinics 
they know of close to their homes or places of employment where they would prefer to be 
vaccinated. Flexibility was highly valued in terms of where and when they could get vaccinated. 
For students, getting vaccinated on campus was mostly preferred. Walk-in availability was also a 
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noted facilitator. Overall participants seemed open about where to get the vaccine as long as it fit 
into their schedule. This sample of men received regular HIV testing which was identified as 
convenient time to get vaccinated. One participated stated: “I would rather go to metro wellness 
[a local HIV testing location]. Especially if…maybe if I won’t like rush to get the vaccine. I’d 
probably wait maybe until my next HIV test” (P17, 22, Black). Subsequent participants were 
probed on this issue and most of them were amenable to getting vaccinated at their HIV testing 
location.  
 By far the most significant external control factor was cost. There was a general sense 
that vaccines are expensive, and participants expressed concerns that they could not afford it. 
Although the majority of participants had health insurance, many were unsure if the vaccine 
would be covered. In all five cases where participants were already vaccinated, they had 
insurance coverage and explicitly stated that they would not have been vaccinated if they had to 
pay the out-of-pocket costs.  
Internal control factors 
 After participants were asked general question about control beliefs, they were probed 
regarding their perceived self-efficacy in getting the HPV vaccine if they had to discuss aspects 
of their sexuality (i.e., sexual behaviors and/or identity). For some participants, this presented no 
issue at all and they described themselves as having high self-efficacy to ask for the HPV 
vaccine even if they had to discuss issues of sexuality. However, other participants expressed 
feeling uncomfortable disclosing their sexuality to healthcare providers. One participant stated, 
“I just feel weird talking to someone like that about those kind of things” (P03, 19, Asian) Others 
said they would feel “uncomfortable” and would be “very selective” about answering questions 
regarding their sexual behavior.  
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Background factors 
 Background factors were explored through general questions about health, healthcare 
experiences, sexuality, and HPV. Through these open-ended discussions the PI gained a nuanced 
understanding of potential background factors that underlie HPV-related beliefs and 
subsequently, HPV-vaccination. A series of generic categories and sub-categories were identified 
that represent these factors and allowed for the extension of the IM to included propositions 
regarding the ways in which these factors might influence HPV vaccine decision-making among 
young MSM. This extended framework is depicted in Figure 4 and described in detail below.    
 
Figure 4: Extended Integrative Model of HPV vaccine decision-making among young male 
sexual minorities 
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Table 4: B
ackground factors im
portant to H
PV
 vaccination am
ong young M
SM
 
 M
ain C
ategory 
G
eneric C
ategory 
Sub-C
ategory 
R
epresentative Q
uotes 
Survey Item
s 
B
ackground 
Factors 
 
H
PV
 K
now
ledge 
and Inform
ation 
 
R
eaction to H
PV
 
inform
ation 
Interviewer: W
hat are your initial reactions about 
the vaccine after hearing this inform
ation? 
 “O
ther than w
hat are the side effects and w
here 
the hell can I get this thing as fast as possible.” 
(P12, 24, Latino) 
 “I w
ould definitely w
ant to go get it, like right 
now
!” (P11, 19, Latino) 
 “Ironically I have a doctor appointm
ent next 
Thursday so I'm
 gonna ask him
 about.” (P20, 23, 
B
lack) 
 
Inform
ation-O
rientation Scale 
 (1) W
hen I take m
edicine, I try to get as 
m
uch inform
ation as possible about its 
benefits and side effects 
 
 (2) B
efore m
aking a decision about m
y 
health, I find out everything I can about the 
issue 
 
 (3) It’s im
portant to m
e to be inform
ed about 
health issues affecting gay and bisexual 
m
en 
 
 (A
dapted from
 D
utta-B
eggm
an, 2009) 
 
Inform
ation 
needs 
Interviewer: W
hat m
ore inform
ation do you need 
about this vaccine before you think you can m
ake 
a decision?  
 “Just think little fact sheet right here kind of 
like...a w
ake up call to say like hey m
aybe it's tim
e 
for ya’ll to get tested for these diseases to get 
vaccine for it. I m
ean you know
...like I said that 
little sm
all fact sheet told so m
uch. It told w
hat it 
is…
w
ho can get it…
w
hat it can cause. G
iven all 
the inform
ation you need.” (P20, 23, B
lack) 
 “I’d be interested in know
ing w
hether the vaccine 
w
ould actually kind of prevent m
e from
 
contracting different strains.” (P21, 26, W
hite) 
 “Is it still as effective as you go up in age?” (P15, 
20, Latino) 
 “It's passed by skin-to-skin contact. Even using 
protection doesn't protect you? W
hat kind of skin 
to skin contact?” (P17, 22, B
lack) 
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Perceived threat 
H
PV
-related 
susceptibility 
“T
o be honest w
ith you I really don't think I have 
it you know
 because I've been tested and I don't 
know
 w
hat tests I w
as being tested for but I know
 
I w
as getting tested for everything.” (P12, 24, 
Latino) 
 “W
ell I w
as already infected w
ith H
PV
 at one 
point. N
ot genital w
arts but a different type of 
H
PV
. I didn't really feel like I w
as m
uch at risk. I 
had m
ore than one boyfriend that had genital 
w
arts. N
ot at the tim
e I w
as dating them
 but...and I 
never caught any of that stuff so I w
as really 
happy that I didn't and I guess I really didn't feel 
threatened by like genital w
arts.” (P18, 24, 
M
ultiracial) 
  “W
ell the fact that it only takes one sexual partner 
that autom
atically puts you at a 10 I think.  D
o I 
w
ant to w
ater it dow
n and say m
aybe six or seven 
just to m
ake m
yself feel better?...then yeah. It only 
takes one.” (P15, 20, Latino) 
 “I don't really have a partner and I don't sleep 
around a lot. I thought it w
as pretty low
 but it only 
takes one tim
e for you to get it so...” (P14, 26, 
B
lack) 
 “M
oderate because I’ve been w
ith m
en w
ho are 
older than m
e, no m
ore than like ten years though, 
older than m
e, but um
m
 I don’t know
. L
ike if 
they’ve really done like w
hat they’ve done, 
com
pared to w
hat I’ve done.” (P07, 19, W
hite) 
 
Please indicate on a scale of 1 to 5 how
 
serious you feel the follow
ing events w
ould 
be for you. 
(1) If you becam
e infected w
ith H
PV
 
(2) If you developed w
arts on or inside your 
anus 
(3) If you developed w
arts on your penis or 
scrotum
 
(3) If you developed anal cancer 
 W
ithout getting the H
PV
 vaccine, w
hat do 
you think the chances are that you w
ill... 
(1) G
et H
PV
 
(2) G
et w
arts on your penis or scrotum
 
(3) G
et anal w
arts 
(4) G
et anal cancer 
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H
PV
-related 
severity 
“N
obody w
ants cancer so it’s scary that how
 a 
virus can go undetected of sym
ptom
s and it causes 
these things…
” (P03, 19, A
sian) 
 “A
nd I w
as surprised that m
ost m
en w
ho get it 
never develop any sym
ptom
s. T
hat’s startling.” 
(P03, 19, A
sian) 
 “W
ell it’s just, that’s scary. Y
ou know
, you just 
don’t know
 if you have it or not.” (P11, 19, 
Latino) 
 “O
h m
y G
od it has no sym
ptom
s! So how
 do you 
know
 if you got it?!” (P12, 24, Latino) 
 “It’s kind of crazy, it stands out too, that, you 
know
, m
ost m
en w
ho get H
PV
 never develop 
sym
ptom
s or health problem
s. So it’s kind of like 
just like a sitting virus kind of thing inside of 
you.” (P12, 24, Latino) 
 “…
you could be carrying som
ething that you 
technically don’t know
 you have, and you could 
have sex w
ith like som
ebody w
ho you’ve been 
together for a long tim
e and incidentally pass it on 
to them
. Y
ou know
 w
hat I m
ean? So that’s kind of 
alarm
ing.” (P12, 24, Latino) 
 
 
A
nogenital w
arts 
H
ad anogenital 
w
arts 
“H
e had anal w
arts. H
e had set up an appointm
ent 
w
ith a doctor to had his rem
oved so after he had 
his rem
oved I noticed the first one for m
e.” (P21, 
26, W
hite) 
 “H
PV
 can com
e in m
any different form
s actually. 
M
ost com
m
on w
ould be in genital w
arts. That's 
personally w
hat I have. W
ell I guess I don't have it 
cause I've had it rem
oved, but it still in m
y 
system
.” (P02, 26, W
hite) 
 
Personal experience w
ith anogenital w
arts 
 (1) H
as a health care provider ever told you 
that you had hum
an papillom
avirus or H
PV
? 
 (2) H
as a health care provider ever told you 
that you had genital or anal w
arts? 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K
now
 som
eone 
w
ho had 
anogenital w
arts 
“I believe I w
as talking about m
y friend w
ho had 
genital w
arts but I’m
 not sure. I w
ant to say I 
probably said I heard there is som
e sort of vaccine 
and then I'm
 sure she talked about it from
 there. I 
don't rem
em
ber exactly.” (P01, 21, W
hite) 
 “N
o the guy that I w
as dating at the tim
e. H
e 
actually had w
arts at the tim
e and so w
e thought 
w
e w
ere being really careful to keep m
e from
 
contracting it but w
e w
eren't very successful, 
obviously...w
e had one sexual encounter before he 
told m
e and I think for him
 he thought that 
condom
 use w
ould protect m
e against it, w
hich 
isn't actually the case.” (P21, 26, W
hite) 
 
(1) To the best of your know
ledge, do you 
personally know
 som
eone w
ho has had 
genital or anal w
arts (other than yourself)? 
 (2) To the best of your know
ledge, do you 
personally know
 som
eone w
ho has had H
PV
 
(other than yourself)? 
  
N
egative em
otions 
surrounding 
disclosure 
Felt judged by 
H
C
P 
“I just think that, in general, fem
ales don’t judge 
as m
uch, I guess you could say w
ith gay m
en. 
U
m
m
, I alw
ays think it’s aw
kw
ard to go in and 
tell like a heterosexual m
ale that I’m
 different than 
w
hat he is. I like to have sex w
ith guys and anal 
sex, and stuff like that, that is a difficult 
conversation to have w
ith a hetero-even if they’re 
com
pletely and fully understanding of it, to m
e it’s 
still em
barrassing. A
nd I can relate m
ore and I’m
 
probably m
ore w
illing to give inform
ation to a 
fem
ale than a m
ale.” (P12, 24, Latino) 
 “I feel like he [his prim
ary care physician] judges 
m
e. I feel like if I had a provider or som
ebody 
w
ho is a little m
ore open-m
inded... m
y doctor is a 
staunch R
epublican, w
hite dude w
ho is like 65 and 
I'm
 sitting there like a gay little Puerto R
ican kid, 
and you know
, it is just alw
ays aw
kw
ard w
hen I 
go to m
y doctor. W
e com
e from
 opposite ends of 
the earth.” (P12, 24, Latino) 
  
Suspicion of healthcare providers 
 (1) I have received low
er quality healthcare 
services as a result of m
y sexual 
orientation 
 
 (2) I prefer that m
y doctor or healthcare 
provider does not know
 that I am
 
gay/bisexual 
 
 (3) I feel uncom
fortable talking about m
y 
sexual orientation or sexual behaviors w
ith a 
doctor or healthcare provider 
 
 (4) There is no reason w
hy m
y doctor or 
healthcare provider w
ould need to know
 that 
I have sex w
ith m
en 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“I'm
 not a real big person on discussing 
orientation because usually if you discuss 
orientation w
ith people they tend to start shoving 
you aw
ay. There is not doubt in m
y m
ind he [his 
prim
ary care physician] knew
 but he learned to 
like form
 a relationship w
ith m
e and m
y fam
ily 
before he started judging m
e” (P20, 23, Black) 
 “I’m
 very uncom
fortable receiving, especially 
specialty like…
w
hen I w
ent to go see like um
m
, a 
gastroenterologist about issues, w
hen he w
as 
straight. I felt like they w
ere judging m
e, I felt like 
I w
as very singled out, I felt like they assum
ed 
that it w
as cause I w
as gay, that’s the first 
question they asked, like w
hen I w
as having issues 
w
ith m
y colon and everything, they w
ere like 
w
hat’s your orientation…
 I alm
ost didn’t w
ant to 
tell them
, because I w
anted them
 to treat m
e as if 
I w
as a straight person and not have those 
preconceived notions in their head.” (P06, 21, 
W
hite) 
N
ebraska O
utness Scale- Concealm
ent 
How
 often do you avoid talking about topics 
related to or otherw
ise indicating your 
sexual orientation w
hen interacting w
ith 
m
em
bers of these groups (e.g., not talking 
about your significant other, changing your 
m
annerism
s)? 
(1) M
em
bers of your im
m
ediate fam
ily (e.g., 
parents and siblings) 
(2) M
em
bers of your extended fam
ily (e.g., 
aunts, uncles, grandparents, cousins) (2) 
(3) People you socialize w
ith (e.g., friends 
and acquaintances) (3) 
(4) People at your w
ork/school (e.g., 
cow
orkers, supervisors, instructors, 
students)  
(5) Strangers (e.g., som
eone you have a 
casual conversation w
ith in line at the store) 
 
LG
B
T C
ultural 
C
om
petence 
 
Lacks know
ledge 
about gay health 
issues 
“A
 gay provider w
ould be m
ore into or up-to-date 
w
ith new
er things that are com
ing out. Especially 
like w
ith the threats that are m
ore for the gay 
lifestyle. B
ecause I really don't think that m
y 
health provider w
ould know
 about H
PV
.” (P12, 
24, Latino) 
 
 
B
ias tow
ard 
LG
B
T
 
“I w
ould just feel w
eird talking to som
eone about 
that [H
PV
 vaccine], and I w
ould not know
 their 
view
s on LG
B
T people. So I feel like there m
ay 
be som
e bias in the inform
ation that they could 
give m
e. E
ven though it’s unprofessional.” (P03, 
19, A
sian)  
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M
anagem
ent of 
disclosure 
A
nonym
ity 
“A
nd typically that is w
here I go [Public H
ealth 
D
epartm
ent]. I guess until recent w
here I can go to 
this care center thing. B
ut I don't like that because 
it doesn't really give the anonym
ity that the health 
departm
ent does…
it is a lot better than going to 
m
y em
ployer health clinic w
here I am
 sitting in a 
w
aiting room
 full of people. It's different for m
e 
because I feel like m
y health care provider...I 
understand there is H
IPA
 and all that stuff and 
they are suppose to keep m
y stuff confidential. 
B
ut I live in a pretty sm
all tow
n and I know
 how
 
that stuff w
orks. So I'd rather not. I go to the 
health departm
ent and every tim
e I go it is 
som
ebody different. It never gets personal. I've 
never built rapport w
ith them
.” (P12, 24, Latino) 
 
 
N
ot relevant 
“I don't think it is any of their [health care 
provider] business really [his sexual behavior], but 
I w
ould've answ
ered truthfully. W
ait, w
ould I 
have answ
ered truthfully? I think I w
ould have. 
…
if you are having sex you are having sex. Y
ou 
are being exposed to these diseases w
hen you're 
having sex. It’s a fact of life...like...w
hatever.  It is 
just like..it is none of your business w
ho I am
 
having sex w
ith. There is the w
hole stigm
a about 
being gay that w
e are prom
iscuous people w
e just 
go around having sex w
ith every guy w
e see and 
therefore are at higher risk that you 
know
…
straight guys do that all the tim
e too.” 
(P15, 20, Latino) 
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HPV knowledge and information 
 Nearly all of the participants had heard of HPV and typically described it as a sexually 
transmitted infection that has multiple “strains” and mostly affects women. The majority (55%) 
mentioned a vaccine, though most were not aware that males could be vaccinated. 
Approximately 41% (n = 9) of men listed genital warts as a distinctive characteristic of HPV 
infection and 36% (n = 8) cancer. When cancer was mentioned it was usually limited to a generic 
explanation (e.g., “life threatening diseases like cancer”) or an explicit mention of cervical 
cancer. No participant mentioned anal, oral, or penile cancer (not even the 5 vaccinated men).  
The main sources of HPV-related information came mostly from female friends, formal sex 
education classes, and Gardasil advertisements. One participant recalled: 
I know that there is a vaccine.  I feel like there is the stupid commercial, well it's not 
stupid it's informative. It was like…primarily for girls but now they are doing it for guys 
as well…the HPV vaccine. (P15, 20, Latino) 
After providing basic information about HPV and HPV-vaccination for males (see 
Appendix 4), participants were asked: “What are your initial reactions about the vaccine after 
hearing this information?” Some of the men expressed a high level of interest and enthusiasm for 
getting vaccinated: “…what are the side effects and where the hell can I get this thing as fast as 
possible” (P12, 24, Latino)! Others expressed intention to speak with their doctors about the 
vaccine in the near future.  
To probe more about their information needs, they were asked: “What is the minimal 
amount of information you need about this vaccine before you think you can make a decision?” 
Some of the men asked basic questions about HPV or the vaccine. These questions typically 
related to: (1) the effectiveness of the vaccine in older males, in males who have already been 
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sexually active, or in males who have already been exposed to HPV; (2) the side effects 
associated with getting vaccinated; and (3) the types of sexual behaviors that spread HPV. 
Telling them that HPV can be transmitted from “skin-to-skin” contact was too ambitious and 
usually prompted more questions about specific behaviors.  Despite these inquires during the 
interviews, collectively this sample of men exhibited a high degree of acceptability and 
willingness to initiate HPV vaccination.  
Perceived threat of HPV infection and disease 
 Perceptions regarding susceptibility to HPV infection were mixed. Some men described 
their risk as high considering that it “only takes one sexual partner” (P15, 20, Latino). Others 
reflected on their sexual histories and relationship status. One participant responded that it was 
hard for him to assess his risk because he was with his “boyfriend-partner, for almost four years” 
and that they “rarely” have other sexual partners (P12, 24, Latino). It was common for 
respondents to discuss their own risk in general terms like “I always use protection to keep 
myself healthy” (P01, 21, White) or “I don’t sleep around a lot” (P14, 26, Black). After reading 
the fact sheet one respondent stated, “I don't really think that most people are going to have 
HPV. I mean…maybe gay men who don't practice safe sex” (P09, 24, White). Overall 
participants seemed unsure on how to respond to questions about their susceptibility to HPV. 
When asked to rate their risk of having been exposed on a scale of 1 to 10 (with 10 being the 
highest risk), most of them indicated that they were at average risk (between 4 and 6). There was 
also a tendency to focus on anal sex as the only risk behavior.  
 When informed that HPV can cause anal cancer and that MSM are at a higher risk of anal 
cancer, most of the respondents described their reaction in emotional terms. They used words 
like “surprising,” “sad,” “concerning,” “scary,” and “shocking.” There was also a strong 
 93 
tendency to describe the infection itself—even in the absence of disease—as distressing. In fact, 
the absence of symptoms in most cases of infection was commonly noted as concern. One 
respondent expressed fear saying “Well it’s just, that’s scary. You know…you just don’t know if 
you have it or not” (P11, 19, Latino). Some of this worry was expressed as concern for 
“spreading” HPV to their sex partners or as discomfort with the idea of a “sitting virus kind of 
thing inside of you” that may cause future disease.  
Anogenital warts 
 Personal experience with anogenital warts—either having had anogenital warts or having 
had a sexual partner with anogenital warts—was closely tied to some of the participants’ 
attitudes and beliefs surrounding HPV and HPV vaccination. Four out of the five participants 
who had received HPV vaccine described anogenital warts as a primary reason for getting the 
vaccine. In each of these cases, the men, or their sex partner at the time, were being treated for 
anogenital warts when a doctor recommended vaccination.  
Sexuality and the patient-provider relationship 
The majority of the young men in this sample had previous experience talking about their 
sexual behaviors in a health care setting—mostly while receiving STI testing. In almost all cases, 
the healthcare provider asked them questions about their sexual behaviors. In some cases these 
interactions were described as negative, affecting their expectations surrounding disclosure, their 
confidence in their healthcare providers, as well as the ways in which they managed disclosure in 
future interactions.  
Negative emotions surrounding disclosure 
Feeling ashamed, awkward, and judged were some of the emotions associated with 
discussing sexual behaviors with a healthcare provider. These feelings stemmed in part from the 
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degree to which they felt their provider was comfortable with them. One participant captured this 
sentiment in his comments about his primary care physician: 
I feel like he judges me. I feel like if I had a provider or somebody who is a little more 
open-minded... my doctor is a staunch Republican, white dude who is like 65 and I'm 
sitting there like a gay little Puerto Rican kid, and you know, it is just always awkward 
when I go to my doctor. We come from opposite ends of the earth. (P12, 24, Latino) 
These negative experiences, or even the anticipation of a negative reaction, play a detrimental 
role in the relationship between these young gay males and their healthcare providers. This is 
particularly true when they are seeking treatment or information on sexual health related issues 
such as HPV vaccination.  
LGBT cultural competence of healthcare providers 
 Previous negative interactions with a health care provider influenced future expectations 
and perceptions regarding the overall cultural competence of healthcare providers in dealing with 
LGBT patients. There was a sense of having to know where a provider stands on issues related to 
sexuality for fear that he or she may be biased or even not competent in providing care. One 
participant stated:  
I would just feel weird talking to someone about that [HPV vaccine], and I would not 
know their views on LGBT people. So I feel like there may be some bias in the 
information that they could give me. Even though it’s unprofessional. (P03, 19, Asian) 
Other participants questioned whether or not they would rely on their health care provider for 
information about HPV. For participants who felt confident in their providers, they tended to talk 
about the established rapport and trust that was proven over the course of multiple interactions. 
Some men expressed feeling more comfortable with female providers, noting that female 
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providers are more comfortable with gay men. Others thought they would get better care with a 
gay provider, one rationale being: 
A gay provider would be more into or up-to-date with newer things that are coming out. 
Especially like with the threats that are more for the gay lifestyle. Because I really don't 
think that my health provider would know about HPV. (P12, 24, Latino) 
 The degree to which the patient-provider relationship would impact HPV vaccination was less 
clear. This relationship was important if it was perceived that asking for the vaccine would 
prompt a discussion of sexual behaviors. It was less important if the vaccine could be obtained 
without discussion of sexual history. In other words, the relationship was important for their 
comfort level regarding their sexuality, not in accepting a recommendation for vaccination.  
Management of disclosure 
When looking for sexual health services, some of the men I talked to will go to a clinic 
focused on STI testing (e.g., public health departments, planned parenthood, university medical 
services) even if they have an established relationship with a primary care provider. Because of 
the perceived stigma and fear of judgment, they value the privacy and anonymity provided by 
these venues when seeking sexual health services (including HPV vaccination). One participant 
stated: 
Because I feel like my health care provider...I understand there is HIPA and all that stuff 
and they are suppose to keep my stuff confidential. But I live in a pretty small town and I 
know how that stuff works. So I'd rather not. I go to the health department and every time 
I go it is somebody different. It never gets personal. I've never build rapport with them. 
(P12, 24, Latino) 
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He actively manages situations in which he expects to be asked questions about his sexual 
behavior favoring the impersonal nature of some public health clinics. A similar concern was 
mentioned in another interview when the participant expressed worry that his family doctor 
could not be trusted to main his confidentiality.  
 Another strategy that participants used to manage discussions of sexuality with healthcare 
providers is to lie.  If they felt particularly uncomfortable or if they believed their sexual 
behaviors were irrelevant, they reported being “selective” about what they disclosed or lying 
about their behaviors. Some men struggled with the idea that their sexuality was ever medically 
relevant citing “sex is sex” no matter the sex of their partners: 
It is just like, it is none of their business who I am having sex with. There is the whole 
stigma about being gay that we are promiscuous people we just go around having sex 
with every guy we see and therefore are at higher risk…straight guys do that all the time 
too. (P15, 20, Latino) 
While HPV did not come up directly in these conversations, it is clear that the relevance of any 
discussion of sexuality to determine eligibility or appropriateness of vaccination can be a 
sensitive issue for some male sexual minorities.    
Trusted sources of health information 
Overall men in this sample appeared accepting, interested, and engaged in discussions 
surrounding HPV and HPV vaccination. Many expressed positive intentions to get vaccinated or 
learn more about the vaccine. While the Internet was listed as the first source of health 
information, many of the participants expressed doubt in the dependability of the health 
information provided on many sites. They tended to adopt an information seeking strategy where 
they looked at a number of sources—usually the first few hits on a basic Google search—and 
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determined in some way if these sources were in agreement. Other standard sources of trusted 
health information were healthcare providers and family members who are connected to the 
healthcare industry in some way.  
One interesting source of health information mentioned in several interviews were 
LGBT-focused centers or groups. These included community-based organizations that offer 
HIV-testing, HIV case management, and other social services for sexual and gender minorities. 
Participants recalled health information presented as part of counseling during HIV testing and 
during social group gatherings in which guest speakers were invited to talk about a variety of 
health issues. These were described as “welcoming” and “non-judgmental” environments and 
participants expressed a great deal of trust and respect for them. One participant mentioned that 
he would prefer to be vaccinated at one of these locations because he was going on a regular 
basis for HIV testing. In this sense it would be more convenient for him. Subsequent participants 
were asked about their thoughts/feelings about getting vaccinated at this type of organization 
(i.e., Community-based LGBT health clinic or HIV testing site). They were overwhelmingly in 
support of that option. The main reason against this option was that the medical staff would not 
know their specific medical history and thus would not be able to identify the potential health 
consequences of getting vaccinated. Overall community-based LGBT organizations were 
identified as a desirable alternative location for HPV vaccination.  
 
Phase 2 Results: Quantitative Survey 
Sample characteristics 
See Table 2 for complete demographic characteristics of the study sample. Participants 
were on average 22 years old (SD = 2.43). They were primarily white (63%) college students 
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(58%) with health insurance (83%) who had a place they usually go to for “routine medical care” 
(74%). The majority identified as gay (75%), but a significant proportion identified as bisexual 
(22%). The number of lifetime male sexual partners was widely varied. Fifty-three (9%) 
respondents reported no male partners. The median number of male sexual partners was 6 
(Interquartile range = 13). 
Most were HIV-negative (67%); however, over a quarter reported never being tested 
(27%). Among those who have received an HIV test, 50% were not tested within the previous 
year. Nearly 15% reported ever being diagnosed with Gonorrhea, Chlamydia, Syphilis, herpes, 
or Trichomoniasis.  Four percent reported a previous diagnosis of genital or anal warts. 
 Overall awareness of the HPV vaccine was limited. After being provided with the 
following information, a minority of participants (39%) indicated that they had previously heard 
of the HPV vaccine.  
A vaccine to prevent HPV (human papillomavirus) infection is available and is referred 
to by several names, such as: the HPV shot, cervical cancer vaccine, GARDASIL®, or 
CERVARIX®. The HPV vaccine is approved for males Currently, the HPV vaccine 
requires 3 shots given over 6 months. The HPV vaccine is proven safe and effective at 
preventing genital warts and cancers caused by HPV (e.g., Anal Cancer). The HPV 
vaccine is recommended by the Centers for Disease Control and Prevention (the CDC) 
for men who have sex with men who are 26 years of age or younger. 
Most participants (63%) also indicated that they did not personally know someone who has 
received the vaccine. And only 8% indicated that a doctor or health care provider recommended 
that they get the HPV vaccine (note that this study excluded men who had already initiated HPV 
vaccination).  
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Descriptive and bivariate statistics of HPV-related beliefs 
Behavioral beliefs 
 The 10 behavioral beliefs elicited from Phase 1 are presented in Table 5 along with the 
means for beliefs strength (b1), outcome evaluations (e1), and the product of the belief strength 
and outcome evaluation (b1e1). The means associated with perceived physical and psychological 
advantages were all greater than the neutral mid-point of the scale (>3) indicating an overall 
positive perception of HPV vaccination. The disadvantages of vaccination were generally 
perceived as unlikely to occur. Outcome evaluations were only assessed for side effects. On 
average, participants indicated little concern regarding vaccine side effects. All of behavioral 
beliefs had significant correlations in the expected direct with the direct measure of attitude—
that is perceived advantages positively correlated with a positive attitude toward vaccination and 
perceived disadvantages negatively correlated with a positive attitude toward vaccination.  
An expectancy-value index of belief strength and evaluation was calculated (6biei) 
reflecting the salient physical and psychological advantages that underlie attitudes toward HPV 
vaccination among this population.  There was a strong positive correlation between this index 
and the direct measure of attitude suggesting that the more participants endorsed this set of 
behavioral beliefs, the more positive their attitude toward HPV vaccination.  
Normative beliefs 
Table 6 contains the normative referents assessed with regard to obtaining HPV 
vaccination within the next 12 months. All of the referents were perceived as being supportive of 
a decision to get vaccinated; however, the value of their influence with regard to this decision 
was low (see values for mi). The degree of social influence is indicating by the expectancy-value 
indicators (n1m1) with anything greater than 9 (the midpoint) indicated some degree of positive 
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influence to get vaccinated. The most frequently mentioned referent group was gay male friends 
who did have a degree of social influence over decisions regarding HPV vaccination. The least 
influential individuals, just at the midpoint of the index, were fathers. All normative referents 
contributed positively to perceived norms as indicated by moderate positive correlations. 
Similarly, the expectancy-value index of normative referents (6nimi) was positively correlated 
with the direct measure of perceived norms.  
Control beliefs 
Table 7 contains the influence of control beliefs on perceived behavioral control 
associated with getting the HPV vaccine within the next 12 months. These beliefs are looking at 
facilitators of vaccination. In particular, having health insurance over the next 12 months was 
strongly endorsed by participants as a key factor influencing their ability to get vaccinated. An 
examination of the expectancy-value indicators (c1p1) shows that health insurance is the strongest 
facilitator of vaccination followed by making vaccine available at HIV testing locations. All of 
the control beliefs exhibit small to moderate correlations with perceived behavioral control. 
Participants expressed a moderate degree of self-efficacy in getting vaccinated if they had to 
discuss their sexual orientation with a healthcare provider. Self-efficacy was also positively 
associated with perceived behavioral control.  
Descriptive and bivariate statistics of model variables 
 Scale means, standard deviations, coefficient alphas, and zero-order correlations for all 
scales are presented in Table 8. All scales exhibited at least acceptable internal consistency (D 
>.65), which is sufficient for the purpose of this research.  The mean for the main outcome 
variable, HPV vaccine intentions, was greater than but close to the scale midpoint (midpoint = 
3), suggesting positive vaccine intentions with widespread indecision. 
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Table 5: B
ehavioral beliefs associated w
ith H
PV
 vaccination and correlations w
ith attitudes 
 B
ehavioral beliefs 
B
elief 
strength 
(b
i ) 
 
O
utcom
e 
evaluation 
(e
i ) 
 
b
1 e
1  
 
C
orrelation 
b
1 e
1  w
ith 
attitude 
 
M
 
SD
 
M
 
SD
 
M
 
SD
 
 
Physical advantages 
 
 
 
 
 
 
 
It w
ould m
ake m
e healthier 
3.29 
1.02 
4.34 
0.70 
14.48 
5.54 
0.42* 
It w
ould prevent m
e from
 getting genital and anal w
arts 
3.86 
1.00 
4.31 
0.86 
16.84 
5.86 
0.40* 
It w
ould prevent m
e from
 getting anal cancer 
3.66 
1.04 
4.40 
0.86 
16.31 
5.97 
0.39* 
Psychological advantages 
 
 
 
 
 
 
 
Feel protected from
 H
PV
 
4.11 
0.85 
3.73 
1.00 
15.64 
5.88 
0.51* 
Feel like there is one less thing to w
orry about 
3.89 
1.06 
3.98 
1.00 
15.90 
6.56 
0.47* 
Less likely to spread H
PV
 to future sex partner(s) 
4.22 
0.86 
4.11 
0.94 
17.64 
5.90 
0.39* 
Expectancy-value index for physical/psychological advantages of 
H
PV
 vaccination (6b
i e
i ) 
 
 
 
 
96.76 
29.34 
0.53* 
D
isadvantages 
 
 
 
 
 
 
 
I w
ill contract H
PV
 from
 the vaccine
a 
1.98 
1.11 
-- 
-- 
-- 
-- 
-0.17* 
N
ot com
pletely protected from
 future H
PV
 infections a 
2.80 
1.06 
-- 
-- 
-- 
-- 
-0.22* 
The vaccine m
ay not w
ork for m
e
a 
2.54 
0.99 
-- 
-- 
-- 
-- 
-0.26* 
I w
ould have side effects 
2.69 
1.00 
2.79 
0.92 
7.83 
4.34 
-0.25* 
B
elief strength and outcom
e evaluation w
ere m
easured on a 5-point bipolar scales 
b
i e
i  ranges from
 1 to 25 w
ith higher values indicating likely and im
portant beliefs 
a O
utcom
e belief w
as not assessed. C
orrelation coefficient represents correlation w
ith belief strength and attitude 
*p<.05 
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Table 6: N
orm
ative beliefs associated w
ith H
PV
 vaccination and correlations w
ith perceived norm
s 
 N
orm
ative beliefs 
n 
B
elief 
strength 
(n
i ) 
 
M
otivation 
to com
ply 
(m
i ) 
 
n
1 m
1  
 
C
orrelation 
n
1 m
1  w
ith 
norm
 
 
 
M
 
SD
 
M
 
SD
 
M
 
SD
 
 
M
other 
513 
3.91 
1.32 
3.19 
1.66 
13.29 
8.72 
0.40* 
Father 
445 
3.48 
1.39 
2.57 
1.59 
9.83 
8.10 
0.33* 
G
ay m
ale friends 
521 
4.19 
0.99 
3.57 
1.43 
15.35 
7.58 
0.39* 
Straight friends 
531 
3.86 
1.14 
2.95 
1.44 
12.00 
7.55 
0.35* 
Expectancy-value index for norm
ative referents (6n
i m
i ) 
 
 
 
 
 
48.65 
22.96 
0.45* 
B
elief strength and m
otivation to com
ply w
ere m
easured on a 5-point bipolar scale  
n
i m
i  ranges from
 1 to 25 w
ith higher values indicating supportive referents 
Statistics are calculated only if referent w
as m
entioned and participant did not indicate “not applicable” 
V
alues of 3 (neutral m
id-point of scales) w
ere im
puted for participants w
ho chose “not applicable” in calculations of 6n
i m
i  
  Table 7:  C
ontrol beliefs associated w
ith H
PV
 vaccination and correlations w
ith perceived behavioral control  
 C
ontrol beliefs 
B
elief 
strength 
(c
i ) 
 
Perceived 
pow
er (p
i ) 
 
c
1 p
1  
 
C
orrelation 
c
1 p
1  w
ith 
PB
C
 
 
M
 
SD
 
M
 
SD
 
M
 
SD
 
 
Find out w
here to get vaccinated 
3.85 
1.01 
4.09 
1.07 
15.79 
6.10 
0.37* 
H
ave health insurance 
4.20 
1.02 
4.02 
1.21 
18.97 
6.45 
0.44* 
D
on’t need an appointm
ent 
3.13 
1.10 
4.44 
1.02 
12.44 
5.90 
0.22* 
A
vailable at H
IV
 testing location 
3.87 
1.13 
4.04 
1.23 
16.21 
7.24 
0.18* 
Expectancy-value index control factors (6c
i p
i ) 
 
 
 
 
63.15 
0.85 
0.42* 
Perceived self-efficacy 
3.42 
1.26 
 
 
 
 
0.42* 
B
elief strength and outcom
e evaluation w
ere m
easured on a 5-point bipolar scale.  
c
i p
i  ranges from
 1 to 25 w
ith higher values indicating stronger control beliefs that can help facilitate H
PV
 vaccination 
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Table 8: Scale m
eans, standard deviations, coefficient alphas and zero-order correlations for scales 
  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
1. Intention 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. A
ttitude 
.47* 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. PH
Y
 A
dvantages 
.47* 
.46* 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. PSY
 A
dvantages 
.54* 
.50* 
.68* 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
5. Low
 efficacy 
-.19* 
-.27* 
-.19* 
-.21* 
-- 
 
 
 
 
 
 
 
 
 
 
 
6. C
ontract H
PV
 
.00 
-.17* 
.03 
.01 
.51* 
-- 
 
 
 
 
 
 
 
 
 
 
7. Side effects 
-.06 
-.25* 
-.02 
-.01 
.45* 
.51* 
-- 
 
 
 
 
 
 
 
 
 
8. N
orm
s 
.43* 
.39* 
.49* 
.54* 
-.14* 
-.01 
-.01 
-- 
 
 
 
 
 
 
 
 
9. N
orm
ative beliefs 
.26* 
.18* 
.31* 
.38* 
-.12* 
.06 
-.04 
.45* 
-- 
 
 
 
 
 
 
 
10. PB
C
 
.27* 
.16* 
.14* 
.20* 
-.16* 
-.14* 
-.16* 
.17* 
.13* 
-- 
 
 
 
 
 
 
11. C
ontrol beliefs 
.35* 
.30* 
.33* 
.38* 
-.16* 
-.10* 
-.03* 
.30* 
.32* 
.42* 
-- 
 
 
 
 
 
12. Self-efficacy 
.14* 
.11* 
.22* 
.17* 
-.09* 
-.02 
-.03* 
.16* 
.20* 
.24* 
.23* 
-- 
 
 
 
 
13. Threat 
.28* 
.27* 
.33* 
.35* 
-.08 
.07 
.08 
.27* 
.24* 
.07* 
.18* 
.04 
-- 
 
 
 
14. Inform
ation-O
 
.26* 
.12* 
.26* 
.32* 
.09* 
-.05 
.06 
.23* 
.21* 
.18* 
.35* 
.23* 
.08* 
-- 
 
 
15. LG
B
T-SU
S 
-.02 
.00 
.02 
.02 
.06 
.16* 
.13* 
-.01 
-.10* 
-.13* 
-.10* 
-.51* 
.01 
-.16* 
-- 
 
16. C
oncealm
ent 
-.04 
.04 
-.04 
-.00 
-.01 
-.12* 
-.01 
-.12* 
-.02 
-.04 
.01 
-.23* 
.03 
-.03 
.22* 
-- 
M
ean  
3.26 
4.23 
47.57 
49.19 
2.67 
1.97 
7.84 
3.75 
48.66 
3.76 
63.15 
3.42 
9.51 
4.24 
2.49 
45.66 
Standard D
eviation 
1.07 
.80 
15.20 
16.82 
.90 
1.11 
4.34 
.79 
22.96 
.85 
18.06 
1.26 
4.99 
.69 
.86 
26.08 
C
ronbach’s alpha 
.90 
.86 
.85 
.91 
.71 
-- 
-- 
.70 
.76 
.70 
.66 
.90 
.96 
.80 
.71 
.71 
PH
Y
 = Physical; PSY
 = Psychological; PB
C
 = Perceived behavioral control; Inform
ation-O
 = Inform
ation orientation; LG
B
T-SU
S = Suspicion of LG
B
T cultural com
petence Scale; C
oncealm
ent = 
N
ebraska O
utness Scale-C
oncealm
ent Subscale 
*p<.05 
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Overall participants expressed positive attitudes toward vaccination, supportive norms, and 
perceived control over their decision to get vaccinated. The mean perceived threat score was 
below the scale midpoint (midpoint = 12.5) indicating low levels of concern among this sample.  
 Zero-order correlations provided initial support for the proposed relationships. As 
expected, attitudes, norms, and perceived control/efficacy exhibited statistically significant 
correlations with behavioral intention. In turn, each of these main determinants of intention were 
significantly correlated with their respective belief measures (i.e., attitudes with behavioral 
beliefs, norms with normative beliefs, and perceived behavioral control with control and efficacy 
beliefs). Notable relationships among background factors include: (1) positive correlations 
between perceived threat and behavioral beliefs; (2) positive correlations between information 
orientation and behavioral beliefs; (3) negative correlation between Outness-concealment and 
self-efficacy; (4) negative correlation between LGBT-SUS and self-efficacy; and (5) positive 
correlation between LGBT-SUS and Outness-concealment.  
Test of an integrative model of HPV vaccine decision-making 
 Structural equation modeling was used to test a comprehensive model of HPV vaccine 
decision-making. In addition to the propositions examined above, the following relationships 
were also modeled because of the theoretical importance identified in Phase 1 qualitative 
interviews (See Figure 4): (1) HIV-positive men will exhibit higher levels of perceived threat 
than HIV-negative men; (2) men in monogamous relationships will exhibit lower levels of 
perceived threat compared to men not in monogamous relationships; (3) men with a history of 
anogenital warts will exhibit higher levels of perceived threat compared to other men; (4) 
knowing someone who received the HPV vaccine will be positively associated with normative 
beliefs; (5) bisexually identified men will score higher on outness-concealment than other MSM; 
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(6) bisexually identified men will score higher on the LGBT-SUS scale; (7) outness-concealment 
will be positively associated with LGBT-SUS.  
Measurement model 
 Confirmatory factor analysis of the measurement model found poor absolute fit of the 
data to the latent factors, F2 (df) = 4.28.76 (254), p<.001; however, the chi-square test is highly 
sensitive to sample size so additional fit indices were examined. All three fit indices suggested 
the measurement model fit the data well (RMSEA = .04 [90% CI: .03, .04], CFI = .97, SRMR = 
.04). Item-to-factor correlations are presented in Table 9. All items significantly loaded on their 
respective factor. No modifications to the measurement model were warranted.  
Structural model 
 The initial structural model tested 28 propositions or structural relationships. This model 
had poor fit among all but one of the indices examine: F2 (df) = 1808.28 (640), p<.001; RMSEA 
= 0.06 [90% CI:.05, .06]; CFI = .85; SRMR = .10. The following relationships were not 
statistically significant (p > .05): Low efficacyÆAttitudes (B = -.04; 95% CI = -.11, .04); 
Contract HPVÆAttitudes (B = -.04; 95% CI = -.10, .02); Perceived ThreatÆContract HPV (B = 
.02; 95% CI = .00, .04); Communication-orientationÆContract HPV (B = -.09; 95% CI = -.24, 
.06); Perceived ThreatÆSide effects (B = .08; 95% CI = -.00, .16); Communication-
orientationÆSide effects (B = .33; 95% CI = -.34, .93); Knew someone who got 
vaccinatedÆNormative beliefs (B = -3.73; 95% CI = -7.16, .10); and having a medical 
homeÆControl Beliefs (B = 3.11; 95% CI = .46, 5.91). These paths were removed from the 
model one at a time starting with the weakest relationships (indicated by lower E values). A total 
of eight paths were removed. The revised model (model 2) approximated acceptable fit: : F2 (df) 
= 1132.22 (503), p<.001; RMSEA = 0.05 [90% CI:.04, .05]; CFI = .91; SRMR = .10. Mplus 
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modification indices were examined to determine if any theoretically relevant paths could be 
added to the model in order to increase fit. Based on this information three additional paths were 
added: (1) a direct path from Physical/Psychological benefits to intention; (2) a direct path from 
perceived threat to normative beliefs; and (3) a direct path from communication-orientation to 
normative beliefs. In addition, control beliefs were allowed to covary with 
Physical/Psychological benefits and normative beliefs. This model exhibited adequate fit and is 
of theoretical importance: F2 (df) = 1265.48 (507), p<.001; RMSEA = 0.05 [90% CI:.05, .06]; 
CFI = .91; SRMR = .09.  
 Determinants of intention. Standardized parameter estimates for the final model (model 
3) are depicted in Figure 5. As is shown, the largest direct effects on HPV vaccine intentions are 
from Physical/Psychological benefits (E = .32, B = .01; 95% CI = .01, .01) and attitudes (E = .27, 
B = .25; 95% CI = .17, .34). This is a slight deviation from the original model where the effect of 
Physical/Psychological benefits is completely mediated by attitudes. Perceived norms had a 
small association with intention (E = .12, B = .12; 95% CI = .02, .20). Perceived behavioral 
control had a moderately strong association with intentions (E = .23, B = .31; 95% CI = .20, .44).  
 Structure of beliefs. There were five key characteristics of HPV-related beliefs that 
underscore the main determinants of intention. This included beliefs regarding the 
physical/psychological benefits of vaccination, which was strongly correlated with positive 
attitudes (E = .55, B = .02; 95% CI = .01, .02). Concern about potential side effects was 
negatively associated with attitudes (E = -.25, B = -.05; 95% CI = -.06, -.03). As was expected, 
normative, control, and efficacy beliefs were each positively associated with their respective 
determinant; however, the relative association of self-efficacy with perceived behavioral control 
was low compared to the others.  
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 Antecedents of beliefs. The strongest antecedents of HPV-related beliefs were perceived 
threat, suspicions of LGBT cultural competence, and information orientation. The larger 
perceptions of threat the higher the perceived benefits of vaccination (E = .34, B = 2.27; 95% CI 
= 1.82, 2.75). In addition, the perceived benefits of vaccination were higher among those with 
higher levels of health information orientation (E = .31, B = 12.79; 95% CI = 8.90, 16.36). There 
was also a strong negative association between those expressing suspicion of LGBT cultural 
competence and self-efficacy (E = -.56, B = -1.63; 95% CI = -2.05, -1.32).  
 Socio-demographic targets. HIV positive men had higher levels of perceived threat (E = 
.13, B = 2.34; 95% CI = .74, 3.83). Inversely, men in monogamous relationships reported lower 
levels of threat (E = -.18, B = -1.67; 95% CI = -2.25, -1.04). Bisexual identification was 
positively associated with both outness-concealment (E = .10, B = 5.91; 95% CI = 1.46, 10.37) 
and suspicions of LGBT cultural competence (E = .21, B = .23; 95% CI = .14, .31).  
 Indirect effects. Indirect effects are displayed in Table 10. In general, the indirect effects 
were relatively small. The most theoretically meaningful indirect effects are from the salient 
belief measures to intentions, mediated by the main determinants of behavior (i.e., attitudes, 
norms, perceived control/efficacy). All of these indirect paths were statistically significant and 
among the largest indirect paths identified in the model.  
Phase 3 Results: Open-Ended Survey 
 The purpose of the open-ended survey was to further identify salient beliefs, information 
needs, and trusted information sources, as well as underlying background factors that influence 
HPV vaccine decisions among young MSM. This was accomplished through the use of a 
vignette that provided context for thinking about vaccination and subsequent open-ended 
questions. 
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Table 9: Item-to-factor correlations for measurement model  
 
 
Latent factor title in bold 
 
 
β (SE) 
Vaccine Intentions  
Find out more information about the HPV vaccine within the next 12 months .72 (.03) 
Make an appointment to talk to a doctor about the HPV vaccine within the next 12 months .93 (.02) 
Get your first HPV shot within the next 12 months .94 (.01) 
  
Direct Attitude  
Not worth it - Worthwhile .81 (.03) 
Harmful - Beneficial .77 (.03) 
A bad thing for me – A good thing for me .80 (.03) 
Unimportant – Important .80 (.03) 
Ineffective - Effective .72 (.03) 
  
Direct Normative influence  
People who are important to me would encourage me to get the HPV vaccine .75 (.04) 
I can think of at least one person in my life who would like for me to get the HPV vaccine .74 (.04) 
Most of my gay/bisexual male friends would get the HPV vaccine if it was offered to them free of 
charge  
.52 (.04) 
  
Direct Perceived Behavioral Control  
There are factors beyond my control that would prevent me from getting the HPV vaccine  .49 (.04) 
I am confident that I can get the HPV vaccine in the next 12 months .84 (.04) 
Getting the HPV vaccine sometime in the next 12 months would be: Impossible for me—Possible 
for me 
.67 (.04) 
  
Perceived Threat  
Threat of HPV infection .82 (.03) 
Threat of Anal Warts .93 (.02) 
Threat of Genital Warts .94 (.01) 
Threat of Anal Cancer .82 (.03) 
  
Information Orientation  
When I take medicine, I try to get as much information as possible about its benefits and side effects .80 (.04) 
Before making a decision about my health, I find out everything I can about the issue .83 (.03) 
It’s important to me to be informed about health issues affecting gay and bisexual men .63 (.05) 
  
Suspicion of LGBT Cultural Competence  
I have received lower quality healthcare services as a result of my sexual orientation .41 (.05) 
I prefer that my doctor or healthcare provider does not know that I am gay/bisexual .80 (.04) 
I feel uncomfortable talking about my sexual orientation or sexual behaviors with a doctor or HCP .67 (.04) 
There is no reason why a doctor or health care provider would need to know that I have sex with 
men 
.61 (.04) 
  
N = 569 
All factor loadings are statistically significant (p < .05) 
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 Figure 5: Structural m
odel of H
PV
 vaccine intentions am
ong young M
SM
 
N
 = 568; Param
eter estim
ates are standardized regression (β) w
eights.  
M
odel Fit Statistics: F
2  (df) = 1265.48 (507), p<.001; R
M
SEA
 = .05 (90%
 C
I: .04-.05); C
FI = .91; SR
M
R
 = .09
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Table 10: Indirect effects on HPV vaccine intention 
 
Indirect paths β (SE) p 
Benefits—Attitudes—Intention .15 (.03) * 
Side effects—Attitudes—Intention -.07 (.02) * 
Normative beliefs—Norms—Intentions  .06 (.03) * 
External control beliefs—PBC—Intentions  .11 (.03) * 
Self-efficacy—PBC—Intentions .04 (.01) * 
Outness—Self-efficacy—PBC—Intentions -.00 (.00) ns 
Outness—LGBT-SUS—Self-efficacy—PBC—Intention -.01 (.01) * 
LGBT-SUS—Self-efficacy—PBC—Intentions  -.02 (.01) * 
Bisexual—LGBT-SUS—Self-efficacy—PBC—Intentions -.00 (.00) ns 
Bisexual—Outness—Self-efficacy—PBC—Intentions .00 (.00) ns 
Threat—Benefits—Attitudes Intentions .05 (.01) * 
Information-O—Benefits—Attitudes—Intentions  .05 (.01) * 
HIV-Positive—Threat—Benefits—Attitudes—Intentions .02 (.01) * 
Monogamous—Threat—Benefits—Attitudes—Intentions -.02 (01) * 
N = 568; Benefits = Physical and psychological benefits; PBC = Perceived behavioral control;  
Information-O = Information orientation; LGBT-SUS = Suspicion of LGBT cultural  
competence Scale; Concealment = Nebraska Outness Scale-Concealment Subscale 
*p<.05 
 
As such Phase 3 serves as a confirmatory check on the findings from the Phase 1 semi-structured 
interviews. The goal of this analysis was to identify new information that was not uncovered in 
the interviews and to shed more light on the decision-making process undergone by MSM when 
thinking about HPV vaccination.  
 The results for this phase are presented along with the vignette that was used to elicit 
responses. This helps to put the findings in context and highlights the key elements involved in 
the decisions surrounding HPV vaccination. The first part of the vignette focused on general 
HPV information as is shown below.  
One respondent commented that “Most information I have heard about it was straight 
female centric” (P25, 24, White), which was a belief supported by other men who made explicit 
mention of cervical cancer.  One participant commented that, “The statistic took me aback 
because it's quite personal- it affects me on a personal level because I am gay and have anal sex 
quite often” (P26, 21, Latino). 
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Vignette Part 1: HPV information 
 
Figure 6a: Part 1 of the vignette 
 
 
Figure 6b: Part 1 of the vignette 
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Others reiterated this thought mentioning, “For something so prevalent among MSM it 
isn’t often talked about” (P27, 18, White). It was mentioned by one respondent, “cancer is a 
serious disease which I didn't know men were vulnerable to based on their sexual habits” (P28, 
26, White). 
Of the 102 participants who commented on the information, 32% mentioned that the 
asymptomatic nature of HPV infection was particularly “alarming.” There was concern that 
“people can be spreading this around without realizing it” (P29, 23, White) or that they “could 
pass something that doesn’t outright affect you but might the next person” (P30, 21, White). This 
was also noteworthy to some men who expressed a belief that most sexually transmitted 
infections result in clinical symptoms.  
Anogenital warts were mentioned much less than cancer, suggesting that warts are the 
most common characteristic associated with HPV among this population. In fact some 
respondents explicitly mentioned that they “already knew this” or disclosed that they previously 
had anogenital warts. With that said, 16% mentioned the fact that HPV can result in anogenital 
warts as impactful.  
Interestingly, approximately 16% of respondents commented on the age recommendation 
as noteworthy. In most of these cases they were surprised of the upper age limit and inquired as 
to why the vaccine isn’t recommended for men of all ages. This finding is highlighted in the 
following remark: “The age recommendation also stood out to me - surely men over 26 are still 
sexually active, so why are they not recommended to get it as well” (P31, 22, White)? This 
suggests that even among those who are aware that the HPV vaccine is licensed for use in males, 
they are unaware of the specific vaccine recommendations for MSM and the reasons behind this 
recommendation.  
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Vignette Part 2: Decision uncertainty 
 
Figure 7: Part 2 of the vignette 
Making a decision: what to do and why? 
 Out of the 102 responses regarding what Brandon should do, 47 (46%) suggested that 
Brandon should consult with a doctor or primary care provider. Some specified a “trusted” or 
“reliable” provider with whom Brandon would feel comfortable discussing his sexual history in 
order to make a good decision about vaccination. For example, one participant stated: “He 
should talk to his doctor and get advice on what to do and to see if Gardasil is the right choice for 
him after being very honest about his sexual behavior” (P32, 24, White). Collectively the 
primary care provider served as the main referent or source of informational support regarding 
HPV vaccination.  
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About 29% recommended that Brandon get tested for HPV in order to determine if he 
should get vaccinated. There was a common misperception that HPV testing is routinely done 
during STI screening for males. The thinking behind this recommendation is expressed in the 
following quote: “The first step should be for him to determine his risk, getting tested for the 
virus and based on those results, proceed with vaccination/treatment” (P23, 22, Black). Inherent 
in this example, and in similar responses, is the notion that one can know his HPV “status” and 
make appropriate health decisions based on that information. There was also a sense of 
responsibility in knowing one’s status: 
It's important to know your health status when having sex with others (moral and public 
health issue). If he finds out his status he can make more informed opinions about 
preventing the spread of HPV or preventing infection from HPV. (P33, 23, White) 
These comments evince a limited understanding of HPV infection, available testing procedures, 
as well as recommendations on vaccination.  
It should be noted that the majority of comments were in favor of Brandon getting 
vaccinated even if they suggested he should consult a health care provider first. However, there 
was one participant who stated that Brandon “doesn’t need it” because “He's 25 and the shot is 
recommended if you’re under 26 so he's close to not needing it” (P34, 25, White). This was not a 
view shared by anyone else but represents an interesting perspective—and perhaps an unintended 
consequence of the age-based vaccine recommendation. For other men the upper age limit 
elicited a sense of urgency since they perceived themselves as coming close to “aging out.”  
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Vignette Part 3: The threat of anal warts 
 
Figure 8: Part 3 of the vignette 
Deciding to get vaccinated: Good or bad? 
 In the vignette, Brandon made an explicit decision to get vaccinated. Out of the 102 
participants who responded, 80% said they would have done the same thing (i.e., decided to get 
the HPV vaccine). These men described Brandon’s decision as “reasonable,” “wise,” and 
“smart.” The fact that someone Brandon knew had anal warts influenced their thinking of the 
issue as is noted in the following comment: 
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I think it's a good decision. The shots are definitely a no brainer over getting HPV and 
anal warts. Finding out somebody you know has it makes it hit more close to home than a 
poster. (P35, 22, White) 
Many of their comments regarding Brandon’s decision described behavioral beliefs endorsing 
the physical and psychological advantages to HPV vaccination. The same participant described 
the value of vaccination: 
If it's as prevalent as the poster says, then why not take the extra step to prevent against it. 
Sure getting 3 shots over 6 months is a little inconvenient, but so are anal warts and 
cancer. If Gardasil is effective, why not get the shots and have one less thing to worry 
about? A small price to pay for peace of mind. (P24, 22, White) 
Other comments referred to protecting partners and contributing “to stopping the spread of 
HPV.” Overall there was a large focus on the importance of prevention and being “better safe 
than sorry.” There were minimal concerns about risks associated with vaccination. While no 
participant noted any specific concerns, some made statements that “you shouldn’t blindly put 
something in your body, the more knowledge the better,” (P36, 21, White) and that they would 
do their own research to determine if the “peace of mind outweighs the inconvenience and 
whatever side effect may exist” (P37, 26, White).  
 Despite their own stated beliefs in the advantages to getting vaccinated, some men who 
indicated they would get vaccinated explained that this was something they would approach with 
little urgency. One man said he would: 
Ask my doctor at my next appointment if he or she thinks I should get the HPV vaccine 
(or test to see if I already have it). I don't know if I would necessarily make a new 
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appointment specifically for that question, because it doesn't seem like an immediate 
concern. (P33, 23, White) 
Another man described his low motivation to get vaccinated: 
I think that I should get the vaccine but probably not get it just because it doesn't seem 
like an impending danger. Out of sight out of mind. (P38, 21, White) 
Both of these men described their perceived susceptibility to HPV infection as “average” and 
indicted that they were “slightly” or “somewhat” concerned about becoming infected with HPV. 
These participants are in contrast to those who described themselves as “Moderately” or 
“Extremely” concerned about HPV infection and who subsequently advocated for Brandon to 
take more immediate action (e.g., “get the shots ASAP”).  
These findings represent the importance of perceived threat in the justifications 
explaining vaccine decisions. Those who perceived their risk as low referred to what they 
believed as limited exposure: “Unlike Brandon I don’t hook-up and have had sex with only a few 
people in my life so my chances of already contracting it would be low” (P39, 25, White). 
Similarly, being in a “monogamous” relationship was used to justify a limited concern regarding 
HPV infection and vaccination. Other respondents countered these claims stating, “all you need 
is one exposure” (P40, 23, White) or “regardless of how much or as little he is having, it is still 
possible that he will get HPV” (P41, 22, White). For some, learning that penetration isn’t 
necessary for HPV transmission elicited threat. One man wrote: “…anal penetration isn’t even 
necessary; you can get it through skin contact. Scary” (P42, 24, Asian).   
There was some ambivalence about Brandon’s decision with 15% stating they were “Not 
sure” if they would have decided to get vaccinated and 5% said they would not have been 
vaccinated. These men described Brandon’s decision as “reactive” and “emotional.” They 
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expressed a strong need for more information and a desire to seek medical advice prior to 
making any decisions. The men selecting “Not sure” (N = 15) questioned the efficacy of getting 
vaccinated in the event that they have already been exposed. This group also tended to focus on 
the importance of getting tested before making a decision. Many of these comments are 
represented by the following statement: 
There are many factors to consider. Getting tested to see if I do not have HPV/HIV, then 
looking to see where I can get the Vaccine, cost, travels, measures, actions. Although I 
would have researched more on HPV then talked about it to a GP or headed to a health 
clinic to find further information. Aside from this I had so many vaccines in my life that I 
later found out are for other things as well, so I would need to look at my full medical 
history to see if I am applicable for the vaccine, as well as other factors like allergies etc. 
that may cause problems. However this would all be discussed with my doctor. (P43, 23, 
Asian)   
The men who indicated they would not get vaccinated described three distinct rationales: (1) they 
already made a decision not to get vaccinated; (2) they do not need the vaccine because they are 
not at risk; and (3) they have already been exposed to HPV so the vaccine would not confer any 
benefit. One of the participants commented that “one experience isn’t enough to change my 
mind” (P34, 25, White) suggesting that Brandon is reacting to a unique situation. Others 
mentioned that they are “not very promiscuous” or not sexually active as reasons not to get 
vaccinated.  
 
 
 
119 
 
Vignette Part 4: Trusted sources 
Preferred places to get vaccinated 
The final passage of the vignette was used to determine where the participants would 
prefer to go to get vaccinated as well as any issues they perceive discussing sexuality and/or 
sexual behavior with their providers. The passage of the vignette read: 
Brandon wanted to get the HPV vaccine but he didn’t know where to go to get it. He 
doesn’t really like going to the doctor and feels a little awkward asking a healthcare 
provider about the HPV vaccine since it’s an STD. He knows it’s unprofessional but 
sometimes thinks that doctors judge him for his sexual behaviors.  
Participants were asked “Where would you go to get the HPV vaccine if you were in Brandon’s 
situation?” Seven categories of locations were described and are numbered in order of the 
frequency in which they were mentioned: (1) Primary care doctor, (2) University/College health 
center, (3) Walk-in or Community Clinic, (4) Planned Parenthood of STI clinic, (5) LGBT-
focused/friendly clinic or provider, and (6) Pharmacy. A number of participants indicated that 
they were unsure about where to go to get vaccinated.  
 Next, participants responded to a structured question asked about the likelihood 
(unlikely-likely) of them getting vaccinated at the four hypothetical locations: (1) HIV testing 
site, (2) Pharmacy with a walk-in clinic, (3) Primary care provider’s office, and (4) a community-
based health clinic servicing LGBT people. Participants were provided with a description of each 
location (see appendix 3). All of the locations were acceptable by a majority of respondents (see 
Table 3).  
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Participants were then prompted to explain what they liked about the locations where they were 
likely to get vaccinated and what they did not like about the other locations. Responses were 
coded and added to Table 11 for comparison.  
 
 
Figure 9: Acceptability of locations for HPV vaccination 
 
Similar responses (e.g., LGBT friendly and accepting environment) were combined into one 
category. A characteristic was considered present for a location if more than one participant 
mentioned it (see Table 11).   
 The perceived benefits associated with HIV-testing sites included convenience, which 
was often described as not needing an appointment and going to a location that they already 
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utilize for HIV testing. These locations were described as discrete where they did not have 
established relationships with any one provider. Participants also believed that HIV-testing sites 
would be LGBT friendly and have staff that is more knowledgeable about LGBT health issues. 
Common concerns included the lack of availability of such locations in more rural areas, that 
some participants were unfamiliar with them, and that they seemed less private than a primary 
care provider’s office. There was also some concern that going to a location associated with HIV 
could be stigmatizing.  
Table 11: Perceived benefits and concerns of hypothetical locations to receive HPV vaccinations 
Categories HIV 
testing 
sites 
Pharmacy Primary 
care 
provider 
LGBT Clinic 
Benefits     
Convenient X X   
Widely Available  X   
Discrete X   X 
Multiple medical services X  X  
Familiar   X  
LGBT Friendly X   X 
Focus on LGBT health X   X 
Know medical history   X  
Privacy   X  
Concerns     
Lacks privacy X X  X 
Not available X  X X 
Stigmatizing X    
Unfamiliar X X  X 
Customer-focus  X   
Judgmental  X X  
Lacks knowledge of LGBT health   X  
Lacks medical professionalism  X  X 
 
 The primary benefits ascribed to pharmacies were their convenience and widespread 
availability—although one participant noted that no pharmacies in his small town offered 
medical services. The concerns over being vaccinated at a pharmacy included lack of privacy 
and being unfamiliar with receiving these types of services at these locations. Participants also 
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noted the customer-focus vs. patient-focus of pharmacies as well as a fear of judgmental or 
unprofessional staff as concerns.  
 The primary care provider was the most likely source of HPV vaccination mentioned by 
participants. Many of them said that they prefer this location for vaccination because their 
providers were familiar to them and knew their medical history. The ability to ask for the vaccine 
while receiving other medical services was also stated as a benefit. However, participants 
without a primary care provider noted the lack of availability. There was some concern that 
primary care providers—some of which were family doctors—would lack knowledge specific to 
LGBT health issues. And although some noted the patient-provider relationship as increasing 
their sense of privacy, others explicitly mentioned a concern that their provider might disclose 
personal information to family members. There was also the fear that a provider might be 
judgmental and some participants preferred to seek sexual health services like HPV vaccination 
at other locations.  
 The perceived benefits of seeking vaccination at community-based LGBT health clinics 
are their specific knowledge of important sexual health issues experienced by LGBT individuals 
as well as their friendly and non-judgmental staff. Participants liked that these clinics are discrete 
and they can go for very specialized services. Others perceived these types of clinics as lacking 
privacy. Community health clinics focusing on LGBT populations are less commonly available 
and many of the participants said they were unfamiliar with such clinics. There was also a 
concern that the staff at these types of clinics would lack the necessary medical professionalism 
as would be found at a primary care provider office.  
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Sources of health information 
Confidence in healthcare providers 
 The data thus far have demonstrated the key role of the primary healthcare provider in 
providing information about HPV vaccination and the prevention of HPV-related diseases. 
Participants were asked if they think their own healthcare providers are knowledge about health 
issues affecting gay and bisexual men and to explain why or why not. A total of 86 responses 
were recorded. Approximately 44% indicated they believed their providers were knowledgeable, 
31% thought they were not knowledgeable, and 22% said they were unsure.  
Confidence in their provider’s knowledge of gay/bisexual men’s health issues resulted 
from previous interactions when the provider asked or answered specific questions about sexual 
health. Evidence of specialized training (e.g., safe zone training) also promoted this confidence.  
Others relied on assumptions. Providers in urban areas with large gay populations were assumed 
to be more knowledge because of frequent interactions with gay/bisexual patients. In many cases 
it was stated that in general doctors are knowledgeable about gay/bisexual men’s health issues 
because they are professionals and there is an expectation that they would be well informed. But 
even the trust and confidence in the competency of their doctors had its limits. Older doctors, as 
well as those from “certain communities,” were described with suspicion, which was related to 
an “old school” mentality, lack of up-to-date training, or judgmental attitudes.  
 Some of these sentiments were also described by the men who expressed a lack of 
confidence in the knowledge of their provider. A general bias toward sexual minorities was 
described. Some of this was based in previous experiences in which doctors were perceived as 
dismissing concerns due to their ignorance of an issue or having witnessed negative treatment of 
other LGBT patients. There was also some reliance on expectations that doctors don’t want to 
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think about gay/bisexual men’s health issues, avoid talking about it, or don’t take them seriously. 
Living in small towns or areas without a large visible gay population was frequently noted as a 
reason for these biases. And while some of the responses described explicit bias, many 
participants wrote about a lack of up-to-date training and a focus on their specific patient 
population that doesn’t include many openly gay/bisexual men.  
 
Emotions surrounding disclosure 
 Experiences disclosing one’s sexual minority status (i.e., identity or behavior) to a health 
care provider were explored through a series of questions asking about history of disclosure and 
emotions surrounding disclosure experiences. Out of the 102 responses, 55% had previously 
disclosed to a healthcare provider, 40% had not, and 6% could not remember. There were three 
sets of comments that described the relevance of disclosing to a HCP. The more common 
opinion was that it is important for a HCP to know about one’s sexual minority status because 
“being gay” or engaging in certain “risks” is of medical relevance.  Others thought it was 
relevant but only in certain situations (these situations were not described). The minority opinion 
was that sexual orientation is not relevant. One participant’s comments were particularly 
informative about this issue: 
It's awkward enough discussing my sex life with friends, so unless I had reason to believe 
I was exposed to an STD, I don't think I'd make it my doctor's business. Even then, I 
would probably leave it to “I think I was exposed, I need a test,” and leave the details up 
to my doctor's imagination. I can't think of a good-enough reason that my doctor would 
NEED to know I'm gay. (P31, 22, White) 
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It is interesting to note that no participants who explicitly questioned the relevancy of their 
sexual behaviors or identity to their medical care had previously disclosed to a HCP. 
Reasons for feeling comfortable disclosing included a strong sense that HCPs are 
professionals and are ultimately motivated to help people. Also they “see all kinds of people” 
including those who share similar sexual activities and risks. Other reasons were based on 
specific experiences with HCPs that were “welcoming,” who built rapport with their patients by 
asking questions and showing non-judgmental interest/concern. It was also assumed that female 
HCPs and those practicing in urban areas or at universities would be accepting.   
In contrast, descriptions of disclosing as uncomfortable were based on previous 
experiences where the HCP provider was perceived as reacting negatively. One participant 
described his perspective as follows: 
It can be very frightening and off-putting to reveal sexual behaviors because doctors do 
judge. You see it on their face, body language, tone of voice, and quality of treatment, 
and the length of time that they spend with you. It's not a comfortable, supporting, or 
healing environment to be in and one should find all of those qualities in a doctor and at 
the facility because their job is to heal, cure, and prevent illnesses. (P45, 25, Black) 
Others reiterated these feelings talking about the way in which their providers “react much 
differently when you say I was with my boyfriend” (P46, 24, White) or seemed “surprised” by 
information about one’s sexuality.   
Participants managed perceptions and expectations of judgment in four distinct ways: (1) 
they avoided bringing up sexual health concerns or lying about sexual behaviors if asked 
directly; (2) sought out non-judgmental providers using the characteristic outlined previously; (3) 
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went to a separate clinic (e.g., planned parenthood) for sexual health services; or (4) accepted the 
fact that people judge but they are not going to let it bother them.   
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CHAPTER 5: DISCUSSION 
  
The primary purpose of this study was to provide information that aids in our 
understanding of the factors important to young MSM when making decisions about HPV 
vaccination. Young MSM represent a distinct group with regard to HPV prevention for multiple 
reasons including their disproportional risk of HPV-related anal cancers, the limited herd 
immunity conferred to them through the vaccination of females, their current low vaccine 
uptake, and their public health relevance as a socially marginalized population. A comprehensive 
study of HPV-related attitudes, beliefs, and perceptions was undertaken and described in this 
manuscript.  The following discussion of these findings is presented in three sections. In section 
one, I provide a summary of the major findings by addressing the three specific aims. In section 
two, I outline the limitations and strengths of each phase and the overall study. And in section 
three the public health implications and directions for future research are discussed. 
Section I: Summary of Major Findings 
Specific Aim 1a: Describe salient outcome, normative, and control beliefs 
 Specific aim 1a was to describe salient behavioral, normative, and control beliefs related 
to HPV vaccination among young MSM. This aim was addressed using qualitative data from 
Phases 1 and 3.  
Behavioral beliefs 
There were three salient categories of behavioral beliefs that included physical and 
psychological advantages, as well as risks or concerns, associated with HPV vaccination.  
128 
 
Participants did not describe any of one specific advantage or risk as being critical in 
determining their attitudes toward vaccination. Instead they described the physical and 
psychological benefits in somewhat generic terms unless they had a personal experience with 
HPV—primarily in the form of anogenital warts. In these cases individuals were able to draw on 
their own experiences, which were used to express their thoughts and feelings about vaccination. 
But most of the men in the interviews and open-ended surveys lacked a specific context, or point 
of reference, in which to evaluate and express their thinking about HPV vaccination.  
Up until their participation in this study, most of the men had little knowledge of HPV 
outside of a general understanding and a perception that HPV was a women’s health issue. 
Limited HPV knowledge—particularly as it relates to the health consequences of HPV infection 
in men—is widely established in the extant literature (Nadarzynski et al., 2014); however, 
participants in this study—when asked in an open-ended format—were unable to describe even 
basic facts about HPV. And while many did correctly identify the link between HPV infection 
and anogenital warts, few understood HPV vaccination as a strategy for men to prevent this 
disease. Once informed, they adopted a positive attitude toward vaccination. This was consistent 
with an implicit—and sometimes explicit—value regarding health: “It’s better to be safe than 
sorry.”  
 Similar to beliefs regarding the advantages of vaccination, those expressing a concern 
over potential limits or risks of HPV vaccination were often generic and without specific details. 
As a result, these beliefs did not appear to exert a strong influence over their ultimate attitude 
towards HPV vaccination. In this sense, beliefs regarding the advantages and risks of HPV 
vaccination appear to be largely fluid and amenable to change in this population. 
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Normative beliefs 
 Normative beliefs—both descriptive and injunctive—were not salient factors in the way 
in which participants described their beliefs regarding HPV vaccination. In fact the general 
sentiment was that HPV vaccination would not be something they would openly discuss with 
friends or family. The limited role of norms in deciding HPV vaccine decisions was also found 
in the quantitative preliminary (Wheldon et al., 2011) and has been noted in focus group 
interviews with MSM (Gutierrez et al., 2013). As sexual minorities, they appeared cognizant of 
the need to conceal or manage information about their sexual behaviors from specific people in 
their lives—most notably parents and heterosexual friends. This was motivated in part by a fear 
of judgment. With that said, older gay friends who take on a mentor-type role were considered 
influential and respected referents in some cases. Overall, the decision regarding HPV 
vaccination would be a private decision made primarily in consultation with a healthcare 
provider. In fact, privacy regarding this decision is important as young MSM who receive health 
insurance benefits through their parents or who see a family practitioner may avoid vaccination 
for fear of disclosure.  
Control beliefs 
 External control factors identified in this study were similar to those found in previous 
quantitative studies (Nadarzynski et al., 2014). These included a focus on cost, availability, and 
convenience. Cost is by far the most important factor related to HPV vaccination (Nadarzynski et 
al., 2014). The data from these interviews overwhelming identify cost as a “make or break” 
proposition. While most participants indicated a willingness to pay a small copay, none would 
accept the full out-of-pocket cost.  
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Limited research is available that explores the acceptability of alterative vaccination 
settings.  Brewer and colleagues (Brewer, Chung, Baker, Rothholz, & Smith, 2014) identified 
pharmacies as a promising setting for HPV vaccination, yet the acceptability of these locations 
among MSM has not been investigated. The acceptability of alternative vaccination settings was 
explored in the qualitative phases. Four distinct preferences for HPV vaccine setting were 
identified.   
There was a subset of men who would only be vaccinated at their primary care provider’s 
office. This desire was motived by a need for their doctor to determine if the vaccine would be 
safe for them given their medical histories. An established patient-provider relationship was 
important for these men. Other men would likely be vaccinated at a variety of locations including 
pharmacies and community-base organization offering health services. The key factor for this 
group was convenience. They do not want to wait, make an appointment, or put much effort into 
finding out where HPV vaccination was available. This group of men seem comfortable getting 
vaccinated almost as an afterthought—for example, if vaccinations were offered during their 
regular HIV testing.  
Another group of men prioritized their privacy above most other considerations. This 
group was more uncomfortable with disclosing aspects of their sexuality and managed their 
patient-provider relationships carefully. For these men pharmacies were too public and did not 
provide a suitable environment for something like HPV vaccination. If they had a good 
relationship with a primary care provider, one in which they felt comfortable, they would likely 
ask for the vaccine in that setting. If they did not have a comfortable and established relationship 
with a primary care provider, this group may be more amenable to vaccination at a clinic that 
caters to LGBT populations. For college students there was a general acceptance of being 
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vaccinated at campus-based health clinics. These locations were perceived as being safe places 
that were accepting and capable of addressing health concerns of male sexual minorities.  
Specific Aim 1b: Determine factors that underlie these beliefs 
 The existing behavioral research on HPV vaccination focused specifically on MSM 
consists primarily of quantitative studies and relies on standard theoretical constructs to explain 
HPV vaccine intention (Nadarzynski et al., 2014; Newman, Logie, Doukas, & Asakura, 2013). 
This limits models of decision-making to the most proximate determinates of intention, 
acceptability, or willingness. Tailoring health education interventions for this population requires 
the identification of modifiable belief structures salient to MSM when making decisions about 
HPV vaccination. This is what was described as the salient beliefs. These are what need to be 
changed in interventions. Insights into how to change them come from the identification of their 
antecedents. In this next section, I will synthesize findings from Phases 1 and 3 (i.e., the 
qualitative investigations) in order to develop general observations regarding key background 
factors that inform decision-making about HPV vaccination among male sexual minorities.  
The HIV lens and HPV threat 
 The key to understanding the way in which young MSM think about HPV prevention is 
to consider the larger sociocultural impact of the HIV epidemic. This population is acutely aware 
of HIV risks (Wagenaar, Sullivan, & Stephenson, 2012) and they encounter HIV messages 
frequently in popular culture, as targets of research, and through pharmaceutical advertisements 
(Salyer, 2001). Their decision-making process regarding HPV vaccination appears to be heavily 
influenced by these sociocultural factors. Subjective risk of HPV infection (i.e., perceived threat) 
was often discordant with objective facts about HPV infectivity and their sexual histories. Risk 
perceptions regarding HPV infection were managed by a dedication to “safe sex,” which was 
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generalized to mean condom use, infrequent anal penetration, and minimizing the exchange of 
semen and blood. Thus the same set of risk factors for HIV transmission was equally applied to 
perceptions of HPV transmission. When learning of the nature of HPV transmission (i.e., skin-
to-skin sexual contact) many participants expressed concern as if their individual “models” of 
risk were challenged by this new information.  
Two other key observations support the claim that HPV—and subsequent decisions 
regarding vaccination—is viewed through the “lens” of the HIV epidemic. There was a focus on 
“knowing your status” and “stopping the spread of HPV.” These are powerful and prevalent HIV 
messages targeted toward the gay community (CDC, Act Against AIDS Campaign). Knowing 
their status before making health decisions about vaccination was commonly mentioned by 
participants yet belies an understanding of HPV infection, available testing procedures, and 
vaccine recommendations. In the absence of knowledge of these facts, male sexual minorities 
rely on heuristics informed by HIV knowledge and the wider practices in the gay community 
(Meadowbrooke, Veinot, Loveluck, Hickok, & Bauermeister, 2014). These messages also appeal 
to a sense of community responsibility, which was reiterated by men in this study in the form of 
protecting future sex partners from HPV through testing, safe sex, and, for some, vaccination. 
Specific Aim 2: Identify information needs and trusted sources of information 
Information needs 
 Men in this study had significant deficits in their basic understanding of HPV and HPV-
related diseases. This lack of knowledge did not impact their enthusiasm for vaccination 
suggesting that a minimal amount of information is needed in order for them to form vaccine 
intentions. The higher-risk of anal cancer associated with HPV infection was often cited as new 
information and had significant implications for the way in which participants understood the 
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benefits of vaccination.  Similarly, anogenital warts and HPV infection, even in the absence of 
clinical disease, elicited a strong negative reaction underlying their sense of threat. Health 
messages can capitalize on these emotional reactions to increase awareness of the benefits of 
HPV vaccination and improve attitudes towards vaccination. Risk messages in the presence of an 
effective prevention strategy can significantly influence behavior (Witte & Allen, 2000).  
Patient-provider communication 
 Healthcare providers are perceived as the primary source of reliable information 
regarding HPV vaccination. The importance of healthcare providers in HPV vaccine decision-
making is well documented (Newman et al., 2013). In this study we call attention to issues of 
sexuality and the patient-provider relationship that may serve as barriers to HPV vaccination. 
Disclosure—or “coming out to a healthcare provider”—is of central importance to HPV 
vaccination among adult MSM since there are different recommendations for vaccination of this 
population compared to the general male population. MSM who are “out” to their healthcare 
providers have more opportunity to receive recommended health services like HPV vaccination. 
Meites and colleagues (2013) found that a large percent of male sexual minorities in their 
national sample did not disclose to their healthcare providers, resulting in missed opportunities 
for preventive services (Meites et al., 2013). In this study we identified a number of factors 
related to disclosure including fear of judgment and mistreatment. Men were found to use a 
variety of strategies to manage their patient-provider relations in order to avoid disclosure or to 
seek out situations in which disclosure becomes more tenable. These data suggest that there is a 
segment of young MSM for whom avoidance of disclosure may serve as a barrier to HPV 
vaccination.  
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Specific Aim 3: Test a structural equation model 
  The integrative model of behavioral prediction described in this study provided a good 
framework from which to understand HPV vaccine decision-making among young MSM. The 
overall model explained approximately 38% of HPV vaccine intentions. This model identified 
key determinants of behavioral intention to get vaccinated, the structure of beliefs that influence 
the key determinants, as well as the antecedents of those beliefs. The model goes one step further 
to identify specific populations of MSM that may require specially tailored health messages or 
other interventions. The findings from this model are summarized below.  
 The strongest determinant of behavioral intention was attitude. According to this model, 
increasing positive attitudes toward HPV vaccination is the best strategy to affect intention and 
subsequent behavior. Attitudes can be changed by increasing beliefs in physical and 
psychological benefits of vaccination and decreasing concerns about side effects. Perceived 
threat and information orientation serve as the key motivational factors related to perceived 
advantages of vaccination. The antecedent role of perceived threat in HPV vaccine decision-
making was identified in a previous study of young MSM (Wheldon et al., 2013). This 
relationship implies that the motivation to process information pertaining to a health threat like 
HPV infection (e.g., information about the advantages of vaccination) varies as a function of 
perceived threat (Chen & Chaiken, 1999; Wheldon et al., 2013). As such, this theoretical model 
predicts that messages regarding the advantages of HPV vaccination—and those that minimize 
negative outcomes—are more likely to be systematically processed if a threat stimulus is present 
(Das, de Wit, & Stroebe, 2003). Similarly, information orientation is a motivational quality that 
primes an individual to process relevant information related to a health risk (Dutta-Bergman, 
2009). Individuals high on health information orientation will likely require little stimulus to 
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motivate information seeking and processing (Dutta-Bergman, 2009). Individuals who are low 
on information orientation can best be reached through passive communication channels (Dutta-
Bergman, 2009). For this population, that may include mobile phone sexual networking 
applications (Holloway et al., 2014).  
 Perceived behavioral control was also a moderate predictor of vaccine intentions. As 
predicted by the IM, perceived behavioral control is a function of external control beliefs and, in 
this model, self-efficacy pertaining to disclosure of sexual orientation. Self-efficacy inversely 
related to both the general tendency to conceal aspects of one’s sexual orientation and a 
suspicion of healthcare providers. Both of these relationships have important implications for 
patient-provider interactions. If the perceived LGBT cultural competency of providers were 
increased, that would increase confidence in disclosing one’s sexual orientation and provide 
more opportunities for healthcare providers to recommend HPV vaccination to this population of 
men.  The qualitative findings provide specific behaviors that providers can adopt in order to 
build rapport with male sexual minorities. At the most basic level, these findings stress the 
importance of asking about sexual behaviors in a way that does not confer judgment and focuses 
on the relevance of this information for optimal medical care.   
 The exogenous variables in the model identified three subpopulations of MSM who may 
benefit from targeted health education intervention. HIV-infected individuals exhibited higher 
perceived threat of HPV, and ultimately higher vaccine intentions. When this relationship is 
understood within the context provided by the qualitative findings, it is clear that HIV-infected 
individuals have different experiences with the healthcare system and are motivated to process 
information about HPV in significantly different ways given their increased risk of cancer. HIV 
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status has consistently been shown to positively correlate with vaccine intentions (Newman et 
al., 2013).  
Typically bisexual identity has been unrelated to HPV vaccine intuitions or acceptability 
(Wheldon et al., 2011) or vaccination status (Reiter et al., 2015). In this study, bisexual identity 
was positively correlated with concealment of sexual orientation and suspicion of healthcare 
providers. While not directly associated with vaccine intention, bisexually identified men may 
not be reached through health education interventions targeting gay men. Rates of nondisclosure 
of sexual minority status to healthcare providers have shown to be higher among bisexually 
identified men (Durso & Meyer, 2013). Limitations of patient-provider interactions experienced 
by these men can result in fewer opportunities for vaccination.  
Finally, men in monogamous relationships exhibited lower levels of perceived threat. 
This relationship supports the finding in the qualitative interviews where men expressed low 
levels of perceived threat as a result of being in a monogamous, or semi-monogamous, 
relationship. Lower perceived threat among men in relationships ultimately resulted in lower 
levels of vaccine intention. Further research is needed to identify the specific targets of 
behavioral intervention for this unique subpopulation.  
Section II: Limitations and Strengths 
Strengths 
This study makes a unique contribution to the behavioral HPV vaccination literature in 
several ways. (1) It is the first systematic study of HPV vaccine decision-making among MSM or 
males in general that uses the IM as a theoretical framework. While several studies have 
explored similar psychosocial constructs (Nadarzynski et al., 2014) as they relate to HPV 
vaccination, no published research utilized a mixed methods approach to elicit salient beliefs 
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directly from the priority population and then tested a structural model of those beliefs. In 
addition, the IM was uniquely expanded to incorporate antecedent factors important for the 
targeting and tailoring of health education interventions. (2) The sequential mixed methods study 
design allowed for a comprehensive exploration of HPV vaccine decision-making. Decision-
making processes surrounding vaccinations among adults are complex and driven by multiple 
factors. The qualitative phases allowed for in-depth exploration of salient beliefs and 
perceptions, while the quantitative survey provided the data needed to validate the theoretical 
propositions. (3) The application of an open-ended survey using a vignette to provide context in 
which to evaluate specific steps in the decision-making process was an innovative approach and 
provided a rich source of data. (4) The use of structural equation modeling, which allows for a 
complex representation of the theoretical constructs through the use of multivariate modeling 
techniques, provided information about the direct and indirect relationship of theoretical 
constructs. Mapping out the structural relationships between theoretical constructs is useful for 
the subsequent application of program planning models. (5) Finally, the use of a ethno-racially 
diverse community-based sample of young MSM in combination with geographically diverse 
samples obtained through Internet-based research recruitment helps to increase the external 
validity of findings and subsequent implications for health education interventions.  
Limitations 
The current study has four major limitations including the use of (1) non-probability 
sampling techniques, (2) cross-sectional data, (3) proxy indicators for vaccine uptake (i.e., 
modeling vaccine intentions), and (4) mode effects of in-person, telephone, and web-based data 
collection.  Probability sampling techniques ensure that every individual or element within the 
priority population from which the research seeks to generalize has a known non-zero probability 
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of being sampled (Fowler, 1993). This is accomplished from operationalizing the conceptual 
population into a sampling frame from which elements are randomly selected. External validity 
is most rigorously established when a sample is randomly generated from a sampling frame that 
closely approximates the conceptual population. This ensures that the sample is representative of 
the population and that findings generated from the sample can be generalized to the population 
within a specified range of confidence.  
There are a number of issues inherent to sampling members of sexual minority 
populations. The target population for this research included men who have ever engaged in 
sexual contact with another male or who identify as gay or bisexual. This conceptual population 
included both gay identified and non-gay identified MSM in order to be inclusive of all those 
who engage, or may engage at some point, in similar behaviors that increase the risk of anal 
HPV infection. This population is based on stigmatized sexual identities and sexual behaviors, 
which are often concealed or “hidden.” Therefore, constructing sampling frames that closely 
approximate these types of conceptual populations is inherently flawed, which results in biased 
and unrepresentative samples.  
In addition to the limitations inherent to the use of non-probability sampling techniques, 
the use of cross-sectional data and proxy measures for behavioral performance (e.g., vaccine 
uptake) limits the degree to which the IM would be directly tested. The IM posits that, in the 
absence of environmental constraints, a given health behavior is determined by an individual’s 
intention to perform that behavior. This proposition could not be tested using cross sectional data 
since no temporal relationship can be established between behavioral intention and behavioral 
performance. Furthermore, the full IM could not be tested since vaccine intention and not 
vaccine behavior (i.e., getting vaccinated or not getting vaccinated) was the final outcome.  
139 
 
Internet-based self-administered surveys have some significant limitations that bear 
consideration. Unequal access to the Internet was a primary concern associated with this survey 
method; however, the most recent data from the Pew Internet and American Life Project 
estimates that approximately 95% of Americans between the ages of 18 and 29 use the Internet.  
In contrast, only 56% of 18 to 30 year olds have a landline telephone in their household. The 
ubiquitous use of the Internet and mobile technologies provides strong rationale for Internet-
based survey research targeting younger cohorts. Internet surveys have been shown to have low 
response and completion rates relative to other survey methods (Cook, Heath, & Thompson, 
2000). These limitations to Internet-based survey research can present a challenge to the validity 
of results utilizing this method.  
Three modes were used to collect qualitative data used in this study: in-person face-to-
face interviews, telephone interviews, and web-based self-administered open-ended survey 
items. It is unclear to what degree these data collection techniques influenced data quality. There 
is a perception in qualitative research that face-to-face interviews result in the richest data, 
providing more context and opportunity to build rapport, interpret non-verbal cues, and ask 
probing questions (Novick, 2008). And there is some empirical support for these claims (Irvine, 
2011) and also in support of the quality of data resulting from telephone interviews (Sturges & 
Hanrahan, 2004).  
Section III: Implications  
Implications for research  
 Longitudinal studies are needed in order to establish temporal relationships between the 
key theoretical variables identified in this investigation and to determine how well they predict 
HPV vaccine initiation as the main outcome. Future research should also replicate the findings of 
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the current study with diverse samples of MSM including those with lower socioeconomic status 
and MSM who do not identify as gay or bisexual. HIV infected MSM are also a unique 
subpopulation that was not fully represented by this research. While the current investigation 
provides needed and useful information, the next steps for vaccine promotion research among 
this population should include community-based needs assessments to identify environmental 
barriers or factors that may facilitate vaccination of MSM in specific community locales. This 
research could benefit by building on the theoretical framework utilized in the current study and 
expanding it using program planning models like the social marketing framework (Kotier & 
Zaltman, 1996) or an intervention mapping approach (Bartholomew, 2011).   
 Promoting HPV vaccination among sexual minorities can be viewed within the larger 
framework of healthcare disparities experienced by this population (Institue of Medicine, 2011). 
Barriers to care center on issues of discrimination and stigma and are rooted in a long history of 
mistreatment of sexual minorities by healthcare systems and personnel. The charge of public 
health research is to identify ways to minimize or eliminate these barriers. In the current 
investigation—which focused on the individual as the unit of analysis—we identified suspicion 
of healthcare providers as a potential barrier to HPV vaccination among young MSM. This 
finding requires further investigation to develop valid and reliable measures of this phenomenon, 
to examine how widespread these perceptions are among subpopulations of MSM, and to further 
describe antecedents that facilitate these beliefs. Research in this area can benefit from and 
expand upon the work done on medical mistrust among other minority populations (Benkert, 
Hollie, Nordstrom, Wickson, & Bins-Emerick, 2009; Buseh, Kelber, Millon-Underwood, 
Stevens, & Townsend, 2014; Guadagnolo et al., 2009).  
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Implications for policy  
This study identifies key points for structural interventions. Policies that allow for and 
promote alternative vaccine settings can help facilitate uptake among young MSM. While 
pharmacies were identified as acceptable locations for a subset of MSM, others would prefer to 
get vaccinated at community-based clinics that offer HIV testing and that are perceived to be 
LGBT-friendly.  A model of LGBT care has been developed and put into practice by places like 
Fenway Community Health in Boston and in other urban centers with established LGBT 
communities (Mayer et al., 2001). The challenge is expanding this model to smaller cities. This 
is an area where community-based participatory research could offer unique insights.  
The age- and sex-based recommendations for HPV vaccination appear to be a source of 
considerable confusion among men in this study and have created a perception that HPV is a 
female problem. These perceptions appear to be enduring even after changes in vaccine policy. 
And while targeted vaccine promotion campaigns can seek to modify these beliefs, simplifying 
HPV vaccine policy would be the most wide reaching and impactful intervention. Given the 
decreasing cost of HPV vaccine, the promise of alternative dosing schedules, the increasing 
burden of HPV-related diseases, and the lack of standardized secondary screening guidelines for 
men, a universal, gender neutral policy recommendation is warranted (Bonanni et al., 2014).   
Implications for practice  
The findings from this study have several implications for public health practice. First 
among these are the implications for health education interventions to promote HPV vaccine 
uptake among MSM. The final IM supported by the findings identified key modifiable 
psychosocial factors including specific beliefs and perceptions that either directly or indirectly 
affect behavioral intention. Risk messages can be designed to influence these beliefs and can be 
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targeted to the specific subpopulations of MSM identified in the model. Promoting beliefs about 
the physical and psychological benefits of vaccination can be accomplished through paring 
information and risk messages. More research is needed to test specific messages, but this study 
has implications for the content of these messages. Rather than framing HPV vaccination as a 
cancer vaccine, which previous research has suggested (McRee, Reiter, Chantala, & Brewer, 
2010), the findings from this study indicate that framing HPV vaccination as a way to prevent a 
sexually transmitted infection may be particularly effect for MSM. Building on existing HIV 
prevention messaging (e.g., “Stop the spread,” “protect you partners”) may also be effective.  
The findings also suggest limited efficacy of interpersonal-based approach to vaccine 
promotion aside from interventions targeting healthcare providers. This research underscores the 
importance of LGBT cultural competency training. Currently there are no specific evidence-
based clinical practices to increase competency, but there are some guidelines that can be 
implemented to begin to address these issues (McNair & Hegarty, 2010).  
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Appendix A: Phase 1 Interview Guide 
 
Date: ____/_____/_____(mm/dd/yy) 
 
Participant ID#______ Time: _______________(AM / PM)  
 
 
Men4Men Health Study 
 
IRB# Pro00012092 
 
 
Interview Guide 
 
INTRODUCTION           
 
Thank you for taking the time to meet with me for this interview.  I recognize that your time is 
valuable and I appreciate your participation.  Before I start, let me take some time to introduce 
myself and explain why I am here to speak with you. 
  
My name is Chris Wheldon from the University of South Florida. I am conducting a research study to 
learn more about your views, beliefs, and attitudes toward health topics that affect sexually active men. 
This interview is one of many interviews that will take place over the next three months.  I want to know 
what are your thoughts, opinions and experiences when it comes to health in your community.  There 
are no right or wrong answers.  I am interested in finding out what you think.  
 
The information I gather will be summarized and shared in order to find better ways to serve the health 
needs of guys like you.    
 
The interview should not last more than 45 minutes.   
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SECTION 1:           BACKGROUND/ATTRIBUTE LISTING              
INTERVIEWER SAY: In order to get to know you please introduce yourself and list 10 things 
about yourself [Have him write them down] 
Probe: I am a brother, son, student etc. 
Probe: Age   |   Sexual Orientation   |   Residence   |   Health Insurance   |   Healthcare place 
 Race/Ethnicity   |   Student   |   Education 
 
 
 
 
 
 
 
SECTION 2:   Health  & Information        
INTERVIEWER SAY: I want to talk a little about health.  
1) What does it mean for you to be healthy? 
 
2) What sort of things do you do to be healthy? 
 
3) What do you think are some major health concerns that affect guys your age  
(Probe: A lot of times we talk about “women’s health” but what comes to mind when I 
say “men’s health”?  
(Probe: What about specific health concerns for gay/bisexual men? How do these differ 
from other men?) 
 
4) How do you find health information? (Probe: What sources do you trust?) 
 
5) Tell me about the last time you went to a doctor or health care provider.  
 
(Probe: What did you see him/her for? Have you ever been tested for HIV/STIs? Where and 
when was the last time?) 
 
6) Have you ever discussed being gay/bisexual with a health care provider. Tell me about that 
experience (Probe: When did this happen? Who initiated the discussion?). 
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SECTION 3:            HPV          
Knowledge 
1) Have you every heard of human papillomavirus (or HPV)? 
 
 
2) What do you know about HPV (Human Papillomavirus)?  
 
 
3) How did you first hear about HPV? What sources would you trust? 
 
 
4) Have you ever heard of a vaccine to prevent HPV? (If yes, what have you heard?) 
 
5) Where did you hear about the HPV vaccine? (Probe: Which of these sources [repeat/display 
response to previous question] would you trust the [most/least] to provide information about 
HPV? 
 
 
[Show HPV Brochure] What stands out or surprises you? What else would you like to know?  
 
a. Based on what you know now about HPV, what do you think your risk is of [having 
been/becoming] infected with HPV? Or developing an HPV related disease? What about 
in 3-5 years from now?  [0-10 scale] 
b. When you try to calculate your risk, what first comes to mind? 
 
 
Outcome beliefs 
6) What do you believe are the [advantages “good things” / disadvantages “bad things”] of 
receiving the HPV vaccine? How would you benefit from the HPV vaccine?   
 
 
Normative beliefs 
7) What individuals or groups would [approve/disapprove] if you decided to get the HPV vaccine? 
Why or why not?  (Probe: Friends? Family? Doctor?) 
 
 
8)  What do you think about people who receive the HPV vaccine?  
 
 
 
Efficacy/Control Beliefs 
9)  What factors or circumstances would [help you/make it difficult or impossible] for you to get 
the HPV vaccine?  
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a. Where would you get it?  [Probe: What about from a primary care provider? Would it 
prevent you from receiving it if you had to discuss your sexuality?  
 
b. How would you pay for it?  
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Appendix B: Phase 2 Survey Instrument 
ETH Which of the following best describes your race or ethnicity (check all that apply)? 
1. White/Caucasian (1) 
2. African American (2) 
3. African (9) 
4. Hispanic/Latino (3) 
5. Asian (4) 
6. Native American (5) 
7. Pacific Islander (6) 
8. Other (7) ____________________ 
 
 
SEX What sex were you assigned at birth, on your original birth certificate? 
x Male (1) 
x Female (2) 
x Other (Please explain) (4) ____________________ 
 
GENDER Which of the following   describes your gender identity, how you think about 
yourself? 
x Man (1) 
x Woman (2) 
x Genderqueer (3) 
x Transgender (4) 
x A gender identity not listed here (please explain) (5) ____________________ 
 
SEXOR How would you describe your sexual orientation? 
x Gay (1) 
x Bisexual (2) 
x Straight / heterosexual (3) 
x Not sure (4) 
x Other (5) ____________________ 
 
STUDENT Are you currently a student? 
x Yes (1) 
x No (2) 
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EDU What is the highest level of education you have completed? 
x Less than High School (1) 
x High School / GED (2) 
x Some College (3) 
x 2-year College Degree (4) 
x 4-year College Degree (5) 
x Graduate/Professional Degree (6) 
 
 
INSURANCE Do you have medical insurance coverage? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
MEDPLACE Is there a place that you usually go to when you need routine medical care 
(e.g., a family doctor, a specific clinic, etc)? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
 
HIVTEST In the past 12 months, how many times have you been tested for HIV, 
including  times you did not get your results? *Including blood or saliva tests specific for 
HIV. Do not count tests you may have had as part of a blood donation. 
x 0 - I have not been tested for HIV in the last 12 months (1) 
x 1 (2) 
x 2 (3) 
x 3 (4) 
x 4 (5) 
x 5 or more times (6) 
 
HIV What is your HIV status? 
x HIV - Negative (1) 
x HIV - Positive (2) 
x Never been tested for HIV (3) 
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STI Have you ever been told by a health care provider that you had either Gonorrhea 
("the clap"),   Chlamydia, Syphilis, herpes, or Trichomoniasis ("trich")? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
OUT_CON How often do you avoid talking about topics related to or otherwise 
indicating your sexual orientation when interacting with members of these groups (e.g., 
not talking about your significant other, changing your mannerisms)? 
______ Members of your immediate family (e.g., parents and siblings) (1) 
______ Members of your extended family (e.g., aunts, uncles, grandparents, cousins) (2) 
______ People you socialize with (e.g., friends and acquaintances) (3) 
______ People at your work/school (e.g., coworkers, supervisors, instructors, students) (4) 
______ Strangers (e.g., someone you have a casual conversation with in line at the store) (5) 
 
HPV101_I Ever heard of HPV? A lot of guys don't know much about it. Read the info 
below and then go to the next page. 
 
HPV_HAD Has a health care provider ever told you that you had human papillomavirus 
or         HPV? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
HPV_WARTS Has a health care provider ever told you that you had genital or anal 
warts? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
KNOW_WARTS To the best of your knowledge, do you personally know someone who 
has had genital or anal warts (other than yourself)? 
x Yes (1) 
x No (2) 
x I don't know (3) 
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KNOW_HPV To the best of your knowledge, do you personally know someone who has 
had HPV (other than yourself)? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
VAC_AWARE Before today, have you ever heard of the HPV vaccine? 
x No (1) 
x Yes (2) 
x I don't know (3) 
 
HPV_VACC Have you ever received the HPV shot? 
x Yes (1) 
x No (2) 
x I don't know (3) 
If Yes Is Selected, Then Skip To End of Block 
 
KNOW_VAC Do you personally know someone who has gotten the HPV vaccine? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
VAC_DRREC Has a doctor or health care provider ever recommended that you get the 
HPV vaccine? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
VAC_INT_D1 Do you intend to get vaccinated against HPV within the next year? 
x Yes (1) 
x No (2) 
x I don't know (3) 
VAC_I2 Now that you know a little about the HPV vaccine I would like to know if you 
will get the HPV vaccine. Respond to the following statements based on what you know 
right now about the HPV vaccine.  How likely are you to do the following: 
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INTENTION1 Find out more information about the HPV vaccine within the next 12 
months 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
INTENTION2 Make an appointment to talk to a doctor about the HPV vaccine within the 
next 12 months 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
INTENTION3 Get your first HPV shot within the next 12 months 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
INTENTION4 How likely are you to get the HPV vaccine if the CDC recommendation 
was changed to include men older than 26? 
x Very Unlikely (6) 
x Unlikely (7) 
x Undecided (8) 
x Likely (9) 
x Very Likely (10) 
 
DOSE_I Each dose can cost up to about $170, so all three shots may cost about $500.  
Many health insurance companies may pay for the HPV vaccines. There are  also 
programs that allow some people without insurance to get a vaccine  for low or no cost. 
Think about what you might do in the next year. Would you... 
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INTENTION5 Get the HPV vaccine if it were offered to you free of charge? 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
INTENTION6 Get the HPV vaccine if it was covered by your health insurance or 
discounted to approximately $30 per dose? 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
ATT Overall, I think that getting the HPV vaccine is... 
 1 (1) 2 (2) 3 (3) 4 (4) 5 (5) 
Not worth 
it:Worthwhile (1) 
x  x  x  x  x  
Harmful:Beneficial (2) x  x  x  x  x  
A bad thing for me:A 
good thing for me (3) 
x  x  x  x  x  
Unimportant:Important 
(4) 
x  x  x  x  x  
Ineffective:Effective (5) x  x  x  x  x  
 
BB_I2 If you got vaccinated for HPV within the next year, how likely are the following 
things: 
 
BB1 It would make me healthier 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
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BB2 It would prevent me from getting genital and anal warts 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
BB3 It would prevent me from getting anal cancer 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
BB_I3 You just told me how you think you might benefit (or not) from the HPV vaccine. 
Now I'd like to know how important each of those outcomes are to you at this point in 
time. 
 
EB1 Being healthy is... 
x Not at all Important to me at this time (1) 
x Very Unimportant to me at this time (2) 
x Neither Important nor Unimportant to me at this time (3) 
x Very Important to me at this time (4) 
x Extremely Important to me at this time (5) 
 
EB2 Preventing genital and anal warts is... 
x Not at all Important to me at this time (1) 
x Very Unimportant to me at this time (2) 
x Neither Important nor Unimportant to me at this time (3) 
x Very Important to me at this time (4) 
x Extremely Important to me at this time (5) 
 
EB4 Preventing anal cancer is... 
x Not at all Important to me at this time (1) 
x Very Unimportant to me at this time (2) 
x Neither Important nor Unimportant to me at this time (3) 
x Very Important to me at this time (4) 
x Extremely Important to me at this time (5) 
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BB_i4 If you got vaccinated for HPV within the next year, how true are the following 
things likely to happen for you?  Would you...? 
 
BB4 Feel protected from HPV 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
BB5 Feel like there is one less thing to worry about 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
BB6 Be less likely to spread HPV to your future sex partner(s) 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
x  
BB_I5 How important are these things to you currently or over the next 12 months? 
 
EB4 Feeling protected from HPV 
x Not at all Important (1) 
x Very Unimportant (2) 
x Neither Important nor Unimportant (3) 
x Very Important (4) 
x Extremely Important (5) 
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EB5 Not having to worry about getting HPV from my sex partner(s) 
x Not at all Important (1) 
x Very Unimportant (2) 
x Neither Important nor Unimportant (3) 
x Very Important (4) 
x Extremely Important (5) 
 
EB6 Protecting my sex partner(s) from HPV 
x Not at all Important (1) 
x Very Unimportant (2) 
x Neither Important nor Unimportant (3) 
x Very Important (4) 
x Extremely Important (5) 
 
BB_I6 We’ve talked to some guys who expressed some concerns about the HPV vaccine. 
How likely do you think the following things are to happen to you if you got vaccinated?  
If I got vaccinated for HPV within the next year… 
 
BB7 I will contract HPV from the vaccine itself 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
BB8 I would not be completely protected from future HPV infection 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
BB9 The vaccine may not work for me 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
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BB10 I would have side effects from the HPV vaccine 
x Very Unlikely (1) 
x Unlikely (2) 
x Undecided (3) 
x Likely (4) 
x Very Likely (5) 
 
EB10 If you did experience side effects from the HPV vaccine, how serious do you think 
that would be? 
x Not serious at all (1) 
x Not serious (2) 
x I'm not sure (3) 
x Serious (4) 
x Very serious (5) 
 
 
NORM_I If you considered getting the HPV vaccine in the next year, there might be 
people (e.g., your family) or groups (e.g., health care providers) who would think you 
should or should not do so. I would like to ask you some questions about this. 
 
NORM1 In general, people who are important to me would encourage me to receive the 
HPV vaccine. 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
NORM2 I can think of at least one person in my life who would like for me to get the 
HPV vaccine. 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
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NORM3 If I decided to get the HPV vaccine within the next year, I would seek advice 
from my friends or family prior to getting vaccinated. 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
NORM4 Most of my gay/bisexual male friends would get the HPV vaccine if it was 
offered to them free of charge. 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
 
 
 
NB Listed below are some people in your life who may approve or disapprove of you 
getting the HPV vaccine. What do you think their opinions would be?  If you don't have a 
relationship with the specific person just choose "not applicable."  1 = Very Disapproving 
2 3 = Neither Approving/Disapproving 4 5 = Very Approving 
______ Your Mother (24) 
______ Your Father (25) 
______ Most of your gay male friends (26) 
______ Your straight friends (28) 
______ Your health care provider (29) 
 
MC When deciding whether or not to get the HPV vaccine, would you seriously consider 
the advice/opinion of...1 = Very Unlikely23 = Undecided45 = Very Likely 
______ Your mother (24) 
______ Your father (25) 
______ Your gay male friends (26) 
______ Your straight friends (28) 
______ Your healthcare provider (29) 
 
Q73 You're swell. Hang in there! Let's assume that you decide to get the HPV vaccine in 
the next 12 months (i.e., by this time next year). Select your responses to the following 
statements accordingly.  
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PBC1 There are factors beyond my control that would prevent me from getting the HPV 
vaccine in the next 12 months 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
PBC2 I am confident that I can get the HPV vaccine in the next 12 months 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
Q168 Getting the HPV vaccine sometime in the next 12 months would be 
x Impossible for me (6) 
x   (7) 
x   (8) 
x   (9) 
x Possible for me (10) 
 
PC What would make it easier for you to get the HPV Vaccine? Tell me below. It would 
make it ____________to get the HPV vaccine in the next 12 months...1 = more difficult 
for me2345 = much easier for me 
______ If I could quickly find out where to go to get vaccinated (1) 
______ If my health insurance covered the vaccine (4) 
______ If I could get it without having to make an appointment (i.e., walk-in) (3) 
______ If I could get it when I get tested for HIV (6) 
 
CB_I Tell me how much you agree or disagree with the following statements 
 
CB1 I can find out where to go to get vaccinated 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Disagree nor Agree (3) 
x Agree (4) 
x Strongly Agree (5) 
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CB2 I will have health insurance during the next year 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Disagree nor Agree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
CB3 I can find a place to get vaccinated where I don't need to make an appointment (i.e., 
walk-in) 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Disagree nor Agree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
CB4 I will get tested for HIV in the next 12 months 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Disagree nor Agree (3) 
x Agree (4) 
x Strongly Agree (5) 
SE_I Assuming you decided to get the HPV vaccine. 
 
SE_GAY1 How confident are you in your ability to get the HPV vaccine if you had to 
talk to your doctor or healthcare provider about your sexual orientation (e.g., that you are 
gay or bisexual)? 
x Not at all confident (1) 
x Somewhat confident (2) 
x Rather confident (3) 
x Very confident (4) 
x Extremely confident (5) 
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SE_BEH1 How confident are you in your ability to get the HPV vaccine if you had to 
talk to your doctor or healthcare provider about your sexual behaviors (e.g., your sexual 
history)? 
x Not at all confident (1) 
x Somewhat confident (2) 
x Rather confident (3) 
x Very confident (4) 
x Extremely confident (5) 
 
SUS Without getting the HPV vaccine, what do you think the chances are that you will…  
1 = Very Unlikely 2 3 = Undecided 4 5 = Very Likely   
______ Get HPV (1) 
______ Get warts on your penis or scrotum (2) 
______ Get anal warts (3) 
______ Get anal cancer (4) 
SEV Please indicate on a scale of 1 to 5 how serious you feel the following events would 
be for you. 
______ If you became infected with HPV (1) 
______ If you developed warts on or inside your anus (2) 
______ If you developed warts on your penis or scrotum (3) 
______ If you developed anal cancer (4) 
 
Q173   Ok! That's enough about HPV!!! I just have a few more questions. Remember to 
enter your email at the end of the survey to enter the drawing for Amazon.com Gift 
Cards. 
 
COMM_I The next few statements focus on health information. Indicate below how 
much you agree or disagree with each statement. 
 
COMM_M1 When I take medicine, I try to get as much information as possible about its 
benefits and side effects 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
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COMM_M2 Before making a decision about my health, I find out everything I can about 
the issue 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
COMM_M3 It’s important to me to be informed about health issues affecting gay and 
bisexual men 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
I5 I would like to ask you about your health care experiences. When I ask about a "health 
care provider" I am referring to a medical doctor or nurse who is licensed to practice 
medicine. Sometimes we call them family or primary care physicians.  
 
DISLOSE Have you ever told any health care provider that you are gay or bisexual or 
that you have sex with men? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
I6 Please tell me how much you agree or disagree with the following statements. 
 
HLTCARE1 I have received lower quality healthcare services as a result of my sexual 
orientation 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
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HLTCARE2 I prefer that my doctor or healthcare provider does not know that I am 
gay/bisexual 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
HLTCARE3 I feel uncomfortable talking about my sexual orientation or sexual behaviors 
with a doctor or healthcare provider 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
HLTCARE4 There is no reason why my doctor or healthcare provider would need to 
know that I have sex with men 
x Strongly Disagree (1) 
x Disagree (2) 
x Neither Agree nor Disagree (3) 
x Agree (4) 
x Strongly Agree (5) 
 
SEX_BEH_I           Now I would like to ask you some questions about your sexual 
activities and experiences. This information is very important to this study.  Each person 
has different sexual experiences, so some questions may not apply to you.  Remember: 
Your answers are anonymous! 
 
SEX_#M In your lifetime, with how many males have you had sex? 
 
REL Are you currently in a monogamous relationship? 
x Yes, with a man (1) 
x Yes, with a woman (2) 
x No (3) 
 
Answer If Are you currently in a monogamous relationship? Yes, with a man Is Selected Or Are 
you currently in a monogamous relationship? Yes, with a woman Is Selected 
REL_LENGTH How long have you been in this relationship? 
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VAC_INT_D2 Last Question!!! And this is a repeat but I’m curious if you’ve changed 
your mind.  Do you intend to get vaccinated against HPV within the next year? 
x Yes (1) 
x No (2) 
x I don't know (3) 
 
OPEN Thank you for taking the survey. On the next page you can submit your responses 
and move on to enter to win a gift card. If you have any thoughts you'd like to share with 
me you can do so below. 
 
CLOSING_I You’re fabulous! Thank you for taking the time to complete this survey. If 
you have any questions about the study or about HPV don’t hesitate to contact me at 
cwheldon@health.usf.edu.  If you are curious about the findings from this study I can 
update you when I am finished. Just send me an email and let me know you are 
interested.  On the next page you can enter to win a gift card for your participation. If you 
are one of the winners the gift card will be emailed to you. This email will not be linked 
to your survey responses in any way. 
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Appendix C: Phase 3 Survey Instrument 
 
D2 What sex were you assigned at birth, on your original birth certificate? 
x Male (1) 
x Female (2) 
x Other (Please explain) (4) ____________________ 
 
Q61 Which of the following   describes your gender identity, how you think about 
yourself? 
x Boy/man (1) 
x Girl/woman (2) 
x Genderqueer (3) 
x Transgender (4) 
x A gender identity not listed here (please explain) (5) ____________________ 
 
D3 How would you describe your sexual orientation? 
x Gay (1) 
x Bisexual (2) 
x Straight / heterosexual (3) 
x Not sure (4) 
x Other (5) ____________________ 
 
D4 Which of the following best describes your race or ethnicity (check all that apply)? 
9. White/Caucasian (1) 
10. African American (2) 
11. African (9) 
12. Hispanic/Latino (3) 
13. Asian (4) 
14. Native American (5) 
15. Pacific Islander (6) 
16. Other (7) ____________________ 
 
D5 Are you currently a student? 
x Yes (1) 
x No (2) 
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D6 What is the highest level of education you have completed? 
x Less than High School (1) 
x High School / GED (2) 
x Some College (3) 
x 2-year College Degree (4) 
x 4-year College Degree (5) 
x Graduate/Professional Degree (6) 
 
HLT1 Do you have medical insurance coverage? 
x Yes, through my employer (1) 
x Yes, through my school (4) 
x Yes, through my parents (5) 
x Yes, through an individual policy (6) 
x Yes, through medicaid or state based program (7) 
x Yes, through another source (8) 
x No, I do not currently have medical insurance (2) 
x I'm not sure (3) 
 
HLT2 Is there a place that you usually go to when you need routine medical care (e.g., a 
family doctor, a specific clinic, etc)? 
x Yes (1) 
x No (2) 
 
HLT3 If you needed to see a doctor for a non-emergency issue, where would you go? 
x My primary care provider (1) 
x Clinic at my school (2) 
x A local walk-in clinic (3) 
x County public health clinic (4) 
x Planned Parenthood clinic (5) 
x Emergency room (6) 
x Other (please explain) (7) ____________________ 
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HIV2 In the past 12 months, how many times have you been tested for HIV, including  
times you did not get your results? *Including blood or saliva tests specific for HIV. Do 
not count tests you may have had as part of a blood donation. 
x 0 - I have not been tested for HIV in the last 12 months (1) 
x 1 (2) 
x 2 (3) 
x 3 (4) 
x 4 (5) 
x 5 or more times (6) 
 
HIV3 Where do you usually go to get tested for HIV? 
 
HIV What is your HIV status? 
x HIV - Negative (1) 
x HIV - Positive (2) 
x Never been tested for HIV (3) 
 
 
HPV1 Has a doctor or other health care provider ever told you that you had human 
papillomavirus or         HPV? 
x Yes (1) 
x No (2) 
x I'm not sure (3) 
 
HPV2 Has a doctor or other health care provider ever told you that you had genital warts? 
x Yes (1) 
x No (2) 
x I'm not sure (3) 
 
HPV3 A vaccine to prevent HPV infection is available and is referred to by several 
names, such as: the HPV shot, cervical cancer vaccine, GARDASIL®, or CERVARIX®. 
Have you ever received the HPV shot or cervical cancer vaccine? 
x Yes (1) 
x No (2) 
x I'm not sure (3) 
 
 
Bran1 Please read Brandon's story and respond to the questions. There are 3 short 
sections to his story and each has a set of questions and areas for you to provide your 
thoughts. This story is based on the experiences of real people who previously 
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participated in this study. Brandon is a young guy in his 20s. He isn't overly concerned 
about health issues but he tries to eat healthy and stay active. He doesn't go to the doctor 
often but he does try to get tested for HIV on a regular basis. He's currently single and 
enjoys hanging out with his friends and meeting new guys. On a recent Friday night he 
was spending an evening out with a group of friends at his favorite hangout. While 
waiting in line to order, he casually scanned the fliers posted on the wall next to him. 
Most of them featured hard bodied men advertising for fundraisers or party events. But 
one flier caught his eye. It read “Cover your BUTT with GARDASIL. HPV affects guys, 
too.” And under the large text it said… 
 
 
Bran2 PLEASE READ THESE HPV FACTS 
 
Bran3          What is HPV?    Why you should care?  HPV is a sexually transmitted virus 
that you can get from skin-to-skin contact during all types of sexual activites. Most 
people will become infected with HPV in their lifetime. Most of the time HPV has no 
symptoms so people don’t know they have it. For most people, HPV goes away on its 
own but if it doesn’t it can cause genital and anal warts and some types of cancers 
including anal cancer. Men who have sex with men are 17 times more likely to develop 
anal cancer than other men. How to prevent HPV? Gardasil—the HPV vaccine—protects 
against genital warts and cancers caused by HPV. HPV vaccine is recommended for men 
26 years old and younger. 
 
StandOut What about this information stands out to you? Why does it stand out to you? 
Please explain in detail. 
 
Learn What did you learn about HPV that you didn't already know? 
 
 
Prisk Without the HPV vaccine, what do you think the chance is that you will be infected 
with HPV at some point in your life? 
x No chance (0%) (1) 
x Very unlikely (2) 
x Unlikely (3) 
x Average chance (50%) (4) 
x Likely (5) 
x Very likely (6) 
x Certain to happen (100%) (7) 
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Concern How concerned are you about getting infected with HPV? 
x Not at all concerned (1) 
x Slightly concerned (2) 
x Somewhat concerned (3) 
x Moderately concerned (4) 
x Extremely concerned (5) 
 
 
Bran4          After reading this information about HPV, Brandon was a little worried. He 
thought HPV was only something women could get. And while he almost always uses 
protection when he hooks up, he couldn’t help but wonder if he has HPV. But Brandon 
wasn’t going to let it bother him. He got his drink and went back to his friends.                
The next day Brandon googled HPV vaccine and read more about it. He read that 
GARDASIL is given as 3 injections over 6 months and that the ideal time to get 
vaccinated is before becoming infected with HPV. Brandon isn’t sure if he can be 
vaccinated. He’s not what his friends would consider “slutty” but he certainly isn’t a 
virgin either. He wonders how he would know if he’s been exposed to HPV. 
 
Decision1 What do you think Brandon should do?   I think Brandon should...(explain in 
detail) 
 
Q67 Why should he do that?  I think Brandon should do that because...(explain in detail) 
 
Decision2 What would you do if you were in Brandon’s situation? Please explain why.  If 
I were in Brandon’s situation, I would... 
 
BranThreat A few weeks passed and Brandon mostly forgot about HPV until one 
afternoon the topic came up while he was hanging out with his friend Jeremy. Jeremy and 
Brandon are best friends, and they share everything. It turns out Jeremy just found out he 
has anal warts! He told Brandon he was having some “issues down there” so he went to 
get it checked out. He spared Brandon the details but told him that, “they aren’t pretty." 
Luckily the warts were all on the outside around his anus so the doctor was able to freeze 
them off so he didn’t need surgery. Jeremy was worried that the warts might come back 
since there is no cure. Brandon was supportive as usual and reassured his friend. But deep 
down he was freaking out. After hearing about Jeremy’s experience Brandon decided that 
he wanted to get the HPV vaccine. He didn’t EVER want to get anal warts. He didn’t 
care if he had already been exposed to HPV. If there was any chance that the HPV 
vaccine would prevent warts or cancer he thought it was worth it.          
 
Threat1 What do you think about Brandon’s decision? I think that Brandon's decision... 
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Threat 1b Would you have decided to do the same thing (i.e., decide to get the HPV 
vaccine)? 
x Yes (1) 
x No (2) 
x I'm not sure (3) 
 
 
Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)? No 
Is Selected 
Threat2_N Why would you decide NOT to get vaccinated? 
 
Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)? 
Yes Is Selected 
Threat2_Y Why would you decide to get vaccinated? 
 
Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)? 
I'm not sure Is Selected 
Threat2_U What are you unsure about? 
 
Answer If Do you have medical insurance coverage? No, I do not currently have medical 
insurance Is Not Selected And Do you have medical insurance coverage? I'm not sure Is Not 
Selected And Is there a place that you usually go to when you need routine medical care (e.g., a 
family doctor... No Is Selected 
BranGet1          Brandon wanted to get the HPV vaccine but he didn’t know where to go 
to get it. He had health insurance but didn’t have a regular doctor or a place he usually 
goes to for care. He doesn’t like going to the doctor and feels a little awkward asking a 
health care provider about the HPV vaccine since it’s an STD. He knows it's 
unprofessional but sometimes thinks that doctors judge him for his sexual behaviors. 
 
Disclose Have you ever told any health care provider that you are 
${q://QID9/ChoiceGroup/SelectedChoices} or that you have sex with men? 
x Yes (1) 
x No (2) 
x I don't remember (3) 
 
Answer If          Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it. 
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for care. 
He doesn’t...  Is Displayed 
Get1 Where would you go to get the HPV vaccine if you were in Brandon’s situation? 
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Answer If          Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it. 
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for 
care...  Is Displayed 
Disclose1 How do you feel about talking to your health care provider about your sexual 
behavior (example: telling him or her you've had male partners)? Do you feel like they 
judge you? Why or why not? 
 
Answer If          Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it. 
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for care. 
He doesn’t...  Is Displayed 
Trust1 Do you think that your doctor or health care providers are knowledgeable about 
the health issues that gay and bisexual men have to deal with? Why or why not? 
 
BranGet2          Brandon wants to get the HPV vaccine but he doesn’t know where to go 
to get it. He has health insurance and a regular doctor he sees, but he feels a little 
awkward asking his doctor for the HPV vaccine. He knows it's unprofessional but 
sometimes he thinks that his doctor judges him for his sexual behaviors. 
 
Get2 Where would you go to get the HPV vaccine if you were in Brandon’s situation? 
 
Disclose2 How do you feel about talking to your health care provider about  your  sexual 
behavior (example: telling him or her you've had male partners)?  Do you feel like they 
judge you? Why or why not? 
 
Trust2 Do you think that your doctor or health care providers are knowledgeable  about 
the health issues that gay and bisexual men have to deal with?  Why or why not? 
 
BranGet3          Brandon wants to get the HPV vaccine but he doesn’t know where to go 
to get it. He does not have health insurance and is worried that the vaccine is too 
expensive. He read that out of pocket the vaccine could cost almost $500 for all 3 shots. 
 
Recom3 What would you recommend that Brandon do? 
 
Decide3 What would you do if you were in Brandon’s situation? 
 
Get3 Where would you go to get the the HPV vaccine if you wanted it? 
 
 
Bran5          Even if he could find some way to get the HPV vaccine Brandon doesn’t like 
going to the doctor and feels a little awkward asking a health care provider about the 
HPV vaccine since it’s an STD. He knows its unprofessional but sometimes thinks that 
doctors judge him for his sexual behaviors. 
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Decide5 How do you feel about talking to your health care provider about  your  sexual 
behavior (example: telling him or her you've had male partners)?  Do you feel like they 
judge you? Why or why not? 
 
Trust5 Do you think that your doctor or health care providers are knowledgeable  about 
the health issues that gay and bisexual men have to deal with?  Why or why not? 
 
Context          Brandon ended up getting vaccinated for HPV and felt good about his 
decision. He felt that he did something that will help to protect his health as well as the 
health of his partners. He found several different locations in his area where he could get 
the HPV vaccine at an affordable price. These included:              A HIV-testing site or 
clinic that offers vaccination in addition to HIV testing. No appointment is usually 
needed. Many of these clinics offer medication and case management for people infected 
with HIV. Some of these organizations now offer HPV vaccination as part of there 
services for gay and bisexual men. A pharmacy with a walk-in clinic (e.g., CVS, 
Walgreens, Target, Walmart, Arlington, and others). These walk-in clinics provide basic 
health care services including vaccinations.     A primary care providers office where you 
can receive routine medical care. This may be a "family doctor"or an in-network doctor 
affiliated with a health insurance organization. Community-based organization that 
“promotes a healthy environment for all regardless of race, ethnicity, religion, sexual 
orientation, gender identity, age or economic status.” They offer a number of health and 
social services and even a weekly social group for young lesbian, gay, bisexual, 
transgender and queer youth.                  
 
PlacesC Assuming you wanted to get the HPV vaccine, indicate below if you would  be 
likely or unlikely to get the HPV vaccination at any of these  locations. 
 Unlikely (1) Undecided (2) Likely (4) 
HIV testing site (5) x  x  x  
Pharmacy with a 
walk-in clinic (8) 
x  x  x  
Primary care 
provider office (9) 
x  x  x  
Community-based 
organization serving 
LGBT people (10) 
x  x  x  
 
 
PlacesO Are there any other locations that you would prefer to get the HPV vaccine? 
Please explain below. 
 
 
Thank you very much for taking the time to complete this survey. Two last important 
questions. 
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Intention Based on what you know right now about HPV and the HPV vaccine, how 
likely is it that you will receive your first HPV shot by this time next year? 
x Very Unlikely (1) 
x Unlikely (2) 
x Somewhat Unlikely (3) 
x Undecided (4) 
x Somewhat Likely (5) 
x Likely (6) 
x Very Likely (7) 
IntentionO You said that you are "${q://QID82/ChoiceGroup/SelectedChoices}" to get 
your first HPV shot by this time next year. Why did you select this response? Is there 
anything you would like to know about the vaccine before making your decision? 
 
OPEN Thank you for taking the survey. On the next page you can submit your responses 
and move on to enter to win a gift card. If you have any thoughts you'd like to share with 
me you can do so below. 
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Appendix D: IRB Approval  
 
 
  
 
March 18, 2013  
  
Christopher Wheldon 
Community and Family Health 
13201 Bruce B. Downs Blvd., MDC 56 
Tampa, FL  33612 
 
RE: 
 
Expedited Approval for Initial Review 
IRB#: Pro00012092 
Title: Men4Men Health Study 
 
Study Approval Period: 3/18/2013 to 3/18/2014 
Dear Mr. Wheldon: 
 
On 3/18/2013, the Institutional Review Board (IRB) reviewed and APPROVED the above 
application and all documents outlined below.  
Approved Item(s): 
Protocol Document(s): 
Diss_IRB_Protocol (APA 6).docx 
 
 
Consent/Assent Document(s)*: 
Name Version 
Phase 1A In person IC 0.01 
Phase 1A online IC 0.01 
Phase 1B and 2 Online IC 0.01 
All consent forms granted a Waiver of Informed Consent Documentation 
 
 
*Please use only the official IRB stamped informed consent/assent document(s) found under the 
"Attachments" tab. Please note, these consent/assent document(s) are only valid during the 
approval period indicated at the top of the form(s).  (Waivers are not stamped). 
It was the determination of the IRB that your study qualified for expedited review which 
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve 
only procedures listed in one or more of the categories outlined below. The IRB may review 
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR 
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56.110. The research proposed in this study is categorized under the following expedited review 
category: 
 
(6) Collection of data from voice, video, digital, or image recordings made for research purposes. 
 
(7) Research on individual or group characteristics or behavior (including, but not limited to, 
research on perception, cognition, motivation, identity, language, communication, cultural 
beliefs or practices, and social behavior) or research employing survey, interview, oral history, 
focus group, program evaluation, human factors evaluation, or quality assurance methodologies. 
 
 
Your study qualifies for a waiver of the requirements for the documentation of informed consent 
as outlined in the federal regulations at 45CFR46.117(c) which states that an IRB may waive the 
requirement for the investigator to obtain a signed consent form for some or all subjects.  
 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval by an amendment. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections.  If you have 
any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
   
John Schinka, Ph.D., Chairperson 
USF Institutional Review Board 
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3/24/2014  
  
Christopher Wheldon 
Community and Family Health  
13201 Bruce B. Downs Blvd., MDC 56  
Tampa, FL 33612 
 
RE: 
 
Expedited Approval for Continuing Review 
IRB#: CR1_Pro00012092 
Title: Men4Men Health Study 
 
Study Approval Period: 3/20/2014 to 3/20/2015 
Dear Mr. Wheldon: 
 
On 3/20/2014, the Institutional Review Board (IRB) reviewed and APPROVED the above 
application and all documents outlined below. 
Approved Item(s): 
Protocol Document(s): 
Diss_IRB_Protocol (APA 6).docx          
 
  
 
Please submit an amendment to the IRB within 30 days to update the recruitment flyer to 
reflect the following changes: include the word "research" on the flyer and provide disclosure of 
the collection of demographic information. Please update the study protocol to indicate the gift 
card compensation amount of $25. 
The waiver of informed consent documentation has been renewed. 
The IRB determined that your study qualified for expedited review based on federal expedited 
category number(s): 
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(6) Collection of data from voice, video, digital, or image recordings made for research purposes. 
 
(7) Research on individual or group characteristics or behavior (including, but not limited to, 
research on perception, cognition, motivation, identity, language, communication, cultural 
beliefs or practices, and social behavior) or research employing survey, interview, oral history, 
focus group, program evaluation, human factors evaluation, or quality assurance methodologies. 
 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval by an amendment. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections.  If you have 
any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
   
John Schinka, Ph.D., Chairperson 
USF Institutional Review Board 
